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ABSTRACT 
Tumours of the brain and the central nervous system (CNS) account for a quarter of all 
childhood cancers. Despite being a rare condition, it is the most frequent cause of death 
from disease in children aged 1-14 years, and accounts for just under a fifth of all 
bereavements in childhood.  Recent medical advancements together with improvements in 
neurosurgery, radiation therapy and chemotherapy have facilitated earlier diagnosis. This 
has resulted in an increase in the aggregated survival rates of children diagnosed with brain 
tumours. As a result, children are living longer with greater neurocognitive morbidity. 
Statistics indicate that 40-100% of long-term survivors of a brain tumour will demonstrate 
some degree of cognitive dysfunction. Hence, the National Health Service (NHS) and other 
international health care providers are increasingly focusing on the rehabilitation needs and 
quality of survivorship of this population. 
 
The objectives of this thesis are to identify and evaluate the effectiveness of interventions 
(pharmaceutical and psychosocial) for cognitive and learning impairment within a paediatric 
neurooncology population. This will be addressed via a systematic review of all current 
research using a selection of Electronic Databases. The result of which will hope to provide 
a guide for appropriate service provision to address long-term neuro-rehabilitation and 
psychological needs in the future. 
 
A limited number of studies were retrieved in this systematic review; only three studies met 
the inclusion criteria. Thus, a narrative review resulted in limited conclusion about the 
effectiveness of psychosocial and pharmaceutical interventions on neurocognitive and 
learning impairments in a paediatric brain tumour population. Of the studies retrieved, all 
demonstrated promising results for the future of paediatric rehabilitation. However, it is the 
limited number of studies retrieved that is of most interest, highlighting a very small 
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evidence base and potentially problematic research design. Solutions to these difficulties are 
suggested. 
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CHAPTER ONE: INTRODUCTION 
 
The detection and management of paediatric brain tumours have developed significantly 
with recent advancements in science (Moore, 2005; Mulhern, Merchant, Gajjar, Reddick, & 
Kun, 2004). The result of this is most clearly illustrated by an increase in survival rates from 
31% (1966-1970) to 71% (2001-2005) (Childhood Cancer Statistics, 2010). However, as 
survival rates increase, the impact of brain tumours and their treatment regimens 
(neurosurgery, radiotherapy and chemotherapy) have become of greater concern to 
clinicians and researchers. Research demonstrates that many children will experience 
neurocognitive deficits as a consequence of both their brain tumour and the medical 
interventions used in their treatment, the results of which have a significant impact on 
children’s cognitive development and learning outcomes (Mulhern et al, 2004).  With the 
decrease in the mortality rate, research has established that children diagnosed with a brain 
tumour are now living longer with greater morbidity; consequently there needs to be further 
interventions to minimise the impact of acquired cognitive and learning deficits (Sands, 
2009). Hence, it is important for practitioners to gain a better understanding of the 
pharmaceutical and psychosocial interventions used to facilitate neurocognitive recovery, 
after the acute phase of treatment, for children surviving a brain tumour. Consequently, this 
understanding will facilitate the development of recommendations for education systems 
and the progression of the child’s transition into adult services later in their life. 
 
The aim of this thesis is to systematically review the literature on the effectiveness of 
interventions (pharmaceutical and psychosocial) aimed at alleviating cognitive and learning 
impairments within a paediatric brain tumour population. 
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1.1 Neurocognitive and Learning Deficits 
To understand the aim of this review it is important to be aware of the outcomes of routine 
assessment in clinical neuropsychology and cognitive research. These include the long-term 
neurocognitive (for example deficits in memory, attention, executive functioning) and 
learning consequences (for the purposes of this thesis this is defined as difficulties in the 
acquisition of new information and/or impaired academic attainment) of brain tumours in a 
paediatric population. It is important to note that neurocognitive consequence impact on 
learning. Thus these deficits are reflected in assessments of cognitive functioning, academic 
attainment and intelligence quotient (IQ). Deficits in visual and motor difficulties, sensory 
impairments and auditory processing can result in difficulties with attention and speed of 
processing, which consequently can impact on academic attainment, particularly the 
learning of new information. 
 
1.1.1 Cognitive Functioning 
A brain tumour can have a profound impact since the development of a space occupying 
lesion, mass effect and its location can have implications for a patient’s neurocognitive 
profile (Iuvone et al, 2011). Additional secondary factors such as neurosurgery, 
chemotherapy and radiation therapy may also have an adverse effect on developing CNS 
and neurocognitive functioning (Moore, 2005). The prevalent neurocognitive impairments, 
which are routinely assessed in clinical neuropsychology and cognitive research include: 
altered processing speed, attention, executive functioning, memory, episodic and working 
memory (auditory and spatial) (Copeland, Moore, & Ater, 1999; Mabbott, Penkman, Witol, 
Strother, & Bouffet, 2008; Mulhern et al, 2001; Mulhern, et al 2004b). Table 1 outlines 
areas of clinical importance and impairments experienced by individuals as a consequence 
of paediatric brain tumours. Although the table examines each deficit individually, it is not  
15 
Table 1. Key aspects of cognitive functioning identified in routine clinical neuropsychology 
assessment and cognitive research of paediatric brain tumours population. 
Cognitive 
Functions 
Definition 
 
Executive 
Functioning  
 
 
Memory 
 
Executive functioning is a complex aspect of cognitive processing, 
which requires the co-ordination of several sub processes to achieve 
a particular goal. Examples include task switching and planning 
(Elliott, 2003). 
Memory involves the structures and processes involved in the 
storage and subsequent retrieval of information. Memory is 
involved in processing of information. This information takes many 
different forms, e.g. images, sounds or meaning. Memory can be 
separated into three separate stages: sensory, short-term, and long-
term (Matlin, 2005). 
Working 
Memory 
Working memory is a temporary storage and workspace in the brain. 
It is a system, which holds and processes moment-to-moment 
information before storing new knowledge in the long-term-
memory. It is important in higher order thinking, learning, and 
achievement. It is also important for cognitive flexibility and 
planning ability, as well as learning and the ability to self-monitor 
(Eysenck & Keane, 2005; Just & Carpenter, 1992). 
Attention Attention is considered the foundation of most cognitive and 
neuropsychological functions. It is the selectivity of processing: how 
we actively process specific information presented to us in our 
environment (Cooley & Morris, 1990; Eysenck & Keane, 2005). 
Processing 
Speed 
The speed at which cognitive processes can be carried out (Bull & 
Johnston, 1997).  
 
. 
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the intention to suggest that each component is neuropsychologically distinct from the 
others. 
 
1.1.2 Academic Attainment 
The learning consequences of paediatric brain tumours are often described in relation to 
academic attainment. These children may experience problems with handwriting, spelling, 
reading, vocabulary, mathematics, attention, ability to complete tasks on time, planning, 
organisation and problem-solving, with literacy and numeracy being the most common 
academic difficulties (Upton & Eiser, 2006). The term learning outcomes has to be treated 
with caution as the learning of new information is not just related to academic attainment, 
but will also affect IQ. In comparison to their healthy peers, the paediatric brain tumour 
population incur secondary consequences such as IQ loss and sub-optimal academic 
achievement (Mulhern & Butler, 2004). It is hypothesised that  learning impairments 
experienced by the paediatric brain tumour population are also closely associated with 
neurocognitive impairments (Mulhern & Butler, 2004).  
 
1.1.3 IQ 
Neurocognitive outcomes in many studies have been conceptualised primarily in terms of a 
measurement of the patient’s overall cognitive ability. This is presented as previously noted  
in an individual’s academic attainment and also in their IQ (Mulhern et al, 2004). 
Subsequently IQ loss has been demonstrated among this population (Mulhern & Butler, 
2004).  A number of studies, which are discussed in this introduction, have used IQ and 
academic achievement as identifiers for neurocognitive impairment, but it is important to 
note no causal relationships have been identified. Thus Dennis, Hetherington, and Spiegler 
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(1998) advocate an investigation of the impact on the “acquisition of knowledge” or the 
process by which children learn and acquire information over time, in addition to assessing 
“knowledge availability” in children. The authors suggest that cognitive deficits may be 
related to deficiencies in the basic processes by which knowledge is acquired. Levisohn, 
Cronin-Golomb, and Schmahmann (2000) suggest that numerous aspects of cognition, 
including attention and working memory, may underlie changes in IQ and academic 
performance. This is supported by Fry and Hale (2000) whose research using a healthy 
population found that almost half of developmental increases in IQ can be attributed to age 
related improvements in working memory and processing speed. They attribute the other to 
alternative forms of maturation, such as the changes in the frontal cortex during childhood 
and adolescence. Thus deficits in areas such as attention and memory may result in 
difficulties acquiring new information; the consequences of which are reflected in IQ and 
academic achievement. Hence, studies need to focus on how brain tumours and their 
treatment affect cognitive components, which are utilised in the acquisition of knowledge. 
Although the distinctions between these factors are important they remain outside of the 
scope of this thesis. 
1.2 Tumour Type and Known Deficits 
As already noted, the degree and type of impairment is dependent upon various factors 
including the type, location, size, invasiveness and treatment performed  (Nejat, El Khashab, 
& Rutka, 2008). For example, Figure 1 demonstrates the varied presentations of patients 
depending upon only the type and location of the brain tumour. Image A illustrates a child 
with a diagnosis of a medulloblastoma who presented with a brief history of nausea, 
vomiting and headaches; this is also associated with memory and attention deficits 
(Crawford, MacDonald, & Packer, 2007). Image B presents a craniopharyngioma (midline 
suprasellar mass lesion with invagination into the third ventricle); this patient presented with 
18 
progressive visual loss and headaches. The neurocognitive deficits associated with this 
tumour include processing speed and memory (Carpentieri et al, 2001; Thompson, Phipps, 
& Hayward, 2005). Image C presents an ependymoblastoma. This patient had a brief history 
of seizures, leg weakness and cognitive impairments to attention and memory (Maksoud, 
Hahn, & Engelhard, 2002). Finally, Image D demonstrates a third ventricular 
pineoblastoma, symptoms included a history of vomiting and headaches and non-specified 
cognitive deficits (Jakacki et al, 1995; Nejat et al., 2008).  
 
Figure 1. Sagittal magnetic resonance images of paediatric brain tumours in different brain 
regions (Nejat et al, 2008)  reproduced with permission. 
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Most paediatric tumours are located within the posterior fossa, particularly in patients 
diagnosed under the age of ten years (Muzumdar, Mahore, Balasubramaniam, & Goel, 
2009).  The posterior fossa is a small space located near the brain steam and the cerebellum, 
as demonstrated in Figure 2. This area is mainly concerned with the maintenance of 
consciousness, respiration, pulse, blood pressure, facial expression and sensations, hearing 
and swallowing mechanisms (Muzumdar et al, 2009). Tumours in this area are at risk of 
blocking the flow of spinal fluid, resulting in increased pressure on the brain and the spinal 
cord due to limited space  (Muzumdar et al, 2009). There are also increasing concerns about 
tumours in the posterior fossa and damage to the cerebellum, which has been noted to 
modulate mental and social functions (Riva & Giorgi, 2000; Schmahmann, 2013). Tumours 
in the posterior fossa can have implications for severe disability in the areas of  hemiparesis, 
speech disorders and facial or ocular muscle palsies, and can lead to hydrocephalus and 
mortality (Muzumdar et al, 2009). 
Figure 2. Posterior fossa ependymoma in an 11-month-old female infant (Vázquez et al, 
2011) reproduced with permission. 
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Brain tumours can occur in different locations, in addition to this there are different types of 
brain tumours. The World Health Organisation has published a classification system for 
tumours of the central nervous system according to their location and histology (Louis et al, 
2007). The most common tumours are supratentorial low-grade tumours, medulloblastoma, 
brain stem glioma, cerebellar astrocytomas, supratentorial high-grade tumours, and 
craniopharyngioma (Strother et al, 2002). However, the most frequent diagnosed malignant 
brain tumour among paediatric patients is that of a medulloblastoma, these account for 10-
20% of all paediatric brain tumours (Dhall, 2009; Whelan, Krouwer, Schmidt, Reichert, & 
Kovnar, 1998). The most prevalent brain tumours and their deficits are displayed in Table 2. 
 
Table 2 demonstrates that each type of tumour can result in a variety of neurocognitive, 
psychological and learning deficits. Furthermore, it illustrates the difficulties in determining 
which factors (location, type and treatment) may account for neurocognitive and learning 
deficits. Evidence suggests that other factors in addition to tumour type (moderating factors) 
may also account for the deficits; these additional factors will be discussed later in this 
introduction. 
 
Although it can be difficult to identify the origin of a deficit, the literature suggests that 
deficits may be a consequence of damage to the cortical and subcortical white matter 
(Moore, 2005; Mulhern et al, 2004b). To further understand the neurocognitive 
consequences of brain tumours, it is important to understand how the brain develops and the 
possible impact that the treatment of paediatric tumours may have on the brain. 
 
 
Tumour Location in the 
brain 
Frequency in Paediatric 
Population 
Interventions Deficits References 
Medulloblastoma Infratentorial 
compartment. 
Tend to be invasive of 
normal cerebellar 
tissue. 
15-25% of paediatric brain 
tumours most frequently 
occur between 3and 4 years 
and 8and 9 years. 
Surgical resection and radiotherapy are an essential part of 
treatment (radiotherapy is either delayed or not given to 
children under the age of three). 
Chemotherapy is used selectively. 
Attention, memory, particularly relating to visual and 
sustained attention, verbal/spatial memory, nonverbal 
abstract thinking, verbal abstract thinking, processing speed, 
executive functioning and language deficits. 
Impact on quality of life. 
Lower academic achievement scores, lower IQ.  
(Crawford et al, 2007; Edelstein, 
Spiegler, Fung, Panzarella, Mabbott, 
Jewitt, D'Agostino, Mason, Bouffet, & 
Tabori, 2011; Modha et al, 2000;  
Mulhern & Butler, 2004;  Mulhern et al, 
2001; Nejat et al, 2008; Ribi et al, 2005; 
Rutka & Kuo, 2004; Whelan et al, 1998). 
 
Ependymoma 
 
Infratentorial 
compartment. 
70% occur in the 
posterior fossa. 
 
 
2-9% of central nervous 
system tumours in this age 
category. 
Peak incident from birth to 4 
years. 
Surgical resection identified as the best cure. However, only 
30-50% can be completely resected. 
Usually require radiotherapy. Chemotherapy is given to 
younger children as a substitute for radiotherapy. 
Attention and visuospatial memory impairments. 
Modest declines in reading, significantly lower IQs, lower 
nonverbal intellectual functioning, lower academic skills in 
writing and math, and impairments in visual–motor abilities. 
(Di Pinto, Conklin, Li, Xiong, & 
Merchant, 2010; Figarella-Branger et al, 
2000; Maksoud et al, 2002; Nejat et al, 
2008) 
Craniopharyngioma Supratentorial. 
Usually occur in the 
Suprasellar region from 
epithelial remnants of 
the Rathke’s pouch. 
Most common intracranial 
tumour of childhood (2.5 -9 
%). 
Peak incident 5-9 years. 
 
Managed with a single shunting system in conjunction with 
endoscopic fenestration of the septum pellucidum. 
Resection of the tumour can be undertaken after the 
ventricles have been decompressed and the patient has been 
stabilized. 
However, the resection must be fully cognizant of the 
critical location of the tumour adjacent to the optic 
apparatus, pituitary gland and stalk, hypothalamus, and 
vessels of the circle of Willis. Stereotactic radiosurgery and 
fractionated radiotherapy are increasingly being used. 
Memory recall decreased manual dexterity, spatial working 
memory, processing speed, language processing and verbal 
memory deficits.  
 
(Carpentieri et al, 2001; Cavazzuti, 
Fischer, Welch, Belli, & Winston, 1983; 
Kalapurakal, 2005; Nejat et al, 2008;  
Thompson et al., 2005; Waber et al, 
2006) 
Table 2.  Paediatric Brain Tumours and associated deficits 
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1.3 Development of the Brain 
The process of neurodevelopment starts soon after conception (DeAngelis, 2000). The 
brain develops sequentially, with the more primitive areas of the brain developing before 
the more sophisticated sections (Perry, 2000). The first areas of the brain to fully 
develop are the brainstem and midbrain, which govern the bodily functions necessary for 
life. At birth, the lower portions of the CNS are very well developed, whereas the higher 
regions (the limbic system and cerebral cortex) are still rather primitive (Perry, 2000). 
The major structures of the brain are well formed by the time of birth, but development 
continues for at least twenty years (Chamley, Carson, Randal, & Sandwell, 2005). From 
birth to five years the cerebral cortex develops rapidly. Throughout this period the 
volume of the brain changes, grey matter volume decreases (grey matter processes 
information involved in muscle control, sensory perception such as seeing and hearing, 
memory, emotions, and speech) and white matter increases (i.e. myelination) (Toga, 
Thompson, & Sowell, In press). Myelination occurs rapidly during the first two years of 
life, particularly in the prefrontal cortex; it then continues slowly until adolescence 
(Casey, Giedd, & Thomas, 2000; Chamley et al, 2005).  
  
White matter has an important function: it facilitates speed and transmission of 
information throughout the brain, thus the structural integrity and maturity of white 
matter pathways are important for enabling a smooth flow of information (Paus, 2005) – 
see Figure 3. The frontal and prefrontal lobes are the last areas of the brain to finish 
myelination. These areas are used for a variety of functions, most particularly, executive 
functioning, which involves the planning and organisation of behaviour, as well as the 
allocation of attention (Paus, 2005). O’Sullivan et al. (2001) has demonstrated diffusion-
related changes in normal white matter that correlate with executive functioning. 
Damage to this area could explain deficits relating to attention, as identified in the 
research literature (Steinlin et al, 2003).  
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Figure 3. Myelin (the protective nerve coating around nerve axons) degradation hinders 
the flow of information within the brain and between the brain and body. (Figure 3 from 
Image © 2009 RelayHealth and/or its affiliates is reproduced with permission.) 
 
 
 
It is postulated that the long-term effects of treatment on white matter result in cognitive 
deficits, as treatment diminishes an individual’s ability to acquire new information, 
rather than a loss of previously learnt information (Palmer et al, 2001). This may be 
secondary to other cognitive processing impairments, including deficits in attention, 
short-term memory, speed of processing, visual-motor coordination and sequencing 
abilities, all of which are supported by white matter tracks (Reddick et al, 2003). 
Reddick et al. (2003) Highlight the importance and implications that a reduction in white 
matter has on neurocognitive functioning. A further model developmental model (Figure 
4) by Reddick et al. (2003) also highlights the relationship between a decreasing normal-
appearing white matter volume and deficits in attention, which are reflected in 
intelligence scores and below average academic achievement. 
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Figure 4. Proposed developmental model of the relationship between normal-appearing 
white matter (NAWM), attention, memory, intelligence (Full Scale IQ (FSIQ) and 
academic achievement (Reddick et al, 2003) reproduced with permission 
 
 
1.3.1 Plasticity and the Early Vulnerability Hypothesis 
Evidence for the importance of early development in the brain emphasises the potential 
hazard for children with a space-occupying lesion who receive neurosurgery, 
chemotherapy and radiotherapy interventions to the brain. However, research has 
identified that the brain may be able to adjust to the potential damage from a tumour or 
treatment for a brain tumour and continue functioning appropriately (Davis, 2010). Two 
competing theories of age-based plasticity and the early vulnerability hypothesis present 
competing perspectives which may explain the cognitive presentations of children with a 
brain tumour in comparison to adults who have similar pathological conditions but have 
severe cognitive dysfunction (Davis, 2010; Dennis, 2000).  
 
1.3.1.1 Early Vulnerability Hypothesis 
 
Current paediatric neurooncology literature suggests that patients who are of a younger 
age when they start treatment will have poorer outcomes than those who are treated later 
in their childhood, due to the vulnerability of the brain during the early stages of 
25 
development (Dennis, 2000; Mulhern, Hancock, Fairclough, & Kun, 1992). Thus 
treatment can be potentially detrimental to the brain’s development. The early 
vulnerability hypothesis suggests that cognitive development is dependent on the 
integrity of a particular cerebral structure at specific stages of development. Therefore, if 
a specific cerebral region is damaged at a critical stage of development it may have 
adverse consequences for cognitive development (Luciana, 2003). 
 
1.3.1.2 Age-Based Plasticity 
 
Further literature indicates that children with an CNS lesion who are given treatment at 
an earlier age will perform better on neuropsychological tasks than those who receive 
treatment later in life (age-based plasticity) (Dennis, 2000). Neuroplasticity suggests that 
the brain can adapt to impairment, as a young brain is immature and less susceptible to 
the impact of cerebral damage. Plasticity is thought to be at a prime stage during early 
development when the central nervous system is less rigidly specialised and synapses 
and dendritic connections remain unspecified (Huttenlocher & Dabholkar, 1997). 
Similarly in a traumatic brain injury population, Anderson et al. (2009) hypothesise that 
in a the flexibility of the brain enables functions to be reorganised and transferred from 
damaged brain tissue to healthy brain tissue. Traumatic brain injury, an injury to the 
brain caused by an external force after birth and acquired brain injury, which include all 
types of traumatic brain injuries and also brain injuries caused after birth by cerebral 
vascular accidents. These are often areas of greater research and can help to inform 
neurooncology findings due to the similarities in presentation and deficits. 
 
The patient’s age/stage of development at the time of treatment is an important factor; it 
has shown to be a moderating factor in the development of cognitive and learning 
deficits not only in relation to the age-based plasticity and early vulnerability hypothesis. 
Research has also shown that neurocognitive impairments may manifest in later life 
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rather than in childhood (Spiegler, Bouffet, Greenberg, Rutka, & Mabbott, 2004). The 
impact of the time since treatment will be discussed later in this review. 
 
 
 
1.4 Primary Interventions 
Alternative hypotheses such as hippocampal neurogenesis (Monje et al, 2007 & Monje 
et al 2012) can be considered as a causative factor in cognitive impairments in a brain 
tumour population. The literature on brain development identifies white matter 
degradation as a key factor in the development of neurocognitive and learning deficits. 
Therefore, it is essential that potential origins of white matter degradation, such as the 
interventions for paediatric brain tumours be considered. The armamentarium currently 
used to treat tumours of the CNS include: neurosurgery, chemotherapy and radiotherapy; 
these can be used independently or in combination. Only a small proportion of tumours 
are treated with surgery alone (Iuvone et al, 2011). The extent, quantity and types of 
these interventions are dependent upon the progression, location and type of tumour 
(Moore, 2005).  
 
The development of effective interventions at the acute phase of treatment for paediatric 
brain tumours is not without problems as clinicians attempt to maintain a balance 
between the effectiveness of interventions and acceptable toxicity. For example, high 
doses of chemotherapy, radiotherapy and less conservative neurosurgery have been 
associated with reduced cancer progression, but with severe morbidity due to changes in 
white matter volume (Moore, 2005).  
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1.4.1 Neurosurgery  
The presence of a brain tumour can potentially have a significant impact on a patient's 
functioning and can be the principle determinant of cognitive deficits, particularly those 
located in the cortex (Iuvone et al, 2011). The resection of a tumour without any 
additional interventions has been demonstrated to have a significant impact on 
processing speed, attention, memory and visual-constructive copying (Steinlin et al, 
2003).   
 
Recent evidence suggests the site of the tumour appears to be the best predictor of 
cognitive deficits. Iuvone et al. (2011) Identified patients with tumours in the 
supratentorial hemisphere to be at greater risk; this contradicts other studies which 
propose there is greater risk to those with hemispheric tumours (Mulhern & Butler, 
2004). As well as finding the site of the tumour to be an appropriate predictor of risk, 
Iuvone et al. (2011) found that the dimension of the tumour and tumour related factors 
(perilesional oedema, compartment/localized hypertension, and hydrocephalus) had a 
greater impact on IQ impairment than tumour location.  
 
Patients can undergo numerous surgical resections during the course of their treatment; 
this indicates the potential for further damage. In a study by Young and Johnston (2004) 
exploring the treatment of eighteen patients for paediatric brain tumours, surgical 
resection was attempted in all patients, second-look surgery in four patients and  
ventriculoperitoneal  shunts  were inserted in two patients. Within this study a total of 
twenty-four operations were performed, illustrating the extensive use of surgery in this 
population.  
 
A limited number of tumours (low-grade) require only neurosurgery. Therefore this 
poses a challenge in identifying the implications of neurosurgery alone on cognition and 
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learning.  Iuvone et al. (2011) Suggests that initial screening for pre-existing 
neurocognitive impairments should not be neglected, as prior assessment could help to 
provide a baseline for assessing the true neurological impact of surgery and other 
interventions. However, in clinical settings this is not always possible due to resources, 
time and the patients’ presentation, which may preclude initial screening. Hence, 
services have to rely on clinical interviews, which emphasise premorbid presentation. 
 
1.4.2 Radiotherapy 
Radiotherapy is an integral part of treatment for many paediatric brain tumours. The 
method by which radiotherapy is delivered varies. Differences include changes in the 
dose of radiation, the size and shape of the radiation beams and the number of treatment 
sessions given to the patient. With advancements in imaging and computing, different 
forms of radiotherapy are becoming available; photon and proton beam radiotherapy are 
currently being used in the paediatric brain tumour population (Yock & Tarbell, 2004). 
  
1.4.2.1 Armamentarium of Radiotherapy 
 
The most common forms of radiotherapy include: conventional x-ray radiation (photon), 
intensity-modulated radiation therapy, stereotactic radiosurgery (gamma knife) and 
proton therapy (Taylor & Maughan, 2010). 
 
Conventional two-dimensional x-ray radiation (photon) is the most common form of 
radiotherapy. External photon beams are directed at the tumour using a medical linear 
accelerator, delivering beams from different angles, which converge on the tumour 
(Taylor & Maughan, 2010). The area around the tumour is also treated to ensure the 
whole tumour is irradiated. However, due to the application of this method, doses are 
kept at a lower level ensuring minimal exposure for healthy tissue surrounding the 
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tumour (Taylor & Maughan, 2010). The superiority of dose distributions has resulted in 
reduced neurocognitive implications (Taylor & Maughan, 2010; Yock & Tarbell, 2004). 
 
Intensity-modulated radiation therapy enables clinicians to shape the radiation beams to 
the three-dimensional shape of the tumour. The radiation is delivered from different 
angles, allowing the dose of radiotherapy to be variable dependent upon more 
metabolically active parts of the tumour. This results in a more precise form of 
radiotherapy, which can deliver a stronger more effective intervention with greater 
protection of surrounding healthy tissue (Taylor & Maughan, 2010).    
 
Stereotactic radiosurgery (gamma knife) is a tool, which focuses thousands of high 
intensity gamma radiations directly onto the tumour without affecting the healthy tissue 
around the tumour. Individually, each radiation beam is too weak to damage healthy 
tissue but when focused precisely on the tumour, the beams intersect and the combined 
radiation is sufficient to treat the targeted area (Taylor & Maughan, 2010). 
 
Proton therapy uses a three-dimensional approach to precisely target tumour cells 
(Taylor & Maughan, 2010). Protons are different from photons because they travel in a 
straight line until the energy is deposited at an end target (Merchant et al, 2008). This 
results in a radiation scatter, which significantly reduces side effects and complications. 
Consequently, this reduces the incidence of late mortality and reduces the risk of 
secondary malignancies from the radiation treatment itself (Merchant et al, 2008). 
 
With the exception of photon radiotherapy each type represents advanced and precise 
forms of radiotherapy which attempt to focus more directly on the tumour with minimal 
affect to surrounding healthy tissue (Taylor & Maughan, 2010). In comparison to 
30 
photons, proton beam radiotherapy, a newer and not widely available intervention, aims 
to improve outcomes (Yock & Tarbell, 2004).  
 
1.4.2.2 Limitations of Radiotherapy 
 
Despite these advancements and the advantages of proton beam radiotherapy, it will take 
years of follow-up research into children who have been treated with protons to confirm 
the benefits of this modality (Merchant et al, 2008). Daw and Mahajan (2013) Concur 
that clinical trials with long-term follow-up are needed to confirm effectiveness of 
proton therapy. It is also important to note that a systematic review of the clinical 
effectiveness of proton therapy has demonstrated that the evidence for the clinical 
efficacy of this treatment relies on non-control studies (Olsen, Bruland, Frykholm, & 
Norderhaug, 2007). For paediatric neurooncology populations, all of the studies 
evidenced were case series and offered no comparison to other treatment strategies 
(Olsen et al, 2007). Therefore, results should be interpreted with caution in regard to the 
effectiveness of this treatment (Brada, Pijls-Johannesma, & De Ruysscher, 2007).  
 
Further limitations of radiotherapy include a risk of secondary malignancies, particularly 
in children (Yock & Tarbell, 2004). Evidence also supports radiation therapy as a 
contributing factor to neurocognitive impairment; deficits include impaired short-term 
memory, working memory, attention span and processing speed (Hoffman & Yock, 
2009; Mabbott et al, 2008; Ris & Noll, 1994; Ullrich, 2009). 
 
In general, the long-term effects of radiation therapy are found to be age-dependent: the 
younger the child is at the time of radiation therapy, the greater the cognitive deficits 
(Prados & Russo, 1998). This may be a consequence of brain immaturity and on-going 
development during the early formative years of a child’s life, when areas of the cortex 
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associated with cognitive functions remain vulnerable to neurotoxins (Moore, 2005). 
Recognising these consequences, children under three years of age pose a challenge to 
treat, as craniospinal irradiation is typically not administered due to the increased risk of 
neurocognitive deficits (Gottardo & Gajjar, 2008). Clinicians in Europe are reluctant to 
irradiate the brain prior to 36 months of age in order to allow for further brain 
development, with the aim of reducing neurocognitive impairment (Davis, 2010). 
However, clinicians in the United States of America offer radiation therapy prior to 36 
months, despite evidence of cognitive dysfunction (Davis, 2010). Mulhern et al. (2004b) 
have emphasised that longitudinal studies consistently demonstrate significant declines 
in IQ over time in patients treated with craniospinal radiotherapy for a medulloblastoma, 
compared to other forms of intervention, which demonstrate less severe deficits in IQ. 
For example, individuals treated for low-grade astrocytoma by surgery alone 
demonstrated less severe deficits in IQ. Significant declines in IQ should be 
investigated, as a healthy child’s IQ is not expected to change significantly over time; 
changes in IQ may possibly indicate cognitive impairment (Meadows et al, 1981;  
Mulhern et al, 2004).  
 
The main cognitive processes, which underlie IQ, consist of processing speed, working 
memory, executive functioning and attention. Declines in IQ can be associated with 
cognitive impairment. Indicators of this can be difficulties with numerical 
ability/arithmetic, comprehension, memory and processing (Mulhern et al, 2004). Other 
possible factors for declines in IQ can include socioeconomic factors, lack of schooling 
and other medical conditions such as hydrocephalus. 
 
It has been hypothesised that a decline in neurocognitive functioning and IQ may be 
linked to the loss of cerebral white matter and a failure to develop white matter at an 
adequate rate in relation to the child’s development (Mulhern et al, 2004). As previously 
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noted, one of the functions of white matter is to increase axonal conduction velocity, 
which facilitates information flow through the brain. Moore, Copeland, Ried, and 
Kopecky (1992) suggested that radiation therapy may impede neuronal transmission 
speed, resulting in slower and disorganised cognitive processing. Including 
neuropsychological toxicity, other serious complications are recognised in the literature, 
such as hormone deficiencies, growth retardation and secondary malignancies (Butler & 
Mulhern, 2005). 
 
However, it is important to note that in the majority of studies exploring cognitive and 
learning impairments post radiotherapy, neuropsychological testing was limited to IQ 
measurements; hence, this may have obscured the possible presence of specific deficits 
of cognitive functions. Iuvone et al. (2011) Evaluation of different cognitive functions 
pre-surgery, demonstrate that cognitive deficits can be found in patients with normal 
IQs; therefore, other assessments should be conducted to control for this possibility. 
Moreover, it is important to be mindful that other factors can be attributed to a decline in 
IQ, such as hydrocephalus (Mulhern et al, 2004). 
 
1.4.3 Chemotherapy  
Chemotherapy is a form or combination of medication, which interrupts the chemical 
process of cell division by damaging the genes inside the nucleus of the cells (Childhood 
Cancer Statistics, 2014). Historically brain tumours were treated by neurosurgery, 
followed by radiotherapy (Prados & Russo, 1998). However, because of the 
vulnerability of the brain both of these interventions are limited and researchers have 
sought methods to delay irradiation to allow for further brain development (Kedar, 
1997). Chemotherapy remains an important part of treatment in the paediatric brain 
tumour population. It allows for a reduction or absence of radiotherapy in patients and 
has been found to increase the disease-free survival in primitive neuroectodermal 
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tumour/medulloblastoma patients (Kedar, 1997). In comparison to radiotherapy, 
chemotherapy is not typically associated with the same levels of toxicity; this is 
particularly important for the treatment of younger children as delaying radiotherapy can 
potentially limit neurocognitive and learning impairments in the developing brain 
(Duffner et al, 1993).  
 
Table 3 demonstrates the varied forms of chemotherapy interventions for paediatric 
brain tumours and the combinations in which they are used to increase disease-free 
survival in patients.  
 
However, it is important to recognise the benefit of using chemotherapy in conjunction 
with other forms of treatment, including neurosurgery and radiotherapy. For example, in 
the results reported in the Medulloblastoma section of Table 3, the patients were given 
adjuvant chemotherapy (following craniospinal irradiation) which facilitated a reduced-
dose radiotherapy (Gottardo & Gajjar, 2008). Table 3 and additional studies also 
demonstrate achievements in the outcomes of studies into children treated for 
Medulloblastoma, however these achievements have been offset by a lack of progress in 
those treated for high-grade glioma (Gottardo & Gajjar, 2008). Furthermore, some forms 
of this intervention still struggle to conquer the challenges faced from neurotoxicity 
(Grill & Bhangoo, 2007). A strong relationship between neurocognitive deficits and the 
types of chemotherapy, for example, the use of intrathecal (method of delivery) 
methotrexate particularly in conjunction with whole brain radiation therapy, has been 
reported to correlate with neurocognitive deficits (Ris & Noll, 1994). 
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Table 3. Chemotherapy Interventions for Paediatric Brain Tumour Populations (Kedar, 
1997; Prados & Russo, 1998). 
Tumour type  Type of chemotherapy Results of previous 
studies 
Ependymoma Combination 
(Cyclophosphamide & 
vincristine) 
Significant response to 
chemotherapy in the 
paediatric studies  
Medulloblastoma A combination of Cisplatin, 
Etoposide, Vincristine, 
Cyclophosphamide, 
Carboplatin and 
Methotrexate. 
Medulloblastoma is one of 
the most chemosensitive 
childhood brain tumours. 
Standard care for 
Medulloblastoma. 
High-grade Glioma Combination (1-(2-
chlorethyl-3-cyclohexyl-1-
nitrosourea (CCNU), 
Vincristine & Prednisone), 
(CCNU & Vincristine) and 
Procarbazine or Topotecan. 
Some sensitivity to 
chemotherapy 
Brainstem Glioma Vincristine, Carboplatin, 
Cyclophosphamide and 
combination 
(Cyclophosphamide & 
Thiotepa) 
A minority of patients with 
a brainstem glioma respond 
to chemotherapy 
Low-Grade Glioma Combination (Actinomycin-
D & Vincristine), (6-
thioguanine, Procarbazine, 
Dibromodulcitol, BCNU & 
Vincristine) and 
(Carboplatin & Vincristine) 
Subset of low-grade glioma 
that respond well to 
chemotherapy 
 
 
Due to the toxic nature of chemotherapy, not only are malignant cells affected, but it can 
also have adverse effects on healthy tissue. The degree of damage depends upon the 
cumulative dose. Common side-effects include alopecia, anaemia, thrombocytopenia, 
granulocytopenia, nausea, vomiting, gastrointestinal side-effects, hypersensitivity 
reactions, organ damage and neurocognitive effects (Kedar, 1997). Common 
neurocognitive effects include deficits in working memory and processing speed 
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(Mabbott et al, 2008). For example, Edelstein, Spiegler, Fung, Panzarella, Mabbott, 
Jewitt, D'Agostino, Mason, Bouffet, Tabori, et al. (2011) explored the neurocognitive 
effects on patients treated for medulloblastoma as a child. The results of this study 
indicate an association between age at diagnosis and poorer IQ and academic 
achievement scores, the youngest being the worst affected. Furthermore, a decline in 
working memory regardless of age at diagnosis was noted. This longitudinal study 
identified the significant later life impairments chemotherapy had on educational and 
occupational attainment. A criticism of much of the literature based on both 
chemotherapy and radiation therapy studies, is that they fail to account for any 
evaluations of pre-treatment neurocognitive deficits; as previously noted, this makes it 
difficult to exclude any prior neurological effects.   
 
Despite the evidence for neurocognitive deficits, chemotherapy has shown to be an 
effective intervention which can delay or prevent the use of radiation therapy for some 
brain tumours, sparing the developing brain from further neurotoxicity; as previously 
noted, damage to cortical and subcortical white matter has been identified as a precursor 
to neurocognitive dysfunction in this population (Paus, 2005). Figure 5 demonstrates a 
decline in white matter and the deficits associated with this decline post-chemotherapy 
in an individual being treated for a primary central nervous system lymphoma 
(Drappatz, Schiff, Kesari, Norden, & Wen, 2007). The left image shows normal white 
matter and the right image, white matter three months later, after six doses of high-dose 
methotrexate. This highlights the development of confluent abnormal T2 hyperintensity 
in the subcortical and periventricular white matter, extending into the internal capsules 
bilaterally with preservation of the corpus callosum. The patient was symptomatic with 
memory loss, inattention, and word-finding difficulties. 
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Figure 5. Highlights a decline in white matter pre and post chemotherapy. (Figure 5 
from Drappatz et al. (2007) reproduced with permission.) 
 
 
1.5 Survivorship and Wellbeing 
Evidence for the neurocognitive and learning consequences of paediatric brain tumours 
indicates that these deficits may also have further negative implications. Neurocognitive 
deficits and learning impairments have been found to impact on both individual 
functioning and quality of survival (QOS), which has consequences for an individual’s 
psychological wellbeing. A continuum of psychological problems has been observed, 
these include: behavioural problems, maladjustment, depressive and anxiety symptoms, 
and poor self-conception of significant emotional dysregulation and severe mental 
illness, including short-term or long-term personality disturbance and psychosis (Turner 
et al, 2009). Turner et al. (2009) highlight the implications of developmental factors as 
patients fail to adapt to developmental challenges, which can emerge when children 
perform increasingly complex tasks at an independent level. This is supported by 
research that suggests a negative association between time since diagnosis and overall 
adjustment (Mulhern, Kovnar, Kun, Crisco, & Williams, 1988; Seaver et al, 1994). 
However, a study by Lannering, Marky, Lundberg, and Olsson (1990), exploring long-
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term survivors of paediatric brain tumours, found self-reported QOS was not related to 
the degree of disability. Those who reported psychological/emotional dysfunction (14%) 
also evaluated their QOS lower than patients with other aspects of long-term sequence, 
which included cognitive, hormonal, motor and visual dysfunction. Although these 
psychological factors are of importance, this thesis will focus only on neurocognitive 
and learning consequences of paediatric brain tumours. 
  
1.6 Moderators 
A variety of other factors have also been associated with neuropsychological 
consequences of children undergoing treatment for brain tumours, for example tumour 
location, the gender of the patient, and neurological complications. The most prominent 
literature is associated with the factors of age and time since treatment. 
 
 
1.6.1 Age 
More pronounced cognitive deficits have been associated with younger neurooncology 
patients. Literature suggests that there is an inverse relationship between younger 
children and neuropsychological and neurobiological severities (Moore, 2005).  Younger 
children have been associated with lower cognitive scores in comparison to children 
who were older at the time of treatment (Aarsen et al, 2009; Mulhern & Butler, 2004). 
Mulhern et al. (2001) found significant associations between age and neurocognitive 
performance among survivors of childhood medulloblastoma. They identified that the 
younger the patient’s age at the time of therapy, and the longer the duration since 
craniospinal irradiation, resulted in further neurocognitive impairment. In comparison, 
Levisohn et al. (2000)  identified that younger age is associated with a more favourable 
cognitive outcome which may reflect the neural plasticity of the brain, analogous to the 
recovery of language following left-hemispherectomy. However, there are a limited 
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number of studies demonstrating this result in comparison to more impaired cognitive 
outcomes.  
 
Research indicates that six years of age is a sensitive period for determining 
neuropsychological outcome during radiotherapy (George et al, 2003; Palmer et al., 
2003; Palmer et al, 2001). However, Steinlin et al. (2003) suggest five to ten years as a 
more vulnerable age range for those at risk of neurocognitive sequelae, and Iuvone et al. 
(2011) conclude that it is unclear if young age is a main risk factor for cognitive deficits 
at diagnosis. Levisohn et al. (2000) suggest that these findings may be a consequence of 
tumour type, as the diagnosis of a medulloblastoma is uncommon in younger children 
and would reflect greater impairment. It is important to note that this may have been a 
representation of Levisohn et al. (2000) patinet sample, as other research suggets it is the 
most common malignant tumour in a peadiatirc population with The frequency peak is 
under five years of age (Miller 1968).  The findings may also reflect a lack of sensitivity 
of neuropsychological testing or that the functional domains in which older children 
experience difficulty (initiation and organisation of speech and visual-spatial 
organisation skills) do not make large developmental gains between the ages of seven 
and eleven years (Levisohn et al, 2000).  
 
With regard to possible explanations of age being a contributing factor to neurocognitive 
deficit; Mulhern et al. (2001) hypothesised that the impact of age during treatment may 
be associated with normal appearing white matter. As previously noted a reduction in 
white matter may result in cognitive deficits, as it diminishes an individual’s ability to 
acquire new information rather than a loss of previously learnt information (Palmer et al, 
2001) . Therefore patients who are younger when they receive treatment may struggle to 
acquire new information in comparison to older children. However, Mulhern et al. 
(2001) research does not support Reddick et al. (2003)  developmental model of a 
relationship between normal appearing white matter and attention, memory, intelligence 
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and academic achievement (Figure 4).  Mulhern et al. (2001) findings could not be 
attributed to memory and attention, only factual information, verbal abstract thinking 
and non-verbal abstract thinking. 
 
1.6.2 Time since Treatment 
Both longitudinal and cross-sectional studies have identified that cognitive functioning 
declines with increasing time since treatment, suggesting that injury may have an effect 
on on-going development with increasing deficits emerging as childhood progresses 
(Mulhern et al, 2004; Mulhern et al, 2001; Spiegler et al, 2004). This has been termed in 
a traumatic brain injury population as  ‘growing into deficit’ (Middleton, 2001). 
Similarly in neurooncology populations Spiegler et al. (2004) suggest that intellect, 
processing speed and visual memory decline as time from diagnosis increases, in 
patients treated for posterior fossa tumours. In support of this, Hoffman and Yock (2009) 
note that IQ continues to decline for a number of years after the completion of treatment. 
Typically, the adverse effects of an intervention have been noted for around one to two 
years post-therapy in neurooncology patients (Butler & Mulhern, 2005). However, 
further studies have demonstrated these effects continue for up to ten years post-
intervention (Edelstein, Spiegler, Fung, Panzarella, Mabbott, Jewitt, D'Agostino, Mason, 
Bouffet, Tabori, et al, 2011; Hoppe-Hirsch et al, 1995).  
 
It is hypothesised that these long-term effects are the result of changes to the structure of 
the brain, in particular the white matter, vasculature and cortical thickness. This can 
adversely effect a child’s ability to acquire skills at the same rate as their peers 
(Edelstein, Spiegler, Fung, Panzarella, Mabbott, Jewitt, D'Agostino, Mason, Bouffet, 
Tabori, et al, 2011). Hoffman and Yock (2009) warn that the impairment of tissue 
growth, development and function are not the only consequences and they suggest that 
over time radiation therapy can also induce secondary cancers.  
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1.6.3 Resilience 
In addition to moderating factors that explain risk and vulnerability, there are also 
factors of resilience that account for results that do not conform to likely trends for 
neurocognitive morbidity.   
  
1.6.3.1 Cognitive Reserve  
 
A reserve against impairment originates from the idea that there does not appear to be a 
direct link between the degree of brain pathology and the clinical manifestation of that 
damage (Stern, 2002). Literature regarding cognitive reserve focuses on two concepts, 
passive and active models. Although these models are described in relation to aspects of 
the patient which can be protective against the effect of biological risk, it is also 
important to state that they can also enhance biological risk (Dennis, 2000). 
 
1.6.3.2 Passive Models 
 
Passive models such as brain reserve, threshold and neuronal, are defined in terms of the 
amount of damage that can be sustained before reaching a threshold for clinical 
expression (Stern, 2002). The threshold model recognises the construct of brain reserve 
capacity. It believes that once individual limits of clinical threshold have been attained, 
and brain reserve capacity is depleted past this threshold, specific clinical or functional 
deficits emerge (Satz, 1993). Therefore greater brain reserve capacity may be seen as a 
protective factor, since an individual may not experience cognitive deficits because their 
capacity has not been exceeded in comparison to an individual with the same tumour 
whose brain reserve capacity has been exceeded.  
 
However, it is important to note that the passive models do not account for individual 
differences in how the brain processes cognitive tasks after impairment. They also do 
not address potential qualitative differences between the consequences of different types 
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of brain tumours (Stern, 2002). This suggests the model alone does not explain all 
aspects of reserve. 
1.6.3.3 Active Models 
 
Stern (2002) suggests that there are two types of active models that explain how the 
brain actively attempts to compensate for neurological damage, these are cognitive 
reserve and compensation models. Cognitive reserve proposes that the brain utilises 
brain networks that are less susceptible to disruption, processing tasks in a more efficient 
manner. The cognitive reserve model also does not assume that patients with the same 
tumour type and location will have similar presentations. Because of individual 
variability in how they cope with the tumour, the same amount of damage will have 
different effects on different people. In comparison, the second model is the 
compensation model, which suggests that patients learn to use brain networks that are 
not normally used by individuals with intact brains, in order to compensate for brain 
damage (Stern, 2002). 
 
 
 
1.7 Aims and Objectives of the Systematic Review 
In consideration of the evidence for neurocognitive and learning deficits described 
above, a systematic review of the effectiveness of interventions (pharmaceutical and 
psychosocial) for cognitive and learning impairment, within a paediatric population 
following the diagnosis of a brain tumour, will be undertaken. This will be addressed via 
a systematic review and meta-analysis (if it is appropriate to integrate the data 
statistically) methodology. Additionally, the implications of this literature on clinical 
and research practice will be addressed in the discussion: 
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 Research Question 1: How effective are interventions (pharmaceutical and 
psychosocial) for cognitive and learning impairment of paediatric patients with 
brain tumours?  
 
 Research Question 2: What are the implications of the literature for clinical and 
research practice? 
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CHAPTER TWO: SCOPING 
 
The Armstrong, Hall, Doyle & Waters (2011) paper has been used as a guide to inform 
the development of this systematic review.   
 
2.1 Identifying the Research Question 
The objectives of this project were to:  
 
Question 1) Systematically review the literature (no restrictions were applied to the 
study design of the literature), to identify the neurocognitive and learning consequences 
of paediatric brain tumours. 
 
Question 2) Systematically review the literature (no restrictions were applied to the 
study design of the literature), to determine evidence for the effectiveness of 
interventions (pharmaceutical and psychosocial) for cognitive and learning impairments 
within a paediatric brain tumour population. 
 
It is hypothesised that conducting a systematic review on both of the above questions 
could be beyond the scope of this thesis. 
 
After the development of the search terms, a trial search was conducted for questions 
one and two. The retrievals from the search for question one were deemed too large to 
be included in this study. An initial search conducted in Medline only in July 2012 
retrieved 6,173 papers.  
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The search was refined to explore the neurocognitive and learning consequences of 
either Ependymoma or Medulloblastoma paediatric brain tumours. The two most 
prevalent malignant paediatric brain tumours were selected in the hope that one of them 
would generate a suitable number of retrievals to be included in the study (Dhall, 2009). 
Furthermore MESH headings of ‘treatments’ and ‘Cognitive Outcomes’ were used in the 
search to broadly identify neurocognitive outcomes and interventions used to treat these 
tumour types. 
 
The results of both searches were considered too extensive for the first section of this 
project (Table 5) in addition to the second section (question two), which retrieved a total 
of 2,513 for both pharmaceutical and psychosocial intervention searches.  
 
 
1) Children AND Ependymoma AND Treatments AND Cognitive Outcomes 
 
2) Children AND Medulloblastoma AND Treatments AND Cognitive Outcomes 
 
A systematic review of literature, to identify the neurocognitive and learning 
consequences of paediatric brain tumours will not conducted. Therefore it is important to 
consider the current literature and possible gaps in this area of research. 
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Table 4.  Search results for independent tumours 
 
Tumour            Electronic database        Papers retrieved    Total number of papers                                                
Ependymoma                         AMED                                  2 
                                                CINAHL                             17 
                                         Cochrane Library                       11 
                                               EMBASE                           412 
                                                Medline                             310 
                                             PsycINFO                                1                                   
                                                                                                                                    753 
Medulloblastoma          AMED                                 1  
 
 
 
 
               1378 
       CINAHL                              45 
Cochrane Library 
EMBASE 
Medline 
PsycINFO 
               40 
             760 
             513 
               19 
 
2.2 Identifying Relevant Studies 
The current armamentarium in the post-acute recovery period used for the rehabilitation 
of the paediatric brain tumour population addresses physical, learning, visual, motor and 
cognitive impairments (Limond & Leeke, 2005). The impact of cognitive and learning 
deficits in paediatric brain tumours are evident from the reviewed literature and are 
becoming more significant as survival rates increase due to scientific advancements and 
high quality health outcomes. Therefore, it is important that evidence for effective 
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interventions directed at restoring areas of deficit or implementing compensatory 
activities are explored. For the purposes of this introduction, a review of the most 
prevalent psychosocial and pharmaceutical interventions administered after the acute 
recovery phase, for paediatric patients with a brain tumour, will be conducted. 
Additional interventions will be identified and explored in the results and discussion 
section of this review. 
 
 
2.2.1 Rehabilitation and Outcome Measures  
 
Various methods of treatment, both psychosocial and pharmacological are utilised in the 
rehabilitation of children with a brain tumor. Wilson (1997) focuses on four different 
aspects of cognitive rehabilitation for brain injury. First, rehabilitation via drills and 
exercises, Secondly, the use of theoretical models of cognitive psychology to identify 
the impairment and thus remediate the deficit. Thirdly, an approach driven by the 
patient, and uses a combination of learning theory, cognitive psychology and 
neuropsychology to identify and inform the intervention. The final approach is holistic, 
which assumes cognitive functions are interlinked and cannot be separated from 
emotion, motivation and non-cognitive functions. Thus all need to be addressed by 
rehabilitation programs. Although Wilson (1997) categories four aspects of 
rehabilitation this thesis recognises that these approaches often overlap and thus will 
explore three approaches: remediation, compensation and a holistic approach. 
 
Although the presentation of patients often reveals potential cognitive deficits, methods 
of assessment are equally as important and outcomes measures need to be utilized 
throughout rehabilitation to monitor the progress of the deficit and the impact of the 
intervention.  
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2.2.2 Remediation 
 
Remediation, specifically cognitive remediation is a method of teaching that targets 
areas of deficit involved in learning and basic day-to-day functioning that may be 
impaired.  The primary aims of remediation are to reinforce specific cognitive deficits. 
 
Remediation is a psychosocial intervention which uses a systematic approach, utilising 
different strategies such as: behavioural interventions, cognitive behavioural therapy, 
instruction in metacognitive strategies, social skills training, traditional brain injury 
techniques such as drills, massed practice (a continuous practice of different cognitive 
drills), and supportive and dynamic psychotherapeutic approaches aiming to improve 
cognitive functioning (Butler & Mulhern, 2005). Outcome measures such as 
standardised tests of working memory and attention function to assess the deficit and 
identify potential progress or decline. 
 
Remediation is based on the principle that the brain can adapt after injury and thus 
reorganise its structural pathways (Luria, 1963). This has important links to neuro 
plasticity and the reorganisation of the brain for functional recovery. Thus Luria suggest 
that by separating cognitive deficits into individual components, which are then 
practiced and over learned on tasks similar to the nature of the component deficit (Butler 
& Mulhern, 2005). Consequently remediation has demonstrated relationships among 
dendrite growth, structured environmental stimulation and the recovery of lost functions 
(Sohlberg & Mateer, 2001).  
 
An important development in remediation is Butler et al. (2008) Cognitive remediation 
programme, which uses techniques from a variety of different disciplines, these include: 
Clinical Psychology, brain injury rehabilitation and special education/educational 
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psychology, to develop a tripartite model. It is a team approach which consists of the 
child, therapist, parent and teachers First, principles of massed practice taken from brain 
injury rehabilitation interventions are used to help develop attention processes (Sohlberg 
& Mateer, 1996). The focus of these interventions is to exercise attention processes in 
the areas of sustained, selective, divided and executive attention control. This is a 
manual approach, during which the child is engaged in a 15 minute learning based 
activity, which is then alternated with more intrinsically interesting activities such as 
board games or computer games (Butler et al, 2008). This process helps the child sustain 
their attention over 20 two-hour sessions. To ensure the task is set at an appropriate level 
for the child, a 50-80% rule of correct responding is followed. If the child falls below a 
50% correct response rate the task is changed to a more suitable basic task. Once the 
child has achieved 80% accuracy, the task will be moved up to the next level of 
difficulty.  If the child did not achieve 80% they would repeat the task (Butler et al, 
2008). 
 
The second part of the tripartite model is the use of metacognitive strategies, which are 
based on techniques used in special education and educational psychology. Strategies 
are taught to each child and as their performance improves, the strategies become part of 
the child’s repertoire and help the child to monitor their own thinking. Each of the 
strategies is idiosyncratic to the participant and as the child progresses over the course of 
the remediation they frequently acquire new and innovative strategies (Butler et al, 
2008). Strategies are categorised into: task preparedness, on-task performance, and post-
task strategies. Within each of these categories are numerous strategies such as ‘hints’. 
This strategy suggests that if a child is struggling, they should be encouraged and taught 
to seek assistance or a hint (Butler et al, 2008). Participants are assigned an individual 
therapist who will monitor their performance whilst participating in the drills. Research 
indicates that techniques such as metacognitive strategies, which teach individuals to 
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monitor their own thinking, have been used to improve attention processes in brain 
injured children (Butler & Mulhern, 2005). 
 
Thirdly, a cognitive-behavioural approach based on the work of Meichenbaum (1977), 
taken from the discipline of Clinical Psychology, completes the tripartite model. A 
cognitive-behaviour approach attempts to: reframe cognitive struggles, provide 
psychotherapeutic support, acknowledge weaknesses and roadblocks to improvement, 
acknowledge learning strengths, monitor their own internal dialogue, stress inoculation 
and encourage the patients to become their own ‘best friend’ rather than ‘worst enemy’, 
ensuring a realistic, positive, and optimistic learning environment (Butler & Mulhern, 
2005). This intervention is directed at developing the participant’s ability to withstand 
distraction and maintain their attention thereby allowing them to improve their verbal 
mediation skills and thus their self-control. The therapist initially models how to self-
talk through a distraction experience.  The participant then practices this with the 
therapist serving as a distracter. Once the dialogue has been successfully incorporated, 
the child is then coached to internalise the dialogue and use it covertly (Butler et al, 
2008). 
 
The majority of cognitive remediation research has been conducted in the field of 
paediatric acquired brain injury. Butler et al (2008) have been at the forefront of 
developing and applying these principles to a paediatric population with neurocognitive 
deficits as a result of interventions for cancer. They have noticed that the techniques 
used in the rehabilitation of a traumatic brain injury population appear to have relevance 
for a paediatric neurooncology population, as they both exhibit similar 
neuropsychological disturbances.   
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In 2002 twenty-one individuals treated for a CNS related malignancy completed a 
cognitive remediation pilot study. The aim of this pilot was to develop an innovative, 
psychologically based outpatient rehabilitation program that would improve 
dysfunctional attention processes and associated neuropsychological deficits (Butler & 
Copeland, 2002). The results identified a statistically significant improvement in all 
attention measures, in comparison to the control group which did not manifest any 
significant changes (Butler & Copeland, 2002). However, it should be noted that neither 
of the groups demonstrated any statistical significance on the arithmetic achievement 
test. Furthermore, the methodology of the study was compromised in that the groups 
used in the study consisted of an unequal sample size and non-random assignment of the 
treatment condition took place. Although limited reviews of the cognitive remediation 
programme have taken place within a paediatric neurooncology population, significant 
support for the programme can be found in brain injury literature (Ben-Yishay & Diller, 
1993; Carney et al, 1999). 
 
Despite the positive results some aspects of functioning, particularly episodic and 
semantic memory/new learning are generally not considered to be amenable to 
remediation and therefore compensatory approaches are recommended (Mateer & 
Sohlberg, 1988; Wilson et al, 1994; Sohlberg & Mateer, 2001). 
 
 
2.2.3 Compensation 
 
 
Compensatory interventions involve the use of strategies and tools designed to enable 
the patient to cope with the impairment. Compensatory methods typically focus on 
activities of daily living and can be provided through the use of assistive technology or 
physical aids (such as a diary) or it can be a strategy (e.g. mnemonics or structured 
templates for following a process). The aim of a compensatory intervention is to 
improve the individual's functioning in the real world and outcome measures are 
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therefore based on goals or improvements in a specific skill (e.g. how many words can 
be read, or whether the knowledge of how to complete long multiplication has been 
learnt).   
 
Compensatory interventions predominantly rely on the accommodation within the 
school setting and the use of assistive technology to help patients to compensate for their 
deficits (Armstrong & Briery, 2004). This approach utilises the individual’s abilities, 
such as memory or processing speed, which have remained unaffected by rehabilitation 
approaches. Accommodation techniques and technologies then work around the 
patients’ areas of deficit and continue to build on their strengths (Armstrong et al, 1999). 
The compensatory model focuses largely on language-based learning and performance, 
with minimal emphasis on visual, motor learning and performance (Armstrong & Briery, 
2004; Brown, 2004). The primary components consist of: extended time limits for 
school examinations, the use of true/false and multiple-choice formats in testing, rather 
than essay examinations, written hand outs in order to decrease demand for copying 
from the blackboard, voice recognition technology and equipment to tape record 
classroom lectures, which may help to minimise the impact of the child’s deficit (Brown, 
2004; Butler & Mulhern, 2005). They can also provide school reintegration 
programmes, special education support, environmental modification and assistive 
technology (Brown, 2004). School based intervention can involve a number of activities 
which are idiosyncratic to the needs of the child, the aim being to socialise and facilitate 
the children back into education and to address their emotional needs (Brown, 2004).  
 
Limited studies have been conducted to demonstrate the effectiveness of these 
interventions (Brown, 2004). However, studies which are often based on feedback from 
teachers and parents report that the techniques are of benefit to the patients (Armstrong 
et al, 1999; Armstrong & Briery, 2004;  Brown, 2004). 
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For example Kerns and Thomson (1998) utilised a memory device to improve 
neuropsychological functioning in those who have severely impaired memory, 
secondary to a brain tumour and treatment. The participant involved in the compensatory 
memory system was provided with a notebook with several sections. These sections 
included: a memory log, in which to make notes to assist their episodic memory; a 
calendar section, which allowed them to keep a record of activities and keep track of the 
passage of time; a ‘things to do section’ which enabled participant to log all of their 
upcoming assignments; an orientation section, which contained important personal 
information, for example, names of teachers, classroom numbers and their counsellor’s 
name; and a transportation section, which contained their bus schedule and a map of the 
school.  Training within this method involves three stages; acquisition, application and 
adaptation. To support the participant, parents were also trained in how to use the 
memory book. Furthermore, role-plays and teacher assistance were used to ensure 
adequate knowledge and the use of the memory book. The participant was instructed to 
use the notebook on a daily basis and was also supplied with a daily checklist to 
supplement the memory notebook. 
 
Although the Kerns and Thomson (1998) study, as a compensatory intervention, is not 
expected to significantly improve memory impairment, it was of benefit to the 
participant. For example academic achievement increased slightly when the raw scores 
were evaluated and participant continued to use the memory system after the trial had 
finished. Furthermore, teachers reported that after the study was completed none of the 
participant had trouble with class attendance or the completion and submission of 
assignments on time, demonstrating a benefit to their daily living (Kerns & Thomson, 
1998). Likewise encouraging results for memory deficits utilising a compensatory diary 
and remediation approach have been demonstrated in acquired brain injury studies 
(Ownsworth & McFarland, 1999). 
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When evaluating the extent of the compensatory interventions needed to aid the patient, 
conventional evaluations can be redundant, as they are often based on static concepts of 
learning disabilities (Armstrong, Blumberg, & Toledano, 1999; Brown, 2004). 
Ecological intervention may need to be intermittently reviewed as the child develops. 
Armstrong et al. (1999) suggest that evaluation should be considered a process, with re-
assessment every 18-24 months or as clinically needed. 
 
Furthermore the evaluation of compensatory methods via outcome measures also needs 
to be addressed. Compensatory interventions such as the Kerns & Thompson (1998) 
memory aid often utilise measures such as the Wechsler Intelligence Scale for Children 
(WISC) to demonstrate the impact on broader deficits, consequently these studies will 
demonstrate limited changer thus limited general recovery of function, which can hinder 
the perceived effectiveness of the intervention. However, some measures such as 
achievement measures (Wechsler individual achievement test (WIAT) and wide range 
achievement test (WRAT)) can be used to measure change brought about by the 
compensatory intervention as they are attainment measures (i.e.as they are looking at 
current level of academic attainment rather than an underlying cognitive function). 
 
Compensatory interventions are often linked with pharmacological interventions and 
cognitive rehabilitation as part of an efficient rehabilitation package. The cognitive 
interventions are indicative of those associated with the aforementioned cognitive 
remediation; pharmacological interventions will be addressed later in this thesis. 
 
 
 
 
 
 
 
 
54 
2.2.4 Holistic 
 
A holistic approach to rehabilitation can be defined as dynamically interlinking 
cognitive, emotional and behavioral aspects of rehabilitation, which is undertaken by 
addressing rehabilitation in an integrated interdisciplinary team approach (Clare, Wilson, 
Carter, Roth & Hodges, 2004). Wilson describes this model of rehabilitation as a 
“partnership” incorporating the medical team, the patient and systemic factors such as 
the individual’s family, friends and significant others from educational/vocational 
settings (Wilson & Gracey, 2005). This approach incorporates elements of exercises 
such as massed practice with goal setting from remediation and compensation 
approaches. A holistic approach to rehabilitation appreciates the need to address 
cognitive, emotional, behavioural and social consequences of the brain injury (Wilson 
2008).  
 
A holistic approach is mindful of the important factors involved in the rehabilitation of 
paediatric neurooncology patients, such as the influence of their environment and 
significant others. Butler and Mulhern (2005) believe it is of great important to educate 
significant others in the patient’s life about their deficits and the specific needs 
associated with their treatment. Rehabilitation literature, such as Butler and Mulhern 
(2005) also suggests that neurooncology patients may require specific provisions and 
support.  
 
 
Butler and Mulhern (2005) support the notion of combining cognitive remediation with 
ecological interventions to maximise therapeutic gains, however noting that children 
cannot be expected to return to a baseline, pre-insult status. They specify that to 
maximise therapeutic gains, changes in environmental demands combined with 
additional rehabilitation may benefit the patient. Additionally, they highlight the 
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importance of remaining mindful of changes in the child’s presentation. As previously 
noted, cognitive functioning declines with increasing time since treatment, therefore the 
patient may develop further deficits as they age (Mulhern, Khan, et al, 2004; Mulhern et 
al, 2001; Spiegler et al, 2004).   
 
A holistic approach to rehabilitation has the largest evidence base in adult brain injury; 
along with memory aids (SIGN, 2013). These methods are not only accessed via 
outcome measures that are typically goal-based, and questionnaires (self and significant 
others), but also a range of standardised neuropsychological tests to ensure there has not 
been general recovery. Measures look at variables hypothesised to be improved directly 
by remediation, or the improvement of underlying skills developed in long-term studies.  
Again academic attainment/achievement measures may also be used. 
 
2.2.5 Pharmacological Interventions 
Neurooncology literature also indicates the need to consider pharmacological 
interventions in addition to psychosocial interventions to manage neurocognitive 
difficulties; specifically attention and working memory which underlie global cognitive 
declines following a paediatric brain tumour (Clark, Baker, Gardner, Pompa, & Tait, 
1990; Whyte et al, 2004). Therefore, in addition to the psychosocial interventions, the 
use of pharmacological interventions will also need to be addressed; the most prevalent 
and researched intervention is Methylphenidate hydrochloride (MPH), a generic form of 
Ritalin (Conklin et al, 2007; Conklin et al, 2010a; Mulhern et al, 2004 & Thompson et 
al, 2001). 
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2.2.6 Methylphenidate Hydrochloride 
 
 
The MPH is a piperidine derived stimulant, namely, methyl-alpha-phenyl 2-
piperidineacetaten hydrochloride (Gagnon, Low, & Schreier, 2005). MPH is thought to 
enhance the functioning of the frontostriatal (anterior) attention network (Rubia et al, 
2011). This is an important function as the frontostriatal systems have been shown to 
play a role in cognition (Chudasama & Robbins, 2003).  
 
Children with brain tumours often present with attention deficits and impulsivity 
(Riddick et al, 2003). MPH works to increase dopamine levels in the brain, dopamine is 
a neurotransmitter associated with attention. The therapeutic effect of stimulants is 
achieved by slow and steady increases of dopamine, which are similar to the way 
dopamine is naturally produced in the brain (Meyers, Weitzner, Valentine & Levin, 
1998).  
 
Results have demonstrated significant improvements in cognitive functioning, 
specifically visual-motor speed, verbal memory, expressive speech function, executive 
function (ability to switch mental set and divide attention), and fine-motor coordination. 
Attention and behavioural improvements among children with brain tumours and other 
cancers of the CNS, specifically in areas of sustained attention and processing speed 
have been noted in previous research (Conklin et al, 2010b). 
 
2.2.7 Methylphenidate and Attention Deficit Hyperactivity Disorder  
 
MPH is synonymous with treatments for attention deficit hyperactivity disorder 
(ADHD) and other diagnoses which result in ADHD type behaviours, such as acquired 
brain injury. The effectiveness of MPH, a stimulant medication, in improving cognitive 
57 
performance, has been demonstrated within these populations (Murray et al, 2008; 
Whyte et al, 1997; Whyte et al, 2004; Willmott & Ponsford, 2009).  
 
Results from the Multimodal Treatment Study of Children with ADHD (MTA), a 
fourteen month, large and comprehensive treatment study of ADHD, which included 
579 children diagnosed with ADHD, aged from 7 to 9.9 years of age, from six different 
sites across the United States of America, established that a combined treatment of 
intensive behavioural treatment and intensive medication management were 
significantly superior to intensive behavioural treatment alone and to routine community 
care, in reducing ADHD symptoms (MTA Cooperative Group, 1999). The combination 
treatment also allowed children to be treated with lower doses of medication (Carey, 
2000). On average, medical management also proved to be more effective than intensive 
behavioural intervention.  
 
However, in a commentary review Carey (2000) notes that the patients receiving just 
medication were also provided with support, encouragement and practical advice; this 
was not deemed to be a behavioural treatment. Moreover readings from an approved list 
and eight additional sessions were also provided for medical emergencies. Although it 
does not define this as behavioural support, the research also does not define what 
support was provided in these sessions or what support the reading list gave. 
Furthermore Carey (2000) suggests the study does not establish that MPH is a specific 
remedy for children with a diagnosis of ADHD. There was minimal reporting of the 
response of the behavioural management programme and the results were varied 
dependent upon the patient’s clinical problems. More importantly, Carey (2000) 
critiques the study for the fact that the diagnostic criterion for ADHD was vague, which 
made it challenging to identify who was included in the study population.  
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The MPH trials were also critiqued by Pappadopulos et al. (2009), who indicated that in 
clinical settings poor adherence and early termination of MPH would impact on the 
effectiveness of the treatment. In the MPH trial they identified a discrepancy between 
parental verbal reports of medication adherence and physiological adherence measures. 
Nearly half of the parents were inaccurate informants of their child’s ADHD medication 
adherence and that they often overestimated actual adherence. 
 
These concerns may address why six to eight years later a study by Molina et al. (2009) 
suggests that the type or intensity of a fourteen-month treatment for ADHD did not 
predict functioning. Despite initial symptom improvement, which was maintained post-
treatment, there was still a significant impairment in adolescence. Thus additional 
interventions are still needed to target specific deficits. 
 
2.2.8 Methylphenidate and Paediatric Neurooncology 
 
In addition to the evidence for the use of MPH in ADHD and brain injury populations, 
there is increasingly reported evidence in favour of the use of MPH with paediatric 
neurooncology populations (Conklin et al, 2010a). As previously noted, children with 
malignant brain tumours may incur damage to cortical and subcortical white matter 
particularly within the frontal and prefrontal lobes (Moore, 2005; Mulhern & Butler, 
2004). These areas have been found to be used in executive functioning which involves 
the planning and organisation of behaviour, as well as the allocation of attention; this 
may therefore account for attention difficulties (Paus, 2005). Thus MPH may be of 
benefit for attention problems in a paediatric neurooncology patient. 
 
Research exploring the use of MPH in children with brain tumours has demonstrated a 
benefit for neurocognitive problems, as demonstrated in Table 4. Table 4 demonstrates 
the use of MPH treatment on neurocognitive impairments; additionally MPH has been 
59 
found to be of benefit for social deficits (Mulhern et al, 2004b). Although  Mulhern et al. 
(2004b) results demonstrated improvement in social behaviours and academic 
competence, there were limited improvements in neuropsychological functioning and 
academic achievement. 
 
Table 5. The Effects of MPH on Neurocognitive Deficits 
Neurocognitive 
Deficit 
Evidence Reference 
Attention Significantly greater 
improvement with MPH than a 
placebo in a patient’s sustained 
attention as well as in an overall 
index of attention problems. 
Improvements in attention 
observed in both the classroom 
and the participant’s home. Also 
significant benefits for the long-
term use of MPH. 
(Conklin et al, 2010a; 
Conklin et al, 2007; 
Conklin et al, 2010b; 
Mulhern et al, 2004a; 
Mulhern et al, 2004b) 
Speed of processing Significant benefits for the long-
term use of MPH. 
(Conklin et al, 2007; 
Conklin et al, 2010b) 
 
In contrast to the improvements in attention and processing speed, the administration of 
MPH has not resulted in a statistically significant and consistent improvement in 
associative learning, verbal memory, IQ and academic skills (Conklin et al, 2010b; 
Thompson et al, 2001). A further limitation of MPH has been linked to the 
pharmacokinetics of MPH. MPH has shown to have a half-life of 4 hours and reaches its 
bioavailability within 90 minutes, suggesting it does not have a lasting effect (Brown et 
al, 1997). In the Mulhern et al. (2004b) literature, there was a trend for teachers to 
perceive more benefits than the parents due to the timing of the lunchtime dose.  
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Despite encouraging literature, Butler and Mulhern (2005) conclude that it is yet 
unknown if MPH ultimately facilitates academic achievement among survivors of 
paediatric brain tumours with attention problems. The majority of these studies have 
relied on either or both parental and teacher reporting, therefore it is important to 
consider the potential for reporting error and bias (Conklin et al, 2010a; Mulhern et al, 
2004b). It was also difficult to differentiate the results between those who had a 
diagnosis of a brain tumour and those who had a diagnosis of leukaemia (Conklin et al, 
2010a; Mulhern et al, 2004b). 
 
2.2.9 Paediatric Rehabilitation 
 
It is important to remember that methods of rehabilitation in paediatric populations are 
often limited and the literature is not extensive in either adult or paediatric populations; 
although an adult population is an area of greater research. Thus alternative diagnoses 
such as brain injury and ADHD, where rehabilitation has been established are drawn 
upon.  
 
Further complications are the context under which major studies have been undertaken. 
In the United States of America a single national outcome study was undertaken, with a 
standard protocol, which incorporated all children with cognitive impairments associated 
with cancer or its treatment. Thus a large majority of research includes other cancer 
diagnoses, which may provide complications when identifying the effects of 
interventions on neurooncology populations. 
 
Considering above research a PICO process was used to frame the clinical question 
considering the research discussed in the introduction chapter. Thus the focus of the 
project will be a systematic review of the literature to determine evidence for the 
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effectiveness of interventions (pharmaceutical and psychosocial) on cognitive and 
learning impairments within paediatric patients with brain tumours.  
 
2. 3 Literature Search of Relevant Studies 
Based on this literature an initial search was constructed on a limited number of data 
bases (Medline), to identify potential relevant studies, with guidance from the Health 
Faculty Team Librarian at the University of Leeds. Also a variety of databases and hand 
journal searches were conducted to identify further resources such as reference lists for 
the final searches.  Studies which did not meet the minimum inclusion criteria such as 
oncology were divided into irrelevant studies and potentially irrelevant studies. The 
potentially irrelevant studies allowed for the identification of articles, which yielded 
appropriate references for secondary searches (hand searching). Secondary searches 
included articles such as Butler and Mulhern (2005), which reviewed interventions for 
the neuropsychological late effects associated with the treatment of acute lymphoblastic 
leukaemia and malignant brain tumours, yet were not included in the results, as the focus 
in the paper was a review not an assessment of an intervention. 
 
 
2.4 Study Selection 
 
Exclusion and inclusion criteria’s were considered, with the support and guidance of 
Consultant Paediatric Oncologists, Consultant Paediatric Neurologist and Consultant 
Child and Adolescent Psychiatrist, Leeds Community Healthcare NHS Trust. Particular 
emphasis was placed during the scoping process on the population inclusion and 
exclusion criteria by narrowing the population to allow for the removal of potentially 
irrelevant papers, this included different diagnosis and the separation of adult and child 
populations.  
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Furthermore, guidance for the development of the population search terms were taken 
from Boluyt, Tjosvold, Lefebvre, Klassen, and Offringa (2008), which aimed to assess 
the usefulness of existing search filters in finding child health search terms. However, it 
is important to note that the search terms of Boluyt et al. (2008) were based on a 
‘sensitive child filter’, which was developed by the Cochrane Child Health Field. 
Although, Boluyt et al. (2008) conclude that the sensitivity of the child health search 
terms were 98% (380/378; 95% confidence interval, 96%-99%). The search terms 
appear limited in that they failed to identify studies which use hyphenated key words, 
these include: Neo-nat*, Post-nat*, Pre-school and Pre-pubescent. 
 
Furthermore, the study contained an error in including the search term Paediatric twice 
and did not identify studies that used alternative spellings of Paediatrics. For example, a 
review of the Neonatal search terms, conducted on 9 March 2012, using Ovid SP 
databases (AMED, EMBASE, MEDLINE, PsycINFO and Web of Science), highlighted 
a further 952 studies which may be of relevance to the review, which were found in the 
Neo-nat* search and not in Neonat*, highlighting the importance of using both 
hyphenated and non-hyphenated words. 
 
2.5 Charting the Data 
 
A database was constructed to identify and consider the population sample utilised in 
this review, specifically the range of diagnosis of the patients retrieved in the initial 
searches. Articles were screened using this basic inclusion and exclusion criteria.  
 
The information extracted from the data screening process for relevant studies was 
placed onto an Access database to ensure accurate recording and transparency to allow 
for conclusions to be drawn about the population/diagnostic criteria in the final review. 
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 2.6 Collating, Summarising and Reporting the Results  
After collating evidence from initial searches based on the effectiveness of psychosocial 
and pharmaceutical secondary interventions it was apparent that the dominant 
methodology reported was the single case. This has implications for the methodological 
quality and the reliability of the results discussed in this thesis. The quality assessment 
of the papers will be discussed in the methodology section of this thesis as some argue 
quality assessment is not an essential aspect of a scoping chapter (Armstrong, 2011).  
 
Furthermore the potential implications of the literature relating to participants with an 
alternative CNS diagnosis such as leukaemia or a co-morbid diagnosis being grouped 
together in the final results section of the studies. For example, mental health problems 
or an epilepsy, will need to addressed in the final systematic review because the 
presence of such diagnoses are significantly associated with neuropsychological 
impairments and may have an adverse impact on the results (Iuvone et al, 2011). 
 
2.7 Optional Consultation 
Consultation was sought from professional in the disciplines noted above during the 
scoping review. It was important to utilise their knowledge and expertise in areas of 
anatomy and current interventions. The development of the extensive search strategies 
was also supported by research assistants who initially developed a basic set of search 
terms for an additional research project. 
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CHAPTER THREE: METHODOLOGY 
This chapter describes the methodology of the systematic review, outlining the 
procedure for data extraction and the proposed method of data analysis. This chapter 
also reviews the development of the study by describing the methods used to inform 
searching, data extraction, synthesis and analysis. An outline of the review process can 
be found in Figure 6. 
 
3.1 Research Design 
A survey of empirical studies comparing psychosocial and pharmaceutical interventions, 
for learning and cognitive outcomes, in a paediatric brain tumour population was 
undertaken. This research design allowed for a rigorous, but objective procedure, for the 
collection and compilation of data to provide evidence-based answers. It also provided a 
transparent analysis, appraisal and synthesis of the best available evidence, whilst 
reducing the potential for subjectivity or bias in the findings. This design allowed for a 
review of research from different disciplines, whilst also considering the impact of the 
interventions.  
 
Clinical decisions are often made based on multidisciplinary team working, thus 
research should also accommodate varied perspective. By combining the evidence-based 
outcome of this review with professional judgement, it will enable clinicians to make 
informed decisions about future policy and intervention within services. Consideration 
was also given to the limitations of this design, including the ability generalise the 
findings and the potential problems of research that utilises small sample sizes. 
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3.2 Development of the Study 
The development of the search terms, data coding and data synthesis were informed by 
the Centre for Reviews and Dissemination (CRD) (Centre for Reviews & Dissemination, 
2009), and the Cochrane Handbook for Systematic Reviews of Interventions (CHSRI) 
(The Cochrane Collaboration, 2011). Further guidance was received from Dr Matthew 
Morrall (Consultant Paediatric Neuropsychologist and Field Supervisor) and Professor 
Stephen Morley (Programme Director at The University of Leeds and Academic 
Supervisor). Supervisory meetings provided opportunities to reflect on the progress of 
this thesis and discuss difficulties and limitations that could hinder the development of 
the thesis.  
 
A protocol was developed as part of the transfer viva exam in September 2012.  The 
protocol outlined the proposed question, which was determined as a result of the scoping 
progress; it gave detailed information regarding the inclusion and exclusion criteria, 
(which are listed below) and described how the review process would be conducted with 
regards to critical appraisal and data analysis. The transfer viva provided an opportunity 
for external clinicians to comment on the protocol. Thus aiding the progress of the study 
and limiting potential bias by providing a clear hypothesis and method without prior 
knowledge of the results. Although the transfer viva was a challenging process it shaped 
the methodology of the thesis, particularly the critical appraisal section. The examiners 
offered guidance and prepared me for the challenges and frustrations of reporting the 
results of studies within a CNS population. 
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3.3 Search Strategy for Identification of Studies 
 
3.3.1 Criteria for Study Inclusion 
The studies to be included in the review were required to meet the following criteria. 
This criterion was determined through the course of discussions with supervisors named 
above and specialists in paediatric and neurooncology fields.  
 Population: Paediatric neurooncology patients, under the age of eighteen 
years. 
 Context: Neurocognitive (Impairment in cognitive domains, including: 
attention, executive functioning, speed of processing, working memory 
and other aspects of memory.) 
 Interventions: The key interventions of interest include both 
pharmaceutical and psychosocial interventions for neurocognitive 
consequences of paediatric brain tumours. 
 Outcomes: Impact on functioning (specific focus cognitive and learning 
aspects of functioning) 
 Study Design: No limits.  
 
3.3.2 Exclusion Criteria  
Literature concerning participants diagnosed with brain tumours at the age of eighteen 
years or over was excluded from this study as was, literature relating to participants with 
a co-morbid diagnosis. Non-English language reports were also excluded. It is 
acknowledged that this might introduce bias (DeAngelis, 2000), but resources for 
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translation were not available. It was hypothesised that this limitation would not impede 
the review, as the majority of paediatric neurooncology studies are published in English. 
 
 
3.3.3 Development of Search Strategies 
To try and eliminate forms of biases such as database, publication bias and source 
selection bias and to increase the yield of relevant studies retrieved; the development of 
search strategies, terms and selection of databases, were informed by a variety of 
different sources. These included:  the research aims and the guidance of CHSRI, Miss 
Janet Morton - Arts and Social Science Faculties Team Librarian, Miss Elizabeth Neilly 
– Health Faculty Team Librarian, Drs Picton, Wilkins and Elliott - Consultant Paediatric 
Oncologists, Dr Livingston - Consultant Paediatric Neurologist at The Leeds Teaching 
Hospitals NHS Trust, Dr Stanley - Consultant Child and Adolescent Psychiatrist, Leeds 
Community Healthcare NHS Trust and Miss Helen Stocks and Miss Kate Ablett - 
former Research Assistants at The Leeds Teaching Hospitals NHS Trust (The Cochrane 
Collaboration, 2011). This was a challenging process and it took considerable time to 
source appropriate individuals. However, consultation with these individuals resulted in 
a list of extensive search terms and databases/journals.  The final search terms used in 
the systematic review are shown in Appendix I. 
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Figure 6: The Process of Systematic Review 
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3.4 Searches: Electronic Databases 
The databases utilised in the search included:  
 The Allied and Complementary Medicine Database (AMED) 
 Applied Social Sciences Index and Abstracts (ASSIA) 
 
 Australian Education Index 
 
 British Education Index 
 British Education Internet Resource Catalogue 
 Current Educational Research in the UK (CERUK) 
 Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
 
 Cochrane Library 
 
 CSA Neurosciences Abstracts 
 
 Digital Education Research Archive 
 
 Education-line 
 Education Literature Datasets 
 EMBASE 
 Education Resources Information Center (ERIC) 
 
 Google Scholar 
 
 Index to these accepted for higher degrees by the universities of Great Britain 
and Ireland 
 
 MEDLINE 
 PsycINFO 
 Scopus 
 Social services abstracts 
 Social Sciences Citation Index 
 Sociological abstracts  
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 UK Official Publications Online 
 Web of Science  
 
 
As previously noted a diverse range of professionals from a variety of different 
academic fields, education, neurooncology and neuropsychology, were consulted to 
confirm that all appropriate search engines had been accessed in the primary search.  
 
In addition to the primary electronic searches, a secondary hand search of reference lists 
from the relevant or potentially relevant articles retrieved in the primary searches were 
undertaken to ascertain any further research that had not been identified in the electronic 
searches. Key author searches such as ‘Mulhern’ were undertaken using Google Scholar. 
Further explanation of this process is given in the data extraction section of the 
methodology. The outcomes of primary and secondary searches are recorded in the 
results section. 
 
The final searches using the above databases were conducted six months prior to the 
completion of the systematic review, in January 2013. The searches were calibrated to 
receive an automatic alert of all new literature that met the search criteria for the review. 
Studies, which were retrieved by the automatic alert between January 2013 and June 
2013, are noted in the discussion, but have not been included in the review.   
 
A detailed search log was kept to ensure the search process could be replicated. The log 
included a record of the detail of how searching was undertaken, for example which 
websites, journals were searched, when and how many time. This also included the list 
of search terms and MESH terms used.  
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3.5 Searches: Hand Searches 
In addition hand searches of relevant non-electronic reviews and journals were 
considered, but no relevant sources were identified during consultation.  Due to time 
constraints key authors were not contacted to identify further studies and potential 
sources of information. This may have limited the identification of further papers, 
authors and search terms. 
 
3.6 Dates Used in the Search Criteria 
The criteria for the search dates used in the review of the empirical literature were set in 
accordance with the first issue of the journals used in the thesis and January 2013 (the 
final search).   However, it was noted that studies of importance were often retrieved 
from a later date (post 2000). It is hypothesised that these dates coincide with 
advancements in the field of paediatric neurooncology, a growing awareness of the 
impact of neurocognitive morbidity and its management. Nevertheless, to ensure the 
searches yielded an appropriate retrieval, the search dates were set idiosyncratically, in 
accordance with the start of each journal. 
 
3.7 Data Extraction 
After all of the retrievals from the search strategies had been extracted and assembled in 
EndNote X5, an initial review of all the retrievals was conducted using a data extraction 
form. The first section involved a data screening process (Appendix II), which involved 
a review of the title and available abstract of each article. Articles were systematically 
screened using the inclusion and exclusion criteria.  
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The information extracted from the data screening process for relevant studies was 
placed onto an Access database to ensure accurate recording and transparency for data 
synthesis. All irrelevant papers from the searches were documented, stating why they 
had failed to meet the inclusion criteria. This information is available on request in 
electronic format, due to the size of the document. Relevant and potentially relevant 
papers and their references were used in the secondary searches and hand searching. All 
relevant papers, which met the inclusion criteria, were retrieved in full.  
 
The data extraction form (Appendix II) used to systematically elicit data was designed 
with reference to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement and CRD (Centre for Reviews & Dissemination, 2009; 
Liberati et al, 2009). The form was designed to be explicit, record relevant details and 
reduce potential errors of judgement and bias.  The data extraction form was assessed for 
its ability to extract appropriate studies and information, by two individuals via a pilot 
study.   
 
3.7.1 Methodological Quality of Studies 
Utilising an appropriate tool for the quality assessment of the retrieved studies is an 
important aspect of any systematic review. The CHSRI emphasise the importance of the 
applicability of the findings, the validity of the studies and the design characteristics, as 
these may impact the interpretation of the results (The Cochrane Collaboration, 2011). 
CHSRI recommend accounting for four areas of bias: selection, performance, attrition 
and detection bias (The Cochrane Collaboration, 2011). However, it is important to note 
that the critical appraisal section of the CHSRI is related to randomised control trials 
only, since the CHSRI only use randomised control trial studies in their systematic 
reviews to ensure they are utilising high quality research. Due to the limited quality of 
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research designs extracted, this thesis will include all research designs, this is supported 
by Schlosser and Sigafoos (2009), who suggest the construct of evidence-based practice 
requires that researches seek out the best available evidence. Additionally Pagliaro, 
Bruzzi, and Bobbio (2010), recognise the quality of Cochrane systematic reviews, but 
suggest they are not as widely used in clinical decision making because of their 
emphasis on methodology and rigor rather than on clinical relevance. Thus the present 
review uses a checklist that assesses potential bias from other research designs. The 
quality appraisal checklist and further questions in the data extraction form were used to 
assess each of these aspects; for example, blinding to interventions and outcomes, 
attrition from the study and reporting of the results. CHSRI suggest using a scale 
identifying the relationship between a score and the degree to which the study is free 
from bias (The Cochrane Collaboration, 2011). However, this can pose a challenge as 
these scales are not supported by empirical evidence and are more suited to the appraisal 
of an RCT.   
 
The Oxford Centre for Evidence Based Medicine (2011) levels of evidence was also 
incorporated into the data extraction form. This was used to reflect the quality of the 
studies assessed in this review, the results of which will be considered in the discussion 
(Howick et al, 1998) (Appendix III). The levels of evidence table shows five levels of 
evidence and allows clinicians to appraise studies for prevalence, accuracy of diagnostic 
tests, prognosis, therapeutic effects, rare harms, common harms and usefulness of (early) 
screening (Howick et al, 2012).  
 
In addition to the levels of evidence, the Downs and Black (1998) checklist, a quality 
assessment tool was amalgamated with the data extraction form. In order to identify an 
appropriate quality assessment tool an Ovid search was conducted in EMBASE, 
MEDLINE and PsycINFO (9 January 2013), however, the search provided a limited 
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retrieval, extracting only two papers (Downs & Black, 1998; Slim et al, 2003). Slim et 
al. (2003) reported a methodological index for non-randomized study instruments. 
Although the twelve-item scale established good inter-reviewer agreement, high test-
retest and good internal consistency, it could only be used to assess non-randomised 
studies. The Downs and Black (1998) checklist assessed the quality of both randomised 
and non-randomised studies.  
 
The Downs and Black (1998) checklist was developed in response to the systematic 
reviews conducted by organisations such as The Cochrane Collaboration. Generally, 
reviews conducted within the Cochrane Collaboration have inclined to focus on 
randomised studies. Non-randomised (or observational) studies are often excluded from 
reviews of treatment effectiveness because of their potential bias. However, the present 
review hoped to include both randomised and non-randomised studies. The Downs and 
Black (1998) checklist is comprised of twenty-seven items, which are distributed 
between five sub-scales. The five sub-scales include: reporting, external validity, bias, 
confounding and power. Answers were scored 0 or 1, except for one item in the 
reporting subscale, which was scored 0 to 2, and a single item on the power sub-scale 
that was scored 0 to 5. This equates to a total maximum score of thirty-one. The 
checklist demonstrated high internal consistency for the quality index, as did the 
subscales apart from external validity. It also demonstrated good test-retest (r = 0.88) 
and inter-rater reliability (r = 0.75), and had good face and criterion validity (Downs & 
Black, 1998).  
 
CRD guidelines suggest that papers should be reviewed independently by more than one 
researcher to increase the reliability of data extraction and decrease bias (Centre for 
Reviews & Dissemination, 2009). In comparison, CHSRI support the use of a single 
researcher, as multiple researchers can create the potential for disagreement (The 
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Cochrane Collaboration, 2011). Thus, it is important to acknowledge that a single 
researcher undertook the extraction and analysis of the data, the researcher had no 
conflicting interests and consequently does not need to be blinded to details of authors 
and journals of the studies. 
 
3.8 Management of References 
The references retrieved from the data extraction have been collated in EndNote X5, 
which facilitated the identification of duplicate studies and also generated a unique 
identification number for each study. The unique identification number was used as an 
identifier in the retrieval and extraction process. 
 
3.9 Pilot Study 
 For the purposes of quality assurance, to establish inter-rater reliability and to ensure the 
data was coded and synthesised correctly, a pilot study was conducted to highlight any 
potential problems and challenges. The pilot study included a review of the data 
extraction form to certify it was concise and could be transposed to the Access database. 
The individuals involved in the pilot were also asked to give feedback with any 
comments about particular difficulties in using the form to extract the data. 
 
Two independent coders, both psychologists, undertook the pilot. Six studies were 
selected from the psychosocial and pharmaceutical intervention searches. This process 
was supported by the CHSRI who suggest a suitable sample should consist of three to 
six articles which span a range of low to high risk bias (The Cochrane Collaboration, 
2011). 
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Following the pilot study, appropriate structural changes were made to the data 
extraction form, to allow space for further comments to be added. Changes were also 
made to the data screening form, as the pilot study showed that articles were not always 
explicit about specific aspects of their studies. For example, studies often reported 
limited information about the specific age range of the participants involved in the study. 
There was also a general reporting of the results in the abstracts, which often made it 
difficult to distinguish the results in relation to different populations used in the studies. 
The data screening form was adapted and the ‘results reported separately for different 
diagnosis’ category was removed for studies that were ambiguous, in order to prevent 
appropriate studies from being excluded.  An example of this was Butler et al. (2008) 
multicentre: randomised clinical trials of a cognitive remediation programme for 
childhood survivors of a paediatric malignancy. It was not clearly reported in the 
abstract whether the results for leukaemia and brain tumour patients were reported 
separately in the results section, which made it difficult to understand whether the study 
met the inclusion criteria of reporting paediatric neurooncology outcomes. 
 
Additional strategies were also identified to ensure the review would be carried out 
effectively. These included supervisory consultations about studies that required further 
debate. This was a challenge set by numerous articles that combined the results of a 
variety of diagnosis. My supervisors and I spent time discussing these articles to 
ascertain if they could be included in the results section. This was a tedious and long 
process but guidance from the pilot study was very useful in implementing this strategy 
and others. 
 
3.10 Data Analysis 
The method of data analysis utilised in this review was dependent upon the studies 
retrieved from the searches. A limited number of studies to be included in this review 
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were retrieved from the search. The final search retrieved three studies that met the 
inclusion criteria. The three studies retrieved were all single case studies. The design and 
limited number of studies included in this review was not considered adequate data for 
inclusion and analysis via a meta-analysis; therefore, it was not appropriate to integrate 
the data statistically via a meta-analysis (Garg, Hackam, & Tonelli, 2008). A narrative 
synthesis of the studies was adopted; this included a descriptive summary of the 
characteristics and findings of the studies, which are included in the results chapter.  
 
3.11Ethical Considerations 
 The methodology for this study involved reviewing previous literature relating to 
paediatric neurocognitive consequences of paediatric brain tumours and the 
effectiveness of interventions (pharmaceutical and psychosocial) for cognitive and 
learning impairment. Thus, no patients were directly involved in the development of this 
research and consequently ethical approval was not sought.  
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CHAPTER FOUR: RESULTS 
This chapter presents the findings from the search for literature regarding psychosocial 
and pharmaceutical interventions for paediatric neurooncology populations. The results 
section contains information from the studies that met the inclusion criteria during the 
data extraction process.  
 
4.1 Overview of the Search Results 
An initial search was conducted on the selected electronic databases (see methodology) 
on 23
rd
 July 2012. This search was repeated in full in January 2013 to identify any 
further studies and to check the accuracy of the search procedure. The results of the 
search process are presented in a PRISMA flow chart (Figure 7) (Liberati et al, 2009). In 
total, the search retrieved 2,513 studies; after adjusting for duplications and studies that 
were not written in English, 2,423 studies remained. Of these, 2,084 were discarded after 
reviewing the abstracts and titles because they did not meet the inclusion criteria (data 
available in electronic format on request). The full texts of 31 studies were reviewed; 29 
of these studies did not meet the inclusion criteria. Two studies were deemed to be 
appropriate and were included in the review. A further 41 studies were identified via 
secondary searches; of these studies one paper was identified for inclusion in the review.  
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Figure 7. PRISMA-: Children AND Brain Tumours AND Treatments AND 
Psychosocial Interventions OR Pharmaceutical Interventions 
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4.1.1 Description of the Included Studies 
A total of three studies were included in this thesis.  
 
a) Aims and Outcomes 
 
Table 6 describes the setting and context of the studies extracted. The aim of the studies 
by Butler (1998) and Kerns and Thomson (1998) are on specific cognitive deficits: 
attention, non-verbal cognitive processes and memory, whilst the third study focuses on 
improving academic skills (Penkman & Scott-Lane, 2007). It is important to note that 
the aim of the third study by Penkman and Scott-Lane (2007) was not to specifically 
evaluate an intervention, but to determine if an intervention could be conducted while a 
patient was receiving intensive medical treatment. The study recognises that patients 
with a diagnosed brain tumour are at risk of cognitive delay, but their focus is not on 
treating cognitive deficits directly. They hope that the prophylactic academic 
intervention will enable patients to solidify basic skills before radiotherapy impairs their 
ability to learn. Thus part of this study also involved determining the effectiveness of 
one-on-one academic tuition in building skills. For the purposes of this thesis the focus 
of the data extracted from this study is on the intervention’s (one-on-one academic 
tuition) ability to improve the patient’s academic skill base. Hence the intervention’s 
focus is on the patients’ ability to continue leaning new information, an important aspect 
in cognition and reflected in learning impairment (Dennis et al., 1998). 
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Table 6. Aims of the Studies Retrieved. 
Study Aim  Main cognitive 
functions evaluated  
(Butler, 1998) The study evaluated an attention process 
training program with an emphasis on skill-
acquisition, massed practice and learning 
strategies. The intervention was designed to 
strengthen attentional, perceptual and non-
verbal cognitive processes. 
Attention, 
perceptual and non-
verbal cognitive 
processes 
(Kerns & 
Thomson, 1998) 
The study described the development and 
implementation of a compensatory memory 
aid. 
Memory 
(Penkman & 
Scott-Lane, 2007) 
This study evaluated the feasibility of 
delivering a prophylactic academic 
intervention to a child, whilst they are 
receiving intensive medical treatment. It 
also determined the effectiveness of one-to-
one academic tuition in building skills with 
a child at risk of cognitive and academic 
delay. 
Academic skills 
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b) Assessment 
 
The design of the studies retrieved which met the inclusion criteria, were case studies 
(Table 7). These studies achieve an evidence level of 4 on the Oxford Centre for 
Evidence Based Medicine (2011). Case studies are often associated with bias related to 
selection, detection, performance, attrition, reporting and publication (Dalziel et al., 
2005). Until like RCTs, which are classified as level 1b, the intervention in case studies 
does not involve a control group. Thus they are considered one of the weakest study 
designs to obtain evidence from, with a low position in the hierarchy of research 
designs. 
 
To consider bias within the studies the sources of funding and other aspects of potential 
bias were considered (Table 7). However, limited information is given in the studies 
regarding funding, the location in which the studies were conducted, and the methods of 
recruitment used. This has further implications for quality of these studies and their 
results. 
 
Table 7. Settings and Context of the Studies Retrieved. 
Study Level of 
Evidence 
Geographical 
location and study 
site 
Recruitment 
(Butler, 1998) 4. Case-study Not identified in the 
study 
Not identified in the study 
(Kerns & 
Thomson, 1998) 
4. Case-study Location unknown, 
the study site was the 
patients’ school 
Not identified in the study 
(Penkman & 
Scott-Lane, 
2007) 
4. Case-study Canada, study site 
unknown 
Purposive sample; children 
treated through the 
southern Alberta children’s 
cancer programme  
83 
c) Participants 
 
All of the participants in the retrieved studies have been diagnosed with a brain tumour 
(Table 8). However, the Butler (1998) study does not identify the patient’s tumour type. 
This may have implications for determining the effectiveness of the intervention, as the 
degree and type of impairment can be dependent upon the type of tumour (Nejat et al., 
2008). Thus the presentation of the patient in Butler’s (1998) study may have minimal 
impairment compared to patients with other tumour diagnoses. 
 
Two studies used a male patient (Penkman and Scott-Lane, 2007, Butler, 1998). The 
third study Kerns and Thomson (1998) used a female patient. The mean age for the 
patients was 10 years (Table 8).  
 
 Limited information was given regarding any previous cognitive and learning 
difficulties prior to the patients’ tumour diagnosis. Only the Kerns and Thomson (1998) 
study noted that there were no development difficulties prior to the patient’s tumour 
diagnosis. Furthermore, none of the studies reported information pertaining to the 
participants’ level/stage of education (Table 8). 
 
 All three patients received a course of radiotherapy, with the patient in the Butler (1998) 
study receiving 2000 cGy and the patient in the Penkman and Scott-Lane (2007) 
receiving a dose of 5580 cGy in 31 fractions. The dosage for the Kerns and Thomson 
(1998) study is not reported. Two of the patients underwent a resection of their tumour, 
with the Kerns and Thomson (1998) patient receiving surgery on two separate occasions 
due to tumour regrowth (Kerns and Thomson, 1998, Penkman and Scott-Lane, 2007). 
The patient in Kerns and Thomson (1998) and Penkman and Scott-Lane (2007) studies 
also received a course of chemotherapy; the chemotherapy (Cisplatin, vincristine, 
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cyclophosphamide) in the Penkman and Scott-Lane (2007) study was adjuvant to 
radiotherapy. 
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Table 8. Patients Recruited in the Included Studies.  
Study Sample size (n), 
age, gender 
Tumour type Deficits or illness 
prior to the brain 
tumour 
Primary treatment interventions  
(Butler, 1998) 1, 10 years old, 
male 
Not stated in the study Not stated in the study Received cranial irradiation (2,000 cGy) 
(Kerns & Thomson, 
1998) 
1, 13 years old, 
female 
Astrocytoma in the 
area of the optic 
chiasm and 
hypothalamic area, 
with extension into the 
third ventricle 
No history of 
developmental 
difficulties. 
Initially underwent craniotomy, with biopsy and debulking of the tumour. At 11- 
years-old a left and right sided VP shunt was placed and irradiation treatment. Due 
to continued growth of the tumour, the patient underwent another craniotomy for 
tumour debulking at 12 years old and a course of chemotherapy.  
(Penkman & Scott-
Lane, 2007) 
1, 8 years old, 
male 
Medulloblastoma Not stated in the study Near gross total resection of the tumour. Additionally cranial irradiation treatment 
(5580 total cGy in 31 fractions) and adjuvant chemotherapy (cisplatin, vincristine, 
cyclophosphamide) with four autologous stem cell transplant procedures. 
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d) Assessment Procedure 
 
All of the patients in the studies were assessed using outcome measures that were 
directly undertaken with the patient and not with a proxy individual such as a teacher or 
parent (Table 9). The most commonly used measures were a variation of the Wechsler 
Intelligence Scale for Children and the WRAML, which were used in all of the studies 
to assess the cognitive impact of the interventions.  
 
In addition to these measures a variety of other assessments were used to evaluate the 
impact of the intervention on a patient’s learning outcome. Both the Butler (1998) and 
Kerns and Thomson (1998) studies used a version of the Wide Range Achievement Test, 
in comparison to Penkman and Scott-Lane (2007) who used the WIAT-II. Additional 
measures were used in the Penkman and Scott-Lane (2007) study to further assess the 
impact of the intervention on the patient’s vocabulary and visual-motor deficits, these 
included PPVT-III, EOWPVT-R and Beery VMI (Table 9). The CPT was used in the 
Butler (1998) study to identify potential cognitive deficits. The computer program is 
commonly used as a screening tool to identify potential attention problems, and as an aid 
in monitoring treatment effectiveness (Conners & Jett, 1999). 
 
All of the studies utilised pre and post-treatment measures (Table 9). However, the 
Kerns and Thomson (1998) study compared the pre-treatment results of the WRAT-R, 
WISC-R and the WRAML to post-treatment scores taken two years post-treatment. The 
study stated that measures were also taken one year after treatment, but in the interests 
of brevity and due to little change in the patient’s performance over time they only 
reported the results two years post-intervention. Penkman and Scott-Lane (2007) also 
conducted a follow up assessment at eight months post-intervention.  
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Table 9. Outcome Measures used in the Assessment of Patients in Studies Retrieved. 
Study Learning outcome  Cognitive outcome Outcome measures 
(direct/proxy) 
Measurement periods 
(Butler, 1998) Continuing performance test 
results, Wide Range 
Achievement Test 3 
(WRAT-3) 
Wechsler Intelligence Scale for Children 3rd 
Edition (WISC-III), the Wide range assessment of 
memory and learning (WRAML) and Continuing 
performance test (CPT) 
Direct Pre (three baseline scores were 
recorded) and post-treatment 
(Kerns & 
Thomson, 1998) 
Wide Range Achievement 
Test-Revised (WRAT-R) 
 Wechsler Intelligence Scale for Children – Revised 
(WISC-R) and WRAML 
Direct Pre and  post-treatment (2 years) 
( Penkman & 
Scott-Lane, 2007) 
Wechsler Individual 
Achievement Test-II 
(WIAT-II) (word reading, 
reading comprehension, 
pseudoword decoding, 
numerical operations, maths 
reasoning and spelling 
subtests 
 WISC-III, WRAML, Peabody Picture Vocabulary 
Test – 3rd Edition (PPVT-III), Expressive  One 
Word Picture Vocabulary Test Revised (EOWPVT-
R) and the Beery Test of Visual Motor Integration 
(VMI) 
 
 
Direct Pre (2 months prior to the initiation 
of the intervention), post-treatment  
(8 months post-intervention follow 
up) 
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e) Intervention 
 
 All of the studies assessed different aspects of cognitive functioning and learning 
outcomes and were given a psychosocial intervention. None of the studies included in 
this review utilised pharmaceutical interventions. A different intervention was utilised in 
each study to explore how it might benefit a paediatric neurooncology population. Thus 
there were limited similarities between the interventions (Table 10). One similarity was 
the importance of academia in a child’s development, therefore all of the studies worked 
collaboratively with the patient’s school as part of the intervention. Both the Butler 
(1998) and Penkman and Scott-Lane (2007) studies utilised a form of hierarchical 
questions or techniques combined with massed practice (a continuous practice of 
different cognitive drills), to develop the patient’s skills. However, the Kerns and 
Thomson (1998) paper use a repetition of learning a strategy and academic information 
(Table 10). 
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Table 10. Interventions conducted by the Included Studies. 
Study Description of the Intervention  Duration of the 
Intervention 
Lead 
Professional  
(Butler, 1998) Hierarchically graded activities were undertaken to strengthen attentional, perceptual, and non-verbal cognitive 
processes. An individual therapist identified ineffective strategies and new strategies were taught. The patient 
received CBT to strengthen their ability to ignore and withstand distraction in addition to a series of activities 
that promoted arithmetic concept development. To maximise effective encoding, the patient brought their 
school homework into therapy to monitor and encourage the use of new strategies 
Six months, with one 
per week, over two 
hours 
Not stated  
(Kerns & 
Thomson, 
1998) 
The memory notebook was collaboratively developed by the patient, teachers and a school counsellor in 
accordance with the patient’s needs. The notebook training programme incorporated behavioural techniques, 
procedural learning, error free learning techniques and effective building strategies. The training programme 
utilised three stages. The acquisition stage focused on the patient’s understanding of the notebook. During the 
application stage the patient recorded and referred to the memory system. The final adaption stage was used to 
modify and adapt the system to the functional needs of the patient and modify any problems. An additional 
daily checklist was developed for the patient in this study. 
The exact time scale 
is not stated. 
However, it is 
estimated ten weeks. 
Used all day in 
conjunction with the 
school timetable. 
Teachers and a 
counsellor 
(Penkman & 
Scott-Lane, 
2007) 
An individual programme of the patient’s strengths and weaknesses was developed based upon academic 
performance and neuropsychological assessment, from which academic objectives were developed. Drills, 
practice and repetition were used. Lessons were created to build on skills as they had mastered. 
Twelve weeks, five 
days per week, two 
hours per day 
School teacher, 
Neuropsychologist 
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f) Outcomes 
 
i. Cognitive Outcomes  
Table 11 demonstrates that the study by Butler (1998) was the only intervention to show 
improvements in the majority of aspects assessed. Improvements were achieved in areas of arithmetic, 
sentence memory and on the Continuing Performance Test. Consequently the pre and post scores 
reflected improvements in the patient’s attention skills. However, the patient’s performance on Digit 
Span decreased from the first and third baseline scores to the post-treatment scores, but it is 
interesting to note that there was an increase from the second baseline score. 
 
Cognitive performance was maintained in the Kerns and Thomson (1998) study, with the patient 
continuing to maintain a high average Full Scale IQ (Table 11). Qualitative feedback from the 
patient’s teachers indicated the patient had made improvements in everyday activities such as 
punctuality and remembering to undertake tasks. However, it is important to note that the patients Full 
Scale IQ dropped by five points, similarly the patient’s verbal IQ (117 to 114) and performance IQ 
(114 to 111) also reduced, although these were not significant declines. The patient also continued to 
demonstrate significantly impaired memory and new learning.  Furthermore, significant raw and 
scaled score declines and below average (25
th
 percentile) abilities were observed in information and 
picture arrangement, indicating the patient was having difficulty acquiring new verbal and social 
information. 
 
ii. Learning Outcomes 
 
All of the studies demonstrated some improvements in learning outcomes, particularly arithmetic 
(Butler, 1998; Kerns & Thomson, 1998; Penkman & Scott-Lane, 2007) (Table 11), but these 
improvements were not maintained long-term in the Penkman and Scott-Lane (2007) study. 
Furthermore, both Kerns and Thomson (1998) and Penkman and Scott-Lane (2007) highlighted 
several declines. The Kerns and Thomson (1998) study indicated a slight decline in age-related 
91 
 
percentile ranking. In the Penkman and Scott-Lane (2007) study, despite the maintenance of 
performance on some subtests, the patient did not achieve his educational objectives in reading and 
writing. Post-treatment follow up did show an improvement approaching seven standard scores on the 
reading comprehension subtest though. 
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Table 11. Outcomes of the Included Studies. 
Study Learning Outcomes Cognitive Outcomes Additional Comments 
(Butler, 
1998) 
Improvements noted in arithmetic 
competence. Improvement in grade 
levels, after the intervention the 
patient was generally within normal 
limits (gained 1.5 to 2.0 grade 
levels). 
Pre and post-measures 
reflect improvements 
in attentional skills  
 
(Kerns and 
Thomson, 
1998) 
There was an increase in scores on 
the WRAT-R spelling, reading and 
math subtests. There was a slight 
decline in age-related percentile 
ranking.  
The patient continued 
to demonstrate a high 
average overall 
intellectual ability. But 
a decline and below 
average abilities (25th 
percentile) in 
information and picture 
arrangement. In 
addition to 
significantly impaired 
memory and new 
learning. 
In addition to the 
outcome measures, 
none of the patient’s 
teachers continued to 
report any concerns 
regarding difficulties 
handing in assignments 
or getting to class on 
time.  
(Penkman 
and Scott-
Lane, 
2007) 
A Significant improvement on 
pseudo word decoding and spelling. 
Although performance on the word 
reading, reading comprehension, 
numerical operations and math 
reasoning showed no significant 
changes. The patient did not achieve 
his educational objectives, in 
reading/writing all words up to and 
including grade 2 level on the Dolch 
sight-reading list. Although 
improvement was demonstrated. 
Achieved objectives to write and 
recognise a phonic vocabulary. The 
patient achieved maths objectives 
set by his tutor. 
 Parent satisfaction 
questionnaires rated 
the patient’s progress 
as considerable. The 
tutor’s perspective 
suggested that the 
patient struggled with 
reading, but had made 
considerable progress 
in this domain; 
progress in 
mathematics is 
described as 
substantial.   
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g) Quality Ratings  
Table 12. Overview of the Methodological Criteria Met or Not Met by the Individual Studies. This is Drawn from the Downs and Black (1998) Quality 
Assessment Tool. 
Study 1. Reporting 2. External 
Validity 
3. Internal Validity – bias 4. Internal Validity – 
Confounding 
5. 
Power 
Total 
Score 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27  
(Butler, 
1998) 
0 0 0 1 0 0 1 0 - 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 5 
(Kerns & 
Thomson, 
1998) 
0 1 1 1 0 1 1 1 - - 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 9 
(Penkman 
& Scott-
Lane, 
2007) 
1 1 1 1 0 1 1 1 - - 1 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 11 
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Due to the limited number of retrievals, no restrictions were made on the methodological 
quality of the studies included in the results. The methodological quality was measured 
using the Downs and Black (1998) assessment tool. Table 12 shows the ratings for each 
of the 5 criteria, if applicable, across all the studies. Each of the criteria is individually 
numbered and corresponds with the note Downs and Black (1998) assessment too 
(Appendix II).  
 
i. Reporting 
This section of the tool assesses whether the information provided in the studies is 
sufficient to allow a reader to make an unbiased assessment of the findings of the study. 
Butler (1998) does not adequately report the main features, such as the characteristics of 
the patient (Table 12).  Although the hypothesis, main outcomes and interventions are 
described, further clarification needed to be provided. Additionally, the procedure is 
described in relation to how the intervention would be administered to a general 
population, with limited details about how it was administered to the patient described in 
the study. For example, it does not state which ineffective strategies were identified or 
what cognitive behavioural interventions were offered to strengthen the patient’s ability 
to ignore and withstand distraction. Although the study does not provide estimates of 
random variability in the data for the main outcomes, Downs and Black (1998) suggest 
that it should be assumed that the estimates used are appropriate.  
 
Alternatively, the Penkman and Scott-Lane (2007) and Kerns and Thomson (1998) 
studies present a clear hypothesis and adequately describe the interventions utilised in 
the studies. Similarly, these two studies also provide details of the characteristics of the 
patients involved in the studies. However the Penkman and Scott-Lane (2007) study 
does mention the patient’s premorbid presentation (prior cognitive or learning 
difficulties), which could be an important factor in the results of this study. Furthermore 
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the Kerns and Thomson (1998) study only comments on the follow up assessment 
results (two year follow up) due to “interest of brevity and because there was little 
change” (Kerns and Thomson, 1998, p82). For the purposes of clarity it would have 
been useful to include all of the results and see what changes the patient made, even if 
they were small gains or further deficits over the two-year follow up. 
 
ii. External Validity 
The Downs and Black (1998) assessment also addressed the extent to which the findings 
of the studies can be generalised to the population from which the study participants are 
derived. Only the Penkman and Scott-Lane (2007) study discussed their selection 
criteria; the sample size of the population from which the patient was drawn was very 
small, thus only one patient met the inclusion criteria. 
 
All of the studies were undertaken from a case series design; therefore limited 
generalisations could be made about the results. Although the results do establish 
mechanisms by which cognitive and learning impairment can be supported. 
 
iii. Internal Validity – Bias 
The internal validity is addressed by the measurement of bias in the intervention and the 
outcome. All of the studies did little to exclude alternative explanations and highlight 
potential limitations in relationships identified in the studies. There were no attempts to 
blind the subjects to the interventions they received. There was also no information 
regarding the blinding of the facilitators measuring the main outcomes. Limited 
information concerning the patient’s compliance with the interventions was also 
discussed. However, the facilitators monitored all of the interventions. 
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Although all of the studies utilised a case series design, none of the measures used the 
reliable change index to identify significant change (Jacobson & Truax, 1991).  
 
Despite the limitations in the internal validity of the studies, all utilised at least one valid 
and reliable outcome measure such as the WISC, WRAML, WRAT and WIAT. 
 
iv. Internal validity – Confounding  
This section assesses the bias in the selection of participants for the studies. It was 
difficult to answer the questions in this section, as the participants were all case series 
designs and limited information was given regarding their recruitment, as previously 
noted in section ii, external validity. Consequently, randomisation was not used in the 
selection criteria. Due to limited information in the analysis it is difficult to determine if 
adequate adjustment was made for confounding aspects.  
 
v. Power 
The power section of the assessment tool attempts to assess whether the negative 
findings from a study could be due to chance. However, as all the studies were case 
series’, sufficient power to detect a clinically important effect could not be achieved. 
 
vi. Overall Quality 
 
None of the studies achieved the total 31 points from the Downs and Black quality 
assessment tool. The Penkman and Scott-Lane (2007) study achieved the highest score 
of 11 points; this is still disappointing though as higher overall scores indicate higher 
methodological quality.  
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4.1.2 Excluded Studies  
A total of 2,511 studies were extracted from the review for not meeting the inclusion 
criteria. 1,876 of these studies were not related to paediatric neurooncology. 1,100 
involved adults or a combination of paediatric patients and adults. 2,397 of the excluded 
studies did not focus on an intervention for paediatric neurooncology patients. 24 studies 
were excluded despite using a paediatric neurooncology population because the results 
of these studies were combined with paediatric patients with a variety of different non-
neurological malignancies.  
 
Of the 41 secondary search results 29 were excluded because they did not focus on an 
intervention for paediatric neurooncology patients and 8 were excluded because the 
results were combined with other diagnoses.  
 
4.1.3 Combined Diagnoses. 
Despite not meeting the inclusion criteria for this thesis, due to limitations of combined 
diagnosis, several of the thirty-one papers retrieved may still have been of benefit to 
paediatric neurooncology rehabilitation literature. Of these studies, nine may have been 
of importance to the results of this thesis.  
 
The patients utilised in these studies included an amalgamation of acute lymphoblastic 
leukaemia and brain tumour patients. Although the number of patients from each 
diagnosis could be identified in the sample, the results for each diagnosis were not 
reported individually. Therefore the results could not be separated to determine which 
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results were related to the brain tumour patients and could not be reported in this thesis 
due to a risk of confounding results. 
 
Despite demonstrating some important results, the excluded studies could not be 
addressed in this thesis. Yaffe et al., (2012) acknowledged the potential bias from 
including excluded research in systematic reviews. Hence, the studies identified as being 
potentially relevant will not be utilised in this thesis. Table 13 and 14 present summaries 
of the outcomes of the studies that demonstrate potentially important findings for the 
paediatric neurooncology literature. 
 
The results of Table 13 demonstrate that psychostimulants such as MPH have 
established improvements in paediatric survivors of brain tumours. Particularly studies 
by Mulhern and Conklin, who have identified meaningful results such as reductions in 
attention deficits. These are important findings due to the prevalence of attention 
problems among the paediatric brain tumour population (Mulhern et al., 2001). It is 
important to note from table 13 that the Conklin et al., (2007, 2010a & 2010b) papers all 
used the same data set, but reported on different factors. Consequently these studies all 
use similar high quality experimental designs, which increase the reliability of their 
outcomes. This is important as all of the studies demonstrated some form of 
improvement cognitive deficits, particularly attention. 
 
Table 14 presents studies that may have provided more insight into the use of 
psychosocial interventions in paediatric patients with cancer of the CNS. The studies 
demonstrated also positive results with deficits in attention. In comparison to the studies 
included in the review, these studies utilised higher quality experimental designs, due to 
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the larger population samples. Thus the outcomes may be a more accurate representation 
of the paediatric population than the single case study design. 
 
4.1.4 Ongoing Studies 
The author knows of no ongoing studies or recently published studies that would be 
relevant to this review. 
 
4.1.5 Significant Studies Not Retrieved in the Search 
A further two studies which may could have been of interest to this thesis were 
identified after the study had been concluded. These included studies by Callu et al 
(2008) and Rankin and Hood (2005).  Both studies discussed cases which explored the 
use of cognitive and support strategies to support patients with a diagnosis of 
medulloblastoma. Despite meeting the inclusion criteria the search did not identify these 
papers. Although this does not reflect a weakness in the search strategies developed for 
this thesis, as they were embedded in more general acquired brain injury papers. 
 
4.1.6 Summary and Conclusions  
Although all three of the studies have their limitations, particularly the methodological 
design, they all demonstrate positive advancements in the rehabilitation of cognitive and 
learning deficits within the paediatric neurooncology population. It is important to 
acknowledge that all of the interventions retrieved in this thesis are related to 
psychosocial interventions. 
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Table 13. An Overview of the Excluded Studies due to Diagnosis Treated with Pharmaceutical Interventions 
Authors Title Design Interventions Outcomes 
Netson et al., 2011 Parent and teacher ratings of attention 
during a year-long methylphenidate trial 
in children treated for cancer. 
A  multiphase longitudinal 
double-blind crossover trial 
 
Dependent upon the trial 
patients randomly received a 
variety of does MPH. 
Parents and teachers reported 
fewer problems in the areas of 
attention/cognitive problems, 
hyperactivity and ADHD 
symptoms one month after 
receiving MPH 
Conklin et al., 2010a Predicting Methylphenidate Response in 
Long-Term Survivors of 
Childhood Cancer: A Randomized, 
Double-Blind, Placebo-Controlled, 
Crossover Trial 
A Randomized, Double-Blind, 
Placebo-Controlled, 
Crossover Trial 
Patients randomly received a 
single dose of MPH (0.60 
mg/kg; maximum 
dose 20 mg) on day 1 and 
placebo on day 2, or the reverse, 
in a double-blind crossover 
design 
MPH provides improvements 
for cognitive and behavioural 
symptoms of inattention in a 
subset of the population. 
Conklin et al., 2010b 
Long-Term Efficacy of Methylphenidate 
in Enhancing Attention Regulation, 
Social Skills, and Academic Abilities of 
Childhood Cancer Survivors  
 
A  multiphase, multisite trial  
Combining numerous 
randomized, double-blind, 
placebo-controlled, crossover 
trials  
 
Dependent upon the trial 
patients randomly received a 
variety of does MPH. The 
dosage ranged from a low-dose 
MPH (0.3 mg/kg; maximum 
dose, 10 mg twice daily to 18 
mg daily and was titrated 
upward to 27 mg/d, and 
possibly 36 mg/d. 
 
 
The findings demonstrated the 
maintenance of attention and 
behavioural benefits of MPH 
over a year. 
Conklin et al., 2007 Acute neurocognitive response to 
methylphenidate among survivors of 
childhood cancer: a randomized, double-
blind, cross-over trial 
A randomized, double-blind, 
cross-over trial 
Patients received MPH 
(0.60 mg/kg of body weight) 
and placebo that were 
randomized in administration 
order across participants. 
Performance was evaluated 
using measures of attention, 
memory, and academic 
achievement.  MPH has a better 
response with male patients who 
were older at the time of 
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treatment and of higher 
intelligence 
Mulhern et al., 2004a 
A randomized, double-blind, placebo-
controlled trial of methylphenidate for 
attention problems in survivors of 
childhood cancer  
 
A randomized, double-blind, 
placebo-controlled trial 
Patients were given a three-
week home cross-over trial of 
Placebo, low dose MPH (LD; 
0.3 mg/kg; maximum dose 10 
mg b.i.d.), and moderate dose 
MPH (MD; 0.6 mg/kg; 
maximum dose 20 mg b.i.d.).  
 
Short-term treatment with low-
dose MPH can reduce 
attentional problems among 
survivors of childhood CNS 
tumours. 
Mulhern et al., 2004b 
Short-Term Efficacy of Methylphenidate: 
A Randomized, Double-Blind, Placebo-
Controlled Trial Among Survivors of 
Childhood Cancer 
 
A randomized, Double-Blind, 
Placebo-Controlled Trial 
Patients were enrolled in a 3-
week home cross-over trial of 
placebo (bid), low-dose MPH 
(0.3 mg/kg; maximum dose, 10 
mg bid), and moderate-dose 
MPH (0.6 mg/kg; maximum 
dose, 20 mg bid).  
 
Statistical significance and 
clinically relevant temporary 
improvement in attention and 
cognitive behaviours, with 
teachers also reporting 
improvements in academic 
competence.  
Thompson et al., 2001 Immediate neurocognitive effects of 
methylphenidate on learning-impaired 
survivors of childhood cancer 
A randomized, double-blinded, 
placebo-controlled trial of MPH 
 
Patients were administered a 
placebo (lactose) or MPH (0.6 
mg/kg; 20 mg maximum)  
 
The results identified a 
statistically significant 
improvement on measures of 
sustained attention and overall 
index of attention problems. 
Although verbal memory 
showed greater improvement 
than the placebo group this was 
not significant. Furthermore, the 
ability to inhibit impulsive 
responding and reaction times 
did not improve significantly. 
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Table 14. An Overview of the Excluded Studies due to Diagnosis Treated with Psychosocial Interventions 
Authors Title Design Interventions Outcomes 
Hardy et al., 2011 Computerized Cognitive 
Training in Survivors of 
Childhood Cancer: A Pilot 
Study 
A single-arm design 
The Captain’s Log intervention 
program, consisted of 33 
multilevel, entertaining, game-
like “brain-training” exercises 
aimed at improving memory, 
attention, concentration, 
listening skills, self-control, 
patience, and processing speed. 
The intervention was conducted 
at least 50 minutes per week for 
12 weeks, including the 2 prior 
cognitive interventions assessed 
with survivors.  
Outcomes demonstrated 
significant increases in working 
memory and decreases in 
parent-rated attention problems.  
Butler et al., 2008 
A Multicenter, randomized 
clinical trial of a cognitive 
remediation program for 
childhood survivors of a 
paediatric malignancy 
 
A multicenter, randomized trial 
Participants given the 
intervention were seen for a 
total of up to 20 two-hr weekly 
sessions over 4–5 months. The 
interventions were 
programmatic but 
individualized, with three 
interdependent components: (a) 
hierarchically graded massed 
practice, (b) strategy 
acquisition, and (c) cognitive–
behavioural interventions 
 
The intervention resulted in 
reports of improved attention 
and statistically significant 
increases in academic 
achievement.  
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Van’t Hooft et al., 2007 
 
 
Sustained favourable effects of 
cognitive training in children 
with acquired brain injuries 
A randomized control trial The Amat-c involves a 
combination of daily practice 
and games/exercises in specific 
attention and memory 
techniques. It utilises behaviour 
modification, focused on 
learning strategies in daily life, 
and on the accomplishment of 
school tasks. The exercises are 
performed for 30 minutes 6 days 
per week for a period of 17 
weeks, and gradually increase in 
difficulty. 
The treatment group exhibited 
significantly more persistent 
improvements in complex tasks 
of attention and memory in 
comparison to the control group. 
However, there were no 
differences on simple reaction 
time tests. 
Butler & Copeland., 2002 
Attentional processes and their 
remediation in children treated 
for cancer: A literature review 
and the development of a 
therapeutic approach 
 
A randomised trial Twenty-one patients completed 
a  cognitive remediation 
program 
 
Those in the intervention group 
demonstrated statistically 
significant improvement on all 
attentional measures. In 
contrast, the comparison group 
did not manifest any significant 
changes. Neither group 
demonstrated statistically 
significant changes on the 
arithmetic achievement test. 
 
104 
 
CHAPTER FIVE: DISCUSSION 
Recent medical developments have resulted in individuals with paediatric brain tumours 
living longer, consequently learning and cognitive deficits within this population have 
become of greater concern to researchers and clinicians. As far as it is known, no 
systematic reviews of the effectiveness of psychosocial and pharmaceutical interventions 
have been conducted. To investigate the research that exists for both psychosocial and 
pharmaceutical interventions, a systematic review was undertaken. The implications of 
the results for both research and clinical practice are stated. 
 
5.1 The Effectiveness of Interventions for Paediatric Neurooncology Patients 
5.1.1 Included Studies 
5.1.1.1 Outcomes 
 
 
A total of three studies were included in this thesis, all of which identify improvements 
in a patient’s neurocognitive and/or learning abilities as a consequence of specific 
psychosocial interventions. Despite these promising findings, it has been difficult to 
evaluate the effectiveness and generalisability of these interventions on the paediatric 
brain tumour population because each intervention aimed to facilitate the rehabilitation 
of different deficits such as memory or academic attainments (such as arithmetic) (Kerns 
& Thomson, 1998; Penkman & Scott-Lane, 2007). The heterogeneity of the patient 
sample also had consequences for the outcomes of this thesis. With no clear delineation 
of many important details such as the patient’s tumour type or prior deficits, it has been 
difficult to make any tangible conclusions. For the purposes of clarity the results will be 
reviewed in relation to the specific neurocognitive and learning outcomes that were the 
focus of the intervention. 
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5.1.1.1.1 Neurocognitive and Learning Outcomes  
 
 
The main focuses of the studies were rehabilitation interventions that targeted some of 
the most prevalent neurocognitive impairments identified in paediatric neurooncology 
literature. These included attention and memory (Copeland et al, 1999; Mulhern et al, 
2001; Mabbott, Penkman, Witol, Strother, & Bouffet, 2008; Mulhern, et al. 2004b). In 
addition to assessing the outcome of the interventions on neurocognitive deficits, IQ 
scores and academic attainment were also an important focus. Reddick et al. (2003) 
proposed a relationship between neurocognitive deficits, academic achievement and 
declining IQ in his developmental model (Figure 4). This model suggested that declining 
IQ and diminishing academic achievement scores may be a direct result of attention and 
memory deficits, which is also linked to a reduction in normal-appearing white matter 
volume.  
 
a)  Attention 
Attention can be separated into a variety of different domains/sub-domains, including: 
focused, sustained, selective, alternating and divided, highlighting the complexities of 
this aspect of cognition (Mapou & Spector, 1995). With focused attention identified as 
the main concern for the paediatric neurooncology population (Dennis et al, 1998) 
Attention has a significant role in information processing, and is thought to be the 
foundation of most cognitive and neuropsychological functions (Cooley & Morris, 1990; 
Eysenck & Keane, 2005). Dennis et al. (1998) suggest that attention may be an 
important factor in the acquisition of new information. The impairment of an 
individual’s ability to acquire new information could be a significant hindrance to future 
learning and development, specifically academic achievement. Therefore it is 
unsurprising that attention is an important aspect of rehabilitation literature and this is 
addressed by the studies retrieved in this thesis. 
106 
 
An evaluation of an attention process training programme was undertaken by Butler 
(1998), which aimed to strengthen attention, perceptual and non-verbal cognitive 
processes. The results of the Butler (1998) study demonstrated an improvement in 
attention skills and areas of arithmetic competence. The patient’s post-treatment scores 
increased over time from the second baseline assessment, but it is important to note that 
the scores never returned to the same level as the initial baseline scores in the WISC-III, 
which measures intellectual functioning, measuring verbal and performance scales (the 
verbal scale includes: general knowledge, language, reasoning, and memory skills, while 
the performance scales measures: spatial, sequencing, and problem-solving skills). 
However, improvements in the baseline scores are noted on the WRAML, an assessment 
which evaluates memory functioning and the WRAT-3, which measures the basic skills 
of reading, spelling and arithmetic, highlighting potential discrepancy between the 
WISC-III scores and the scores for the WRAML and the WRAT-3, as these tests utilise 
similar cognitive functions such as attention and memory.  
 
The discrepancies in the scores may be accounted for by improvements in memory in 
the WRAML and WRAT-3. Sentence memory in the WRAML evaluates immediate 
verbal memory and arithmetic skills, which have been linked with visuo-spatial working 
memory (Ashkenazi, Rosenberg-Lee, Metcalfe, Swigart, & Menon, 2013; Sheslow & 
Adams, 2009). Whereas digit span and arithmetic both explore freedom from 
distractibility, which incorporates aspects of attention and working memory (Kaufman, 
1994). 
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i. Limitations of the Butler (1998) study 
 
Although the Butler (1998) study provides some positive results which support the use 
of an attention process training programme, there are also a number of factors which 
make it difficult to draw clear conclusions from the findings. Limited information is 
given about the patients utilised in the study, providing the reader with just the patient’s 
type of tumour and any previous cognitive or learning difficulties. There is no 
information regarding the sample from which the patient was drawn or what methods of 
selection were used. Butler himself recognises that gains made by the patient during the 
intervention may not have been a direct result of treatment efforts and may instead have 
been gained via recovery processes and/or typical development. Thus further research 
considering how different aspects of attention, for example, focused, selective, 
sustained, alternating and divided, can be incorporated into rehabilitation strategies, 
needs to be undertaken to support this finding. 
 
Furthermore, the study only presents a brief analysis of the findings. It does not account 
for the missing results for the post-treatment Verbal IQ score. There is also no 
explanation for the decrease in functioning between the patient’s baseline and second 
scores, although it is hypothesised that this may be the consequence of the patient’s 
radiotherapy treatment. Mulhern et al. (2004a) suggest that a decline in a patient’s IQ 
may be linked to the loss of cerebral white matter and a failure to develop white matter 
at an adequate rate in relation to the child’s development. White matter depletion is 
noted to be associated with radiotherapy and may help to explain the differences 
between the baseline scores (Moore, 2005).  
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ii.Recommendations 
Attention process training programmes require testing on a larger scale, with more 
participants. This study was published in 1998 and may have been the initial work for 
some of Butler’s more recent studies using cognitive behavioural therapy and 
metacognitive strategies techniques as part of the cognitive remediation intervention 
(Butler & Copeland, 2002). It is disappointing that Butler’s more recent studies utilised 
heterogeneous patient populations (brain tumour and leukaemia patients), as they 
provide support and reinforce the results of this study by demonstrating improved 
attention and academic achievement via randomised studies. 
 
b)  Memory 
Memory is a vital storage system, but it also is involved with many other important 
functions, such as cognitive flexibility and planning ability, as well as the ability to self-
monitor, it is also important in higher order thinking, learning, and academic 
achievement. (Eysenck & Keane, 2005; Just & Carpenter, 1992). Because of these 
functions memory is an important focus for rehabilitation interventions. The study 
conducted by Kerns and Thomson (1998) focused on the development and 
implementation of a compensatory memory aid. 
 
The results of the Kerns and Thomson (1998) study demonstrated that the patient 
maintained an average overall IQ score on the WISC. Although there was no 
improvement in the results of the outcome measures, these are positive findings as a 
compensatory aid should enable the patient to maintain their level of functioning. 
Previous studies have demonstrated that children who develop a brain tumour and 
undergo a variety of different primary interventions have an increased risk of cognitive 
and learning deficits, which are often demonstrated by secondary consequences such as 
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IQ loss and sub-optimal academic achievement (Butler & Mulhern, 2004). Therefore 
being able to maintain an overall level of cognitive functioning/academic achievement 
demonstrates a possible improvement in some areas of cognitive functioning. 
 
Despite these positive findings, it is of concern that the patient demonstrated problems 
with memory and new learning on the WRAML, and information and picture 
arrangement on the WISC, which may indicate difficulties in acquiring new verbal and 
social information. As previously noted Dennis, Hetherington, and Spiegler (1998) 
suggest cognitive deficits may be related to deficiencies in basic processes by which 
knowledge is acquired by considering evidence for the negative long-term effects of 
primary treatments, such as neurosurgery, chemotherapy and radiotherapy, on white 
matter. Supporting research which links cognitive and academic deficits to a diminished 
ability to acquire new information, rather than a loss of previously learnt information 
(Palmer et al., 2001).    
 
Other important findings from the compensatory memory study are related to academic 
achievement. Although some of the patient’s scores increased slightly, the patient 
demonstrated a slight decline in age-related percentile ranking on the WRAT-R. This 
may suggest that although the intervention has provided some support for a range of 
academic challenges, the patient’s level of academic achievement was still below that of 
the normal population. Improvement was also evident to the patient’s teachers, who 
reported positive feedback in that they had no concerns about the patient handing in 
assignments or getting to class on time. However, this functional outcome is susceptible 
to bias and cannot be appropriately measured.  
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c) Academic Achievement 
The Penkman and Scott-Lane (2007) study focused solely on academic skills. The 
study’s aim was to primarily evaluate the feasibility of delivering a prophylactic 
academic intervention to a child, whilst they are receiving an intensive medical 
treatment. As previously noted, this was not the main focus of this thesis. This thesis 
was concerned with the outcomes related to the effectiveness of the one-to-one academic 
tuition, and how it facilitates the development of compensatory skills.  
 
The results suggest that the patient was able to make improvements above the pre-
treatment baseline measures in areas of reading, particularly the ability to apply phonetic 
decoding skills, written language and the ability to spell. Although the results indicate 
improvements in the areas of word reading, reading comprehension and pseudo word 
these were not significant improvements. The patient did not improve in the areas of 
Numerical Operations and Mathematical Reasoning, which are both composite scores on 
the WIAT-II. As previously described, this may also be related to potential memory 
deficits (Ashkenazi et al., 2013). 
 
Likewise the patient only met one of his educational objectives, which was to write and 
recognise a phonic vocabulary of twenty-nine graphemes. The patient was not able to 
read and spell all words up to and including grade two level on the Dolch sight-reading 
assessment. It is interesting that the mathematical objectives were not evaluated, 
particularly when numerical attainment was the only aspect that the patient did not 
improve upon on the WIAT-II test results. The study stated there were no measures 
available to systematically evaluate this aspect of academic achievement. 
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It is evident that there is support for specific educational tutoring programs, which show 
some efficacy at improving selected academic skills (i.e. mathematics). Although it 
seems that these programmes do not specifically address the cognitive deficits that 
underlie survivors’ academic problems. 
 
i. Prophylactic Interventions 
This study assessed the feasibility and effectiveness of an individualised prophylactic 
academic intervention. Although the study is related to a medical treatment, with the aim 
of improving academic skills in a patient who is at high risk of cognitive delay. It is still 
important to address the controversy surrounding the ethics of utilising a prophylactic 
intervention.  
 
Prophylactic interventions are preventative interventions that are used to prevent rather 
than treat a problem. Hence it is important to determine if the intervention is in the 
patient’s best interests and if it will be of benefit to the patient. Hodges, Svoboda, and 
Van Howe (2002) feel that this is of high importance when working with paediatric 
populations, as children are unlikely to give meaningful informed consent. They believe 
children should not have to undertake a prophylactic intervention when other more 
conservative interventions exist. The Penkman and Scott-Lane (2007) do not address the 
ethics of using a prophylactic intervention, but they note the evidence for cognitive 
delay and impaired academic achievement in their rational of the study. 
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5.1.1.2 Impact of Moderating Factors on Interventions 
  
The impact of moderating factors on the results are further aspects which need 
considering in the context of the results. 
 
a) Age 
Research indicates that six years of age is a critical period for determining 
neuropsychological outcomes during primary treatment, particularly for those under 
three years of age (George et al., 2003; Palmer et al., 2003; Palmer et al., 2001). It was 
difficult to determine the impact of age on the results, as the patients’ age ranged 
between eight and thirteen years of age. This also made it difficult to comment on the 
impact of the early vulnerability hypothesis, which will be reviewed later in this 
discussion. 
 
b) Impact of Time since Treatment 
Although the interventions utilised in the studies appear to have been of benefit to the 
patients, there was limited long-term follow-up in many of the studies. Limited long-
term follow-up could have potentially negative implications for the effectiveness of the 
interventions, as previous long-term studies have recognised that cognitive functioning 
can decline with increasing time since the patient’s primary stage of treatment. 
 
The patient in the Penkman and Scott-Lane (2007) study started the prophylactic 
academic intervention ten weeks post-radiotherapy and during chemotherapy. In 
comparison to the other studies, the Penkman and Scott-Lane (2007) intervention was 
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delivered during a different period of the patient’s treatment pathway. Part of the aims 
for this study was to identify the effectiveness of a preventative treatment. Therefore the 
patient did not receive/complete their primary treatment before starting the intervention, 
which could have implications for the development of neurocognitive impairments and 
learning outcomes. The outcome measures were recorded eight months post-treatment 
and demonstrated continued improvement in nearly all areas of academic attainment, but 
did not achieve all educational objectives.  
 
Similarly the Kerns and Thomson’s (1998) compensatory memory system intervention 
also used follow-up measures, although these were more longitudinal, two years post-
treatment and the results were varied. In comparison, the Butler (1998) study conducted 
post-treatment assessment immediately after the treatment was completed; 
demonstrating positive outcomes. 
 
Butler and Mulhern (2005) suggest that the adverse effects of a primary medical 
intervention have been noted at around one to two years post-therapy. The results of the 
Kerns and Thomson (1998) were taken at a later stage post intervention in comparison to 
the Butler (1998) study, thus the Kerns and Thomson (1998) study may reflect a more 
effective intervention. Although the Butler (1998) study demonstrates more positive 
results than the other studies, it has limited follow-up results. It is also important to be 
aware that the study maybe further limited by the variation in the patient’s method and 
intensity of primary stage of treatments and the time scales at which these were 
undertaken prior to the assessment of the secondary intervention, as these factors may 
also have potential negative implications for the effectiveness of the interventions.  
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5.1.1.3 Comparisons to Normal Development  
 
The studies retrieved demonstrated improvements in learning outcomes, particularly 
arithmetic (Butler, 1998; Kerns & Thomson, 1998; Penkman & Scott-Lane, 2007). 
However, the studies fail to account for maturation of the brain and improvement that is 
expected in normal development as children grow older. Consequently, this makes it 
difficult to determine whether the improvement made by the patients as a result of the 
intervention was greater than what is naturally anticipated. 
 
a) Plasticity and the Early Vulnerability Hypothesis 
Historically, interventions have focused on compensating for acquired deficits patients 
incur as a consequence of a brain tumour. Ecological interventions, such as 
accommodation within the school setting and the use of assistive technology have 
helped patients to compensate for their deficits (Armstrong & Briery, 2004). Similarly, 
the Kerns and Thomson (1998) study utilises a compensatory technique, a memory aid, 
to compensate for the patients’ memory problems. However, the Butler (1998) and 
Penkman and Scott-Lane (2007) studies were not restricted to compensatory 
interventions; for example the Penkman and Scott-Lane (2007) gave tutor sessions. 
Utilising theories of neuroplasticity, research would suggest that younger patients may 
receive greater benefit from these interventions because the brain can adapt to acquire 
new skills via these pragmatic approaches (Huttenlocher & Dabholkar, 1997). Thus 
interventions that enable the brain to develop further methods of functioning as the child 
develops may be of more benefit to the paediatric neurooncology population. 
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However, it should be noted that due to the age range of the participants in the studies, 
the results might be connected to the early vulnerability hypothesis. The patients were 
aged between eight and thirteen years, therefore, the early vulnerability hypothesis 
would suggest that the patients had favourable outcomes because they were at later 
stages of their development and their brain structure may have been further developed. 
Due to the limited age range and number of patients involved in this review it is difficult 
to determine the impact of these hypotheses on paediatric neurooncology rehabilitation. 
 
5.2 The Effectiveness of Pharmaceutical Interventions for Paediatric Neurooncology 
Patients 
This thesis aimed to look at the evidence for both psychosocial and pharmaceutical 
interventions for cognitive and learning impairment for paediatric neurooncology 
patients.  However, none of the papers retrieved in the search met the inclusion criteria 
for this thesis. Thus no conclusions can be drawn about the effectiveness of this method 
of intervention for paediatric neurooncology patients. 
 
5.3 Extraction of Additional Studies  
The criteria for the search dates utilised in the review of the empirical literature were set 
in accordance with the first issue of the journals and January 2013 (the final search), 
which was six months prior to the anticipated completion date of this thesis. From 
January, the searches were calibrated to receive an automatic alert of all new literature 
that met the search criteria for the review. Studies that were retrieved by the automatic 
alert between January 2013 and June 2013 are noted in Appendix IV. None of the 
studies retrieved from the automatic alerts were of use to this thesis.  
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5.4 Critical Reflections 
The PRISMA statement provides a beneficial tool for the critical appraisal of systematic 
reviews. Thus the PRISMA statement checklist (2009), reflections of the rigorous 
methods used in the review and consideration of potential bias on the quality of this 
thesis has been considered (Moher et al., 2009). The evidence for the PRISMA 
statement checklist is presented in Appendix V.  
 
It is important to note that as this is a thesis a systematic review registration number was 
not attained. A protocol was developed to reduce bias and for the assessment report in 
the transfer viva, however this was not registered. The protocol has been incorporated 
and acknowledged in chapters two and three of this thesis. In addition to an internal 
review appraisal the transfer viva was an opportunity to gain an external review 
appraisal. This helped to reflect and appraise the project and reduce potential bias.  
 
Despite attempts to reduce potential bias, it is challenging to eliminate bias completely, 
thus steps have been taken to raise awareness and reduce potential bias. A PICO process 
was used to frame the clinical question, during the development of this review. This 
ensured the review was useful, creditable and relevant. It may have been useful to 
develop a systematic descriptive map to help guide the question based on available 
research and uncover gaps in the research field. 
 
The PICO process also helped to guide the development of the inclusion and exclusion 
criteria. Although these were devised stringently, it is important to remain mindful of the 
potential bias this may have introduced.  
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In an attempt to reduce bias the methodology of this thesis was developed 
systematically, rigorously and explicitly. The search strategies were developed in 
collaboration with different members of a multidisciplinary team, thus ensuring an 
internal review appraisal was utilised.  This helped to make certain the search terms 
were rigorous and inclusive, producing a comprehensive and unbiased attempt to 
uncover published and unpublished, easily accessible and harder to find studies. 
Similarly the same extensive procedure was undertaken with the selection of the 
databases.   
 
Aspects such as the search log included details of both electronic and hand searches 
which were undertaken to help replicate the study and identify different varieties of 
literature including studies which may have not been published. Unfortunately due to 
time constraints it was not possible to contact authors individually to ascertain details 
that may have aided this thesis. This may have increased the bias of utilising published 
studies reporting statistically significant results. Utilising reference managing tools such 
as EndNote was valuable resource to identify duplicates and sort the references. 
 
The data analysis procedure was also at risk of bias. It was challenging to describe the 
studies during the synthesis, as pooling the details and results into a group of studies 
could not be achieved. For example assessing the summary of measures section, as the 
outcomes of primary interest were different between the studies (memory, attention and 
academic achievement). Thus a common summary measure was not chosen. This had 
consequences for the planned method of analysis, meta-analysis, which could not be 
undertaken due to aforementioned differences. 
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As part of the data analysis a data extraction form was developed. This form also 
considered the critical appraisal of the extracted research. The aim of the form was to 
ensure the validity, reliability and potential bias had been acknowledged. The potential 
weaknesses of the critical appraisal of the data extraction from are discussed further in 
the limitations of this review. 
 
5.5 Limitations of the review 
 
5.5.1 Number of Included Studies 
The aim of systematic reviews are to summarise large quantities of data explicitly and 
transparently, ensuring the process is accountable, replicable and updateable, thus 
reducing bias which can occur in other approaches to reviewing research evidence. Only 
three studies retrieved met the inclusion criteria for this review. Due to the limited 
number of retrievals it is difficult to present clear findings regarding the effects of 
psychosocial interventions on paediatric brain tumour populations. Additionally no 
conclusions could be made regarding the search investigating the effectiveness of 
pharmaceutical interventions, without the risk of creating potentially biased conclusions; 
as no studies met the inclusion criteria that utilised pharmaceutical interventions. 
A further consequence of the limited retrieval was the method of data analysis that was 
utilised in this thesis. Only a narrative review of the results could be undertaken, as a 
meta-analysis required more than three included studies. Although a narrative review 
has many benefits, such as providing a broad overview of relevant information, it does 
not allow for the data to be mathematically combined, which may have provided a more 
precise estimate of the underlying “true effect”. 
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5.5.2 Heterogeneous Patient Samples 
The heterogeneity of the patients recruited in each of the studies was diverse. The 
variations in the population included their gender, age, tumour type, the primary 
interventions the patients received, the time span of the patient’s treatment pathway and 
the cognitive/learning intervention assessed by the study. Literatures suggest that each of 
these factors can have an impact on the degree and type of impairment, which may also 
have consequences for the effectiveness of the interventions (Moore, 2005; Nejat et al., 
2008; Spiegler et al., 2004). 
 
5.5.3 Methodological Quality  
A critical appraisal of the studies retrieved in this thesis was undertaken using the 
Downs and Black quality assessment tool (1998), to ensure a structured, reliable and 
appropriate appraisal was conducted. The Downs and Black quality assessment tool 
(1998) was used to identify risk of bias, choice of outcome measure, statistical issues, 
quality of reporting, quality of the intervention and generalisability. The results of the 
appraisal identified some important limitations, specifically in the methodological 
quality of the studies. 
 
The quality of the evidence used in this review is impeded by the methodologies of the 
studies. Hence Cochrane reviews have a strict inclusion criterion that limits included 
studies to randomised control studies (RCT) only. Thus, it was important that this thesis 
was mindful of the quality of the literature in the review as there was an absence of 
RCTs and other ‘gold standard’ methodological approaches. 
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The Penkman and Scott-Lane (2007) study achieved the highest score of 11 points out of 
a total of 31 points on the Downs and Black quality assessment tool. Despite having the 
highest score of the three studies, it still represents a lower quality study in general 
research. All three studies had limitations related to insufficient information to allow a 
reader to make an unbiased assessment of the findings of the study, internal/external 
validity and power. 
 
On reflection, the Downs and Blacks critical appraisal tool was not the most appropriate 
method to assess the quality of the studies. The Critical Appraisal Skills Programme has 
specific critical appraisal checklists, such as the case control study checklist, which 
would have been more appropriate (Critical Appraisal Skills Programme, 1993).Or the 
single-case experimental design scale by Tate et al. (2008), a critical appraisal tool 
which provides a brief and valid evaluation of methodological quality of single-subject 
designs.  
 
5.5.4 Outcome Measures 
The aim of rehabilitation within paediatric neurooncology services is to promote 
continued learning and help patients maintain an adequate level of cognitive functioning; 
Limond and Leeke, (2005) equate this to an improvement in daily functioning. Yet in 
the studies retrieved in this thesis emphasis is generally placed on the results of 
standardised outcomes, to identify the impact of interventions on general ability. Thus 
the results of assessments such as the Wechsler Intelligence Scales, Wide Range 
Achievement Test and the Wechsler Individual Achievement Test-II demonstrated 
findings that have limited interpretation regarding the adaptive functioning of the 
patients in the studies. However, it is important to note that the use of such measures 
does promote replicability, as they are valid and reliable. Despite the validity and 
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reliability of these measures it is still important to consider interpersonal and contextual 
factors that may impact upon reliability.  
 
In addition to the above limitations, the Kerns and Thomson, 1998 and the Penkman and 
Scott-Lane, 2007 studies both comment on the use of non-standardised teacher and 
parent reports of progress and satisfaction. Although these progress reports do offer 
some important reflections, Limond and Leeke, (2005) suggest the use of standardised 
satisfaction measures are “more appropriate” than rehabilitation feedback. This is 
particularly important as standardised measures can allow clinicians to compare their 
outcomes with alternative interventions. Such measures also enable the incorporation of 
the results into a meta-analysis. Furthermore, if the same measures were used across 
different treatment centres this would allow for further comparative analysis.  
 
5.5.5 Stringent Inclusion Criteria 
The stringent restrictions on the diagnosis of the patients used in this thesis were a 
particular problematic limitation. Many potentially useful studies retrieved in the 
searches could not be included in the final results. The search demonstrated limitations 
regarding the integrating of different diagnoses in the results sections of many of the 
studies retrieved. Thus several of the studies met the inclusion criteria in all aspects but 
diagnosis (Conklin et al, 2010a; Conklin et al, 2007; Conklin et al, 2010b; Mulhern et al 
, 2004a; Mulhern et al, 2004b; Netson et al, 2011; Thompson et al, 2001). This was 
primarily related to pharmaceutical studies, which explored the use of MPH in the 
rehabilitation of paediatric populations. Similarly a number of psychosocial studies also 
met the inclusion criteria in all aspects but diagnosis for example Butler et al, 2008, 
Hardy et al, 2011, Van’t Hooft et al, 2007 and Butler & Copeland, 2002. The majority of 
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these studies were primarily conducted utilising cognitive remediation. Cognitive 
remediation provides a systematic approach, utilising different strategies such as: 
behavioural interventions, cognitive behavioural therapy, instruction in metacognitive 
strategies, social skills training, traditional brain injury techniques such as massed 
practice, and supportive and dynamic psychotherapeutic approaches to improve 
cognitive functioning (Butler & Mulhern, 2005).  
 
These studies amalgamated the results of patients diagnosed with a brain tumour or 
acute lymphoblastic leukaemia. Consequently, the results could not be separated to 
identify which results came from which population. As the focus of this thesis was on 
only paediatric brain tumours, the results of studies which combined patients with a 
diagnosis of acute lymphoblastic leukaemia and brain tumours would not be utilised in 
this study as there was a potential risk of confounding results and bias. 
 
5.5.6 Education Literature 
Education is an important facet in the continued development of children, particularly 
those diagnosed with a brain tumour, as it can be used to identify, or facilitate the 
rehabilitation of, cognitive and learning deficits. Despite the importance of education, 
the education literature and databases reviewed in this thesis contained nothing of 
relevance for the rehabilitation of cognitive and learning processes in children diagnosed 
with a brain tumour. It is astonishing that in their own right education services have not 
undertaken a key role in rehabilitation in this field, particularly as cognitive and learning 
deficits are being diagnosed in children from an early age. Subsequently, children with a 
brain tumour are at a disadvantage. The consequences of this may not often be fully 
recognised until later life as literature states that cognitive and learning deficits develop 
with time since treatment, as the child ‘grows into their deficit’ (Mulhern et al, 2004a; 
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Mulhern et al, 2001; Spiegler et al, 2004). Further research is required utilising 
educational interventions, as they may have a positive impact on a child’s development 
and help to reduce or support emerging deficits. 
 
5.6 Recommendations for Further Research and Clinical Practice 
With the growing number of survivors of paediatric brain tumours, survival is no longer 
the only concern to clinicians. Clinicians and researchers also need to address the 
neurocognitive and academic requirements of this population as they become 
increasingly recognised by research and literature. Although evidence for the prevalence 
of neurocognitive deficits and learning impairments exists, the evidence base is limited 
and no national programme/guidelines have been developed to support the rehabilitation 
needs or provide educational support for this population (Brown, 2004).  
 
The current volume of literature for paediatric brain tumour is not concordant with the 
concern that is currently identified for this population. It is hypothesised that this may be 
a consequence of numerous aspects. Neurooncology is a largely associated with a 
medical model, with concerns orientated towards survival rather than cognitive and 
learning deficits. This model has implications for research that is also largely focuses on 
the survival of this population. Subsequently, from a psychological perspective, this can 
have an impact on our clinical training and the clinical research we are encouraged to 
undertake in training.  
 
Therefore it is important to consider the current asymmetry between clinical concern and 
the research enterprise and what this means for the future involvement of Clinical 
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Psychology. It is also important not to neglect the important role of the health care and 
education systems, and to consider what each can bring to rehabilitation services. 
 
5.6.1 Current Clinical Practice  
Nationally, paediatric neurooncology rehabilitation services are limited. From a 
psychological perspective the focus of their work is predominantly on 
neuropsychological assessment, and rehabilitation services are often restricted to 
interventions that predominantly focus on helping the patient compensate for their 
deficits.  These include compensatory  interventions such as special education support, 
environmental modification and assistive technology (Brown, 2004). As seen in this 
thesis, there is limited evidence in favour of these interventions. However, some 
cognitive function, for example episodic memory cannot be restored. Thus 
compensatory interventions can be vital to support a patient to achieve an appropriate 
level of functioning. It is also important to consider the disadvantage of a patient’s 
geographical location, as different services offer varied levels of support.  It seems the 
NHS has not developed to meet the unique needs and problems of a paediatric 
neurooncology population and as a consequence these children are at a disadvantage.  
 
Although there is a limited evidence base for neurocognitive and learning interventions 
in paediatric neurooncology populations a significant evidence base has developed in 
acquired brain injury and ADHD populations. It would be useful for neurooncology 
research and clinical practice to take guidance from the MTA trials for the treatment and 
management of cognitive deficits (MTA Cooperative Group, 1999). 
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a) Services 
In light of the evidence that exists for neurocognitive and learning deficits, uniformed 
health care services are needed to ensure they are supporting patients and working 
alongside education systems to provide appropriate interventions in addition to 
neuropsychological assessment. Value can be added to clinical services by harnessing 
the skills and expertise of Clinical Psychology and Clinical Neuropsychology to conduct 
complex neuropsychological assessments and formulation and influence a medical 
driven model of service. A shared understanding of uniformed outcome measures need 
to be agreed upon to ensure all deficits and learning problems are being identified and 
thus supported. A battery of assessments should be developed nationally between 
services to ensure this collaborative approach. This would also have positive 
implications for further research 
 
In addition to health care services, education systems need to be utilised to ensure 
interventions are being conducted appropriately and children are supported in academia. 
Links between these services are vital to allow for consistent care, particularly as the 
child develops. All of the interventions in this thesis placed emphasis on academia; 
however, as previously noted there are currently limited interventions for children in 
schools, as there is no evidence base for compensatory interventions. Thus it is 
important to consider how equipped schools are to work with children with the 
challenges of cognitive and leaning deficits. The patients and their families are often 
offered limited support and subsequently schools are lacking in the knowledge and 
understanding of their educational needs and the ability to provide much needed support 
to patients and their families. Steps need to be taken to ensure that academic institutions 
are providing patients with a paediatric brain tumour long-term support within schools. 
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With an aging population not only do services need to ensure the child is supported as 
they move through the educational system but that they are also supported as they make 
the transition  into adulthood, careers and adult services. Thus communication between 
adult and child services is also a key factor. 
 
b) Moderating Factors 
A consideration of the moderating factors, which may impact on the effectiveness of 
interventions, also needs to be addressed in clinical settings and research. This thesis has 
noted potential implications of the effect of time since treatment. Until further research 
has been undertaken to determine the impact of this factor, it is important for patients to 
maintain links with treatment facilities and for teachers to be aware of the phenomenon 
of ‘growing into a deficit’. Thus it may also be important to consider if rehabilitation 
strategies should be more appropriate at different developmental stages. 
 
c) Method of Intervention 
A vast amount of neurorehabilitation research and literature is limited in that the main 
focus of the interventions are on the acquisition of strategies designed to improve 
performance in cognitive and academic outcomes. Likewise this was evident in the 
studies retrieved in this thesis. These rehabilitation programmes require lots of 
resources, since one-to-one sessions are often idiosyncratic and are required for a 
prolonged period of time. Furthermore, the mode of treatment is impractical for larger 
groups of survivors who live near medical centres that could provide the program. 
Therefore it is critical that effective home/school-based interventions are developed; 
interventions that are relevant to a wide-range of potential patients who will not be 
restricted by time, distance or cost. 
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5.6.2 Further Research 
The findings of this thesis indicate that further evaluations of the effectiveness of 
different pharmaceutical and psychosocial interventions need to be undertaken to enable 
the development of evidence-based practice for paediatric neurooncology populations. 
This thesis has demonstrated limited conclusions, but has highlighted the potential for 
further research in different aspects of paediatric neurooncology rehabilitation. This also 
highlights an opportunity for Clinical Psychology to use its skills and research expertise 
to help develop an evidence base and add further value to clinical practice. 
 
 a) Attention 
When considering the focus of further research it is important to acknowledge that trying 
to categorise cognition can be an arbitrary process, as it can be challenging to separate 
processes and systems in the brain. Pribram (1997) emphasises the importance of the 
critical relationships among components of cognition and between these components 
and learning processes. Thus impairments to attention systems and other cognitive 
processes are of importance to rehabilitation strategies.  
 
Limond and Leeke (2005) suggested that attention rehabilitation strategies fall into four 
categories which include: attention process training, self-management strategies, 
environmental modifications and psychosocial support for emotional and social factors; 
these are often used in combination. Attention process training is identified as being the 
focus of most intervention research (Limond & Leeke, 2005). This is unsurprising as 
attention processes have demonstrated to be the foundation of most cognitive and 
neuropsychological functions (Eysenck & Keane, 2005). However, Ylvisaker and 
Feeney (1998)  identify four more traditional types of approaches, these include: a 
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processing specific hierarchically organised restorative approach, a task specific skills 
based approach, a compensatory approach that attempts to improve performance by 
helping individuals develop strategic procedures and a compensatory approach which 
modifies an individual’s tasks or environment. All approaches to rehabilitation should be 
considered and potentially combined to develop an effective and efficient rehabilitation 
intervention. 
 
Literature indicates that deficits in attention are often the result of damage to the 
reticular activating system within the brain stem, in addition to bilateral cortical damage 
(Ylvisaker and Feeney, 1998). Ylvisaker and Feeney (1998) suggest that many patients 
will experience fatigue, which can negatively impact alertness. Patients will most often 
experience impairments to prefrontal structures which have consequences for executive 
or supervisory control attention processes (Shallice, 1988). Executive attention control 
processes include: sustaining attention, concentrating (directing) attention, sharing 
(dividing) attention, suppressing attention (filtering), switching (shifting) attention, 
preparing attention and setting attention (Ylvisaker and Feeney, 1998). These complex 
systems need to be addressed in rehabilitation interventions.  
 
Dennis, Hetherington, and Spiegler (1998) go on to suggest deficits in areas such as 
attention may result in difficulties acquiring new information, which can be reflected in 
a patients IQ and academic achievement. Thus interventions that are aimed at 
developing attention processes should be promoted within rehabilitation services and be 
the focus of further research. Literature suggests that cognitive remediation and MPH 
are two such interventions, which may offer valuable rehabilitation, particularly to those 
with attention difficulties (Butler & Copeland, 2002; Conklin et al, 2010a) 
 
129 
 
The MTA studies, which compared four distinct treatment strategies during childhood 
for patients with a diagnosis of ADHD, are a good example of how combined 
interventions are demonstrated to be significantly superior to standalone treatments. 
Thus developing a study that explores the impact of combined psychosocial and 
pharmaceutical interventions on learning and neurocognitive deficits in a paediatric 
neurooncology population on a larger scale is required. 
 
In comparison, it is questionable how feasible it would be to commission non-drug 
related research with a child population; currently less than five percent of all registered 
studies involve children and a non-drug related intervention (Modi, Clark, Wolfe, 
Costello, & Budge, 2012). This may explain the limited number of studies retrieved 
from search one and may also account of the lack of research in educational settings.  
 
A single centre study would not be appropriate; similar to the MPH trails it is 
recommended that further research should be replicated in numerous centres that may 
allow for the collection of quality single case studies or higher-level quasi-experimental 
randomised study designs utilising the same outcome measures. 
 
b) Methodologies  
There is a clear need to address the methodological difficulties that are highlighted in 
this thesis. The methodologies of the studies included in this thesis have limited the 
generalisability of the findings. Ideally future research should focus on utilising 
experimental designs, particularly RCTs. The Oxford Centre for evidence-based 
research identifies that RCTs are level one evidence, which is regarded as the highest 
level of evidence. However implementing RCTs in this area of research may not be 
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feasible as paediatric neurooncology populations are small in comparison to other 
childhood illnesses. As a result compromise about methodological quality and sample 
size needs to be addressed. 
 
Potential ethical considerations of not giving all patients the best available interventions 
or at the most appropriate stage during the recovery process would also need to be 
addressed. RCT’s require control groups thus patients may not receive appropriate 
treatment at the appropriate stage of treatment. Utilising higher level quasi-experimental 
randomised study designs that yield more convincing evidence for causal links between 
interventions and outcomes may help to develop an evidence-base for paediatric 
neurooncology patients.  Alternatively using the RoBIN-T scale for single case design, 
may help to identify experimental versus non-experimental single-case designs and rate 
the methodological quality of experimental single-case designs (Tate et al, 2013). 
 
c) Core Outcome Measures and Further Research 
Systematic reviews are often limited by the inconsistencies in the outcomes used in 
clinical trials in specific areas of health care; paediatric neurooncology is no exception.  
Among the three studies retrieved there were limited consistencies in the outcome 
measures used. However, without some form of outcome protocol there is no guarantee 
that similar outcome measures will be used in future research. Williamson, Altman, 
Blazeby, Clarke, and Gargon (2011) suggest that clinicians/researchers should agree on 
a set of outcome measures to allow for the development of a further systematic review, 
which can utilise a meta-analysis to identify appropriate interventions. Agreeing on a set 
of measures will reduce the risk of measuring inappropriate outcomes, help to simplify 
the reporting of outcomes, and reduce the reporting of s selective reporting of outcomes 
will be reduced. The Core Outcome Measures in Effectiveness Trails (COMET) 
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initiative aims to provide guidance for researches to develop consistencies within 
research and allow for the better reporting of systematic reviews (Williamson et al., 
2011).  Thus a recommendation for further research would be to utilise the COMET 
initiative and to agree on a set of outcome measures that would appropriately measure 
the impact of psychosocial and pharmaceutical cognitive and learning deficits.  
 
d)  Update of this Review 
It is hoped that the results of this thesis and the recommendations made will be used to 
continue developing and conducting research in the field of psychosocial and 
pharmaceutical interventions in paediatric neurooncology. Building upon the results of 
this thesis, considering its limitations and further research, another systematic review 
should be undertaken to identify any further developments in this research.  
 
5.7 Summary and Conclusions 
Research identifies that tumours of the brain and the CNS account for a quarter of all 
childhood cancers (Cancer Research UK, 2010). Although brain tumours in the 
paediatric population are a rare condition, it is the most frequent cause of death from 
disease in children aged 1-14 years, and accounts for just under a fifth of all 
bereavements in childhood cancers (Cancer Research UK, 2010). Earlier detection and 
medical advancements have resulted in increased survival rates and consequently 
children are living longer with a greater risk of deficits in attention, working memory 
and processing speed which may lead to the secondary consequences of IQ loss and 
academic problems (Sands, 2009). Hence the objectives of this thesis were to identify 
and evaluate the effectiveness of psychosocial and pharmaceutical interventions for 
cognitive and learning impairment within a paediatric neurooncology population.  
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The results presented in this thesis demonstrate limited conclusions regarding the 
effectiveness of psychosocial and pharmaceutical interventions for cognitive and 
learning deficits. They identify a limited evidence base, which does not contain any 
RCTs or controlled trials. Additionally, few conclusions, comparisons and 
generalisations can be made about the results due to the heterogeneity of the patients, 
treatment variables and outcome measures used in each of the studies. Hence there were 
difficulties in identifying common aspects among the results and in determining whether 
the results had been hindered by the methodologies or if the interventions were 
inefficient. Despite the limitations in the generalisability of the papers reviewed in this 
thesis, neuropsychology remains an important part of neurorehabilitation, providing 
information and encouraging the awareness of patients’ cognitive and learning strengths 
and weakness and utilising their strengths to compensate for their deficits. This thesis 
highlights that Clinical Psychology, with the support of Neuropsychology needs to be 
providing and coordinating rehabilitation, in addition to offering neuropsychological 
assessment and consultation to significant others, teachers and professionals as part of a 
neuropsychological intervention.  
 
The limited conclusions the studies retrieved in this thesis report some important 
conclusions that are relevant to paediatric brain tumour populations and may help to 
guide future clinical interventions and research. Although all of the results come from 
individual cases, all of the interventions indicate some positive neurocognitive and 
learning outcomes, specifically in the area of attention (Penkman  & Scott-Lane, 2007). 
It is important to note that this is still a new area of research, as previously discussed, 
recent medical advancements have reduced rates of morbidity and disability and 
clinicians and researches are attempting to explore alternative interventions which have 
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been successful in other population groups, such as MPH and the success it has 
demonstrated in treating attention deficits in ADHD populations (MTA Cooperative 
Group, 1999). Developing a national research project on a similar scale to the MTA 
trials would help to develop a large sample within this small population.  If this is to be 
achieved a national protocol needs to be developed alongside COMET to design a 
uniformed approach for assessment and intervention. To be of clinical importance, 
further research needs to consider both psychosocial and pharmaceutical interventions 
and to develop an appropriate service provision that can address long-term 
neurorehabilitation and psychological needs. Cognitive remediation and MPH may be 
potential interventions as they address issues of attention deficits and other cognitive, 
learning and psychological problems. 
 
These interventions highlight an important research opportunity, the opportunity to 
determine whether or which stimulants and cognitive interventions should be central to 
clinical practice in a paediatric brain tumour population by ensuring routine scrutiny of 
cognition, particularly attention and scholastic outcome. It is important that paediatric 
rehabilitation services are delivering optimum care as patients may continue to utilise 
rehabilitation services throughout childhood and as they transition into adulthood and 
later life.  
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APPENDICES 
Appendix I: Search terms  
Children AND Brain Tumours AND Treatments AND Psychosocial OR 
Pharmaceutical Interventions 
 
• Children 
Mapping terms: Paediatrics etc (where appropriate) 
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Search terms: infant OR infan* OR newborn OR newborn* OR new-born* OR 
baby OR baby* OR babies OR neonat* OR neo-nat* OR perinat* OR postnat* 
OR child OR child* OR schoolchild* OR schoolchild OR school child OR 
school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* 
OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR 
juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR 
prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR 
peadiatric* OR post-nat*  OR Preterm* OR Prematur* OR Postmatur* OR Pre-
pubescen* OR schools OR nursery school* OR preschool* OR pre school* OR 
pre-school* OR Schoolchild* OR secondary school* OR primary school* OR 
secondary school* OR elementary school* OR elementary school OR high 
school* OR highschool* OR school age OR schoolage OR school age* OR 
schoolage* OR infancy OR schools OR nursery OR infant OR newborn 
 
Mesh terms- Infant[MeSH] OR  OR Child[MeSH] OR Adolescent[MeSH] OR 
Minors[MeSH] OR Puberty[MeSH] OR Pediatrics[MeSH] OR Schools[MeSH] 
 
 
• Brain Tumours 
 
Mapping term: Brain tumours/Brain neoplasms etc 
Search terms: ("Acquired brain injur*" OR ABI* OR Angiolipoma OR 
Anaplastic OR "Anaplastic astrocytoma*" OR "Anaplastic ependymoma" OR 
"Anaplastic ganglioglioma" OR "Anaplastic haemangioendothelioma" OR 
"Anaplastic haemangiopericytoma" OR "Anaplastic Medulloblastoma" OR 
"Anaplastic Oligoastrocytoma" OR "Anaplastic Oligodendroglioma" OR 
"Angiocentric ganglioglioma" OR "Angiocentric giloma" OR Angio* OR 
Astroblastoma OR Astrocytoma* OR "Astrocytic tumo?r*" OR "Acoustic 
neuroma*" OR Atypical OR "Atypical choroid plexus papilloma" OR "Atypical 
teratoid rhabdoid tumo?r*" OR ATRT* OR "Central neurocytoma" OR 
"Cerebellar liponeurocytoma" OR Chordoma* OR Chondro* OR 
Choriocarcinoma OR Choroid OR "Choroid glioma of the third ventricle" OR 
"Choroid plexus papilloma" OR "Choroid plexus carcinoma" OR "Choroid 
plexus tumo?r*" OR "Clear cell" OR "cerebral lymphoma" OR "cerebral 
metastases" OR "CNS ganglioneuroblastoma" OR "CNS neuroblastoma" OR 
CNS AND "primitive neuroectodermal tumo?r*" OR Craniopharyngioma* OR 
"Desmoplastic medulloblastoma" OR "nodular medulloblastoma" OR "Diffuse 
astrocytoma" OR "Diffuse melanocytosis" OR "Dysembryoplastic 
neuroepithelial tumo?r*" OR DNET OR "Embryonal carcinoma" OR 
"Embryonal tumo?r*" OR Ependymoblastoma OR Ependymoma* OR 
"Ependymal tumo?r*" OR "Epithelioid haemangioendothelioma" OR 
"Epithelioid MPNST" OR "Ewing sarcoma-PNET" OR "Extraventricular 
neurocytoma" OR "Fibrillary astrocytoma" OR Fibrosarcoma OR Fibrous OR 
Fibroblastic OR Ganglio* OR "Gemistocytic astrocytoma" OR "Germ cell 
tumo?r*" OR Germinoma OR "Giant cell glioblastoma" OR Glioma* OR 
Gliosarcoma OR "Glioblastoma multiforme" OR Glioblastoma OR "Gliomatosis 
cerebri" OR "Granular Cell tumo?r*" OR "Granulocytic sarcoma" OR 
Haemangio* OR "Haematopoietic neoplasms" OR Hemangio* OR 
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Hemangioblastoma* OR Hibernoma OR "Intracranial solid neoplasm*" OR 
"Intracranial germ cell tumo?r*" OR "Intracranial germinoma" OR "Kaposi 
sarcoma" OR "Large cell medulloblastoma*" OR Leiomyo* OR Lipo* OR 
Lymphoma* OR "Lymphomas neoplasms" OR "Lymphoplasmacyte-rich" OR 
"Malignant fibrous histiocytoma" OR "Malignant lymphomas" OR "Malignant 
melanoma" OR "Malignant peripheral nerve sheath tumo?r*" OR "Malignant 
perineurioma" OR "Meningeal melanomatosis" OR Medulloblastoma* OR 
"Medulloblastoma* with extensive nodularity" OR Medulloepithelioma OR 
"Melanotic MPNST" OR Melanocytoma OR Meningioma* OR Meningothelial 
OR "Mesenchymal tumo?r*" OR Metaplastic OR "Metastatic neuroblastoma" 
OR "Metastatic tumo?r*" OR Microcystic OR "Mixed germ cell tumo?r*" OR 
"MPNST with glandular differentiation" OR "MPNST with mesenchymal 
differentiation" OR "Myxopapillary ependymoma" OR "Neuroepithelial 
tumo?r*" OR Neurofibroma* OR Neuro-oncolog* OR neurooncolog* OR 
Oligodenrogli* OR "Oligoastrocytic tumo?r*" OR Oligoastrocytoma OR "Optic 
pathway glioma" OR Osteo* OR Papillary OR "Papillary giloneuronal tumo?r*" 
OR "Papillary tumo?r* of the pineal region" OR Papilloma* OR Paraganglioma 
OR Perineurioma OR Pilomyxoid OR Pilomyxoid AND astrocytoma* OR 
Pinealoma OR Pineoblastoma OR Pineocytoma OR "Pineal parenchymal 
tumo?r* of intermediate differentiation" OR "Pineal region tumo?r*" OR 
"Pituitary adenoma*" OR "Pituitary tumo?r*" OR "Pilocytic astrocytoma*" OR 
Pituicytoma OR (Posterior adj2 fossa*) OR Plasmacytoma OR "Pleomorphic 
xanthoastrocytoma" OR Plexiform OR PNET* OR "Primary melanocytic 
lesions" OR "Primitive neuro-ectodermal tumo?r*" OR "Primitive 
neuroectodermal tumo?r*" OR "Primitive neuro-ectodermal tumo?r*" OR 
"Protoplasmic astrocytoma" OR Psammomatous OR Retinoblastoma* OR 
Rhabdoid OR Rhabdomyo* OR "Rosette-forming giloneuronal tumo?r* of the 
fourth ventricle" OR Secretory OR "Solitary fibrous tumo?r*" OR "Spindle cell 
oncocytoma of the adenohypophysis" OR "Subependymal giant cell 
astrocytoma*" OR Subependymoma OR BT* OR Teratoma OR "Teratoma with 
malignant transformation" OR "tumo?r* of the Meninges" OR "Tumo?r* of the 
sellar region" OR "tumo?r* of meningothelial cells" OR "Tumo?r* of the pineal 
region" OR Transitional OR "Yolk sac tumo?r*") 
 
 
 Treatments 
Search terms: ("surgical intervent*" OR "physical intervent*" OR (Radiation 
adj2 therap*) OR radiotherap* OR Irradiat* OR "intracranial biopsy" OR 
Avastin OR CRT OR "conformal radiotherap*" OR "conformal radio therap*" 
OR "conformal radiotherap*" OR "conformal radio therap*" OR "craniospinal 
radiotherapy" OR chemotherap* OR Craniotomy OR cyberknife OR 
methotrexate OR neurosurg* OR neuro-surg* OR (tumo?r* adj2 resection) OR 
radiosurg* OR "gamma knife" OR "gliadel wafer" OR (stereotactic adj2 surg*) 
OR (proton adj2 therap*) OR brachytherap* OR "tumour resection" OR 
"stereotactic biopsy" OR Interferon OR "intrathecal chemotherapy" OR 
"Intensity-modulated radiotherapy" OR "Intensity modulated radiotherapy" OR 
"ventriculo-peritoneal shunt" OR stimulant* OR IMRT OR "intensity modulated 
radiation therapy" OR methylphenidate OR MPH OR atomoxetine OR 
dexamfetamine OR modafinil OR concerta OR ritalin OR biphentin OR attenta 
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OR methylin OR metadate OR equasym OR rubifen OR motiron OR stimdate 
OR daytrana OR strattera OR "3rd ventricle ostary" OR "Third ventricle ostary" 
OR temozolomide OR "ventriculoperitoneal shunt" OR "VP shunt" OR 
dexedrine OR medikinet OR provigil OR amphetamine OR pemoline) 
 
 Psychosocial Interventions 
Search terms: (Neuro-psych* adj2 interven*) OR (Neuro-psych* adj2 rehabilit*) 
OR remediat* OR interven* OR assistive technology OR Attention* process 
train* OR behavio?r* program* OR behavio?r* modification OR behavio?r* OR 
cognit* OR cognit* aid* OR compensatory strateg* OR (interven* adj2 
recommend*) OR (interven* adj2 plan*) OR learn* program* OR ecological 
adj2 intervent* OR environmenta* adj2 intervent* OR environmenta* adj2 
modification OR metacognit* strateg* OR metacognit* train* OR (Neuro* adj1 
educat*) OR Neuro* behavio?r* OR psycholog* interven* OR AMAT-C OR 
Amsterdam memory and attention training for children OR (Cogmed* adj2 
train*) OR goal OR management train* OR GMT* OR Assist* technolog* OR 
adaptive technolog* OR Self-help device* OR assist device* OR multimodal 
interven* OR NeuroPage* OR Vicon Revue* OR ViconRevue* OR SenseCam* 
OR PDA* OR Personal digital assistant OR palmtop computer* OR 
Psychosocial* intervent* OR Psycho-social* intervent* OR Psycho-educational 
intervent* Or Psychoeducational intervent* OR Psychotherap* OR practice drill* 
OR CBT OR (Cogn* adj2 therap*) Or Cogn* adj2 Remediat* OR educat* 
support OR Educat* program* OR Famil* function* OR Famil* therap* OR 
Adjuvant* psych* therap* OR Coping strateg* OR Counsel* OR Group* 
support* OR Group* meeting* OR (Web-based adj2 intervention) OR Systemic 
approach* OR School* based intervent* OR Systemic intervention* OR (Internet 
adj2 intervent*) 
 
 
 Pharmaceutical Interventions 
 
Mapping term: Psychotropic agent/ Antidepressant/ Anti-psychotic/ 
Search terms: (cogniti* ad2 enhance*? OR (memory adj2 enhance*?) OR 
nootropic* OR stimulant* OR psycho-stimulant* OR neuro-enhance*? OR 
SMART drug* OR methylphenidate OR Ritalin OR MPH OR Atomoxetine OR 
Dexamfetamine OR Concerta OR attenta OR Methylin OR metadata OR 
equasym OR rubifen OR motiron OR stimdate OR daytrana OR strattera OR 
Dexedrine OR medikinet OR Provigil OR amphetamine OR pemoline OR 
adderall OR modafinil OR antipsychotic* OR MAOI* OR monoamine oxidase 
inhibitor* OR isocarboxazid OR pheniprazine OR marplan OR nardil OR SSRI* 
OR Selective Serotonin Re-uptake Inhibitor* OR fluoxetine OR sertraline OR 
citalopram OR paroxetine OR dapoxetine OR fluvoxamine OR faverin OR 
escitaopram OR prozac OR lustral OR cipramil OR seroxat OR cipralex OR 
serotonin-norepinephrine reuptake inhibitor* OR SNRI* OR venlafaxine OR 
effexor OR desvenlafaxine OR duloxetine OR tetracyclic antidepressant* OR 
TeCA* OR mirtazipine OR amoxepine OR loxapine OR maprotiline OR 
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mianserin OR oxaprotiline OR tricyclic* OR amitriptyline OR triptizol OR 
imipramine OR trofrani OR cycloserine) 
 
 
MESH Terms  
(child* OR infant* OR pediatric* OR paediatric* OR adolescent*) and (“brain 
neoplasm*” OR “brain tumor*” OR “brain tumour*”) and (“central nervous 
system” stimulant*) AND (“psychological intervention*”) OR (“psychotropic 
drug*” OR “antidepressive agent*” OR “antipsychotic agent*”) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Data screening and extraction form 
 
Date:................................................. 
Record Number:............................... 
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1. Study  Eligibility- Based on the title and available abstract  
Is the study written in English?             YES NO 
Were all the participants <19 years?         YES NO MAYBE 
Is the tumour investigated neurological?                  YES NO 
Does the study determine the effectiveness 
of a pharmaceutical or non- pharmaceutical 
intervention?                
YES NO 
Is the intervention aimed at neurocognitive/ 
learning outcomes?            
YES NO 
                                          
Do not proceed if any of the above answers are ‘No’. If study to be included in 
‘Excluded studies’ section of the review, record below the information to be inserted 
into ‘Table of excluded studies’. 
 
 
 
 
                     Psychosocial intervention                       Pharmaceutical intervention 
Continue review?                          Yes                                     No  
                                 Irrelevant study                              potentially relevant study 
Please give details……………………………………………………………… 
 
 
 
 
 
 
Data Extraction From 
1. Study Characteristics (Page ..........) 
Author(s):..................................................................................................................
.................................................................................................................................. 
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Date of article: .......................................                       
Title:..........................................................................................................................
.................................................................................................................................. 
Type of publication (journal name)…...................................................................... 
            Full paper                   Abstract/ summary only (e.g. unpublished/work in     
progress) 
Rationale (Page ..........) 
What is the rationale (clear reason and justification for the 
research):..................................................................................................................
.................................................................................................................................. 
 
Is there a clear research 
question?:.................................................................................................................. 
.................................................................................................................................. 
 
Co-morbidity/other diagnosis examined in the 
paper:........................................................................................................................ 
.................................................................................................................................. 
Tumour type(s) investigated in the study:................................................................ 
.................................................................................................................................. 
2. Methodology  (Page .........) 
Care setting the study was undertaken in:................................................................  
Research Design/level & grade of evidence   (Please select from Appendix I).......................................... 
Population from which the sample was drawn: ....................................................... 
Inclusion criteria....................................................................................................... 
.................................................................................................................................. 
Exclusion criteria:..................................................................................................... 
.................................................................................................................................. 
 Demographics (Page …………) 
Patients age (mean/range):...................................................... 
Gender (please insert the number of each if known):                Female                    Male 
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Ethnicity:.................................................................................................................. 
Socio-economic status:............................................................................................. 
Sample selection- Appendix III 
 Multistage    Non probability                 Quota 
 Purposive 
sample                  
 Opportunistic 
sample 
 probability    
 Not stated                                Stratified random                    Prospective 
 Other (please specify)   
 
Method of randomisation: ………………………………………………………... 
Allocation concealment to groups:……..…………………………………………. 
Patients (Page……) 
Number available  
Number invited  
Number excluded  
Number participated  
Number completed  
Number in each trial  
 
Is the selection of the participants appropriate to the design?.................................. 
.................................................................................................................................. 
Methods for handling missing data:………………………………………………. 
Additional Information:............................................................................................ 
.................................................................................................................................. 
 
3.Intervention (Page..........) 
Intervention given to the treatment group(s):……………………………………... 
…………………………………………………………………………………….. 
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Intervention, if given to the comparison group(s):………………………………... 
…………………………………………………………………………………...... 
Psychosocial 
Description of the intervention:................................................................................ 
.................................................................................................................................. 
Aim of the intervention:........................................................................................... 
.................................................................................................................................. 
Pharmaceutical 
Description of the intervention:................................................................................ 
.................................................................................................................................. 
Aim of the intervention:...........................................................................................     
.................................................................................................................................. 
Duration of intervention: 
Who delivered the intervention:………………………………………………....... 
Was this person(s) blinded?                       Yes                  No                         Not 
stated 
Was the patient blinded?                           Yes                    No                        Not 
stated 
Blinding:            Not applicable 
 
Outcome Measures (Page: .........) 
             Psychometrics                                Interviews                                       
 
When were they measured........................................................................................                                         
 
Psychometrics 
              Direct (with the child)                                    Proxy Delete as appropriate -  
                                                                            parent, teacher, carer, clinician 
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Assessments used .................................................................................................... 
.................................................................................................................................. 
Conducted by............................................................................................................ 
Interview  
              Structured                                    Unstructured 
               Direct (with the child)                 Proxy Delete as appropriate - 
                                                     parent, teacher, carer, clinician 
Conducted by............................................................................................................ 
Data collection 
Description of data collection:…………………………………….......................... 
.................................................................................................................................. 
Data collected by:…………………………………................................................. 
Length of follow-up:................................................................................................. 
 
3. Analysis (Page .......) 
Description of analysis employed:........................................................................... 
…………………………………………………………………………….............. 
.................................................................................................................................. 
Adjustment for confounding:.................................................................................... 
.................................................................................................................................. 
.................................................................................................................................. 
 
 
 
4. Results:    Outcomes of Interventions (Page .........) 
Are the results:        Psychosocial               Pharmaceutical    
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Type of 
outcome 
Group Description of outcome Improvement  
Neuro- 
cognitive 
Intervention  
 
 
Comparison  
 
 
Ability Intervention   
Comparison   
Academic 
Attainment                                         
Intervention   
Comparison   
Conduct Intervention   
Comparison   
Affect Intervention   
Comparison   
Social 
functioning 
Intervention   
Comparison   
Potential 
side effects                                           
Intervention   
Comparison   
Other Intervention   
Comparison   
 
Additional information:............................................................................................ 
.................................................................................................................................. 
.................................................................................................................................. 
.................................................................................................................................. 
7. Conclusions (Page .........) 
Summary of main findings:...................................................................................... 
160 
 
..................................................................................................................................
..................................................................................................................................
..................................................................................................................................
.................................................................................................................................. 
Have they stated clear limitations in the research:................................................... 
..................................................................................................................................
..................................................................................................................................
..................................................................................................................................
.................................................................................................................................. 
Implications of the literature for clinical and research practice? ............................. 
..................................................................................................................................
..................................................................................................................................
..................................................................................................................................
....................................................................................................................... 
Source(s) of funding:................................................................................................ 
………………………………………………………………………...................... 
…………………………………………………………………………………..…
…………….............................................................................................................. 
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Quality Appraisals of Studies 
Questions Yes NO Partially/ 
Unable to 
determine 
1. Reporting 
Is the hypothesis/aim/objective of the study clearly described? 
 
1 
 
0 
 
N/A 
Are the main outcomes to be measured clearly described in the Introduction or Methods section? 
If the main outcomes are first mentioned in the Results section, the question should be answered no. 
1 0 N/A 
Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case-control studies, a case-definition and the source for 
controls should be given. 
1 0 N/A 
Are the interventions of interest clearly described?       
Treatments and placebo (where relevant) that are to be compared should be clearly described. 
1 0 N/A 
Are the distributions of principal confounders in each group of subjects to be compared clearly described?       
A list of principal confounders is provided. 
2 0 1 
Are the main findings of the study clearly described?      
Simple outcome data (including denominators and numerators) should be reported for all major findings so that the reader can check the major 
analyses and conclusions. (This question does not cover statistical tests which are considered below). 
1 0 N/A 
Does the study provide estimates of the random variability in the data for the main outcomes?                                                           
In non normally distributed data the inter-quartile range of results should be reported. In normally distributed data the standard error, standard 
deviation or confidence intervals should be reported. If the distribution of the data is not described, it must be assumed that the estimates used 
were appropriate and the question should be answered yes. 
1 0 N/A 
Have all important adverse events that may be a consequence of the intervention been reported?  1 0 N/A 
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This should be answered yes if the study demonstrates that there was a comprehensive attempt to measure adverse events. (A list of possible 
adverse events is provided). 
Have the characteristics of patients lost to follow-up been described? 
This should be answered yes where there were no losses to follow-up or where losses to follow-up were so small that findings would be 
unaffected by their inclusion. This should be answered no where a study does not report the number of patients lost to follow-up. 
1 0 N/A 
Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability 
value is less than 0.001? 
1 0 N/A 
2. External validity: All the following criteria attempt to address the representativeness of the findings of the study and 
whether they may be generalised to the population from which the study subjects were derived. 
Were the subjects asked to participate in the study representative of the entire population from which they were recruited? 
The study must identify the source population for patients and describe how the patients were selected. Patients would be representative if they 
comprised the entire source population, an unselected sample of consecutive patients, or a random sample. Random sampling is only feasible 
where a list of all members of the relevant population exists. Where a study does not report the proportion of the source population from which 
the patients are derived, the question should be answered as unable to determine. 
 
 
1 
 
 
0 
 
 
0 
Were those subjects who were prepared to participate representative of the entire population from which they were recruited?  
The proportion of those asked who agreed should be stated. Validation that the sample was representative would include demonstrating that the 
distribution of the main confounding factors was the same in the study sample and the source population. 
1 0 0 
Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive? 
For the question to be answered yes the study should demonstrate that the intervention was representative of that in use in the source population. 
The question should be answered no if, for example, the intervention was undertaken in a specialist centre unrepresentative of the hospitals most 
of the source population would attend. 
1 0 0 
3. Internal validity – bias       Was an attempt made to blind study subjects to the intervention they have received?  
For studies where the patients would have no way of knowing which intervention they received, this should be answered yes. 
1 0 0 
Was an attempt made to blind those measuring the main outcomes of the intervention? 1 0 0 
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If any of the results of the study were based on “data dredging”, was this made clear? 
Any analyses that had not been planned at the outset of the study should be clearly indicated. If no retrospective unplanned subgroup analyses 
were reported, then answer yes. 
1 0 0 
In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the 
time period between the intervention and outcome the same for cases and controls?  
Where follow-up was the same for all study patients the answer should yes. If different lengths of follow-up were adjusted for by, for example, 
survival analysis the answer should be yes. Studies where differences in follow-up are ignored should be answered no. 
1 0 0 
Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example nonparametric methods should be used for small sample sizes. 
Where little statistical analysis has been undertaken but where there is no evidence of bias, the question should be answered yes. If the 
distribution of the data (normal or not) is not described it must be assumed that the estimates used were appropriate and the question should be 
answered yes. 
1 0 0 
Was compliance with the intervention/s reliable? 
Where there was non-compliance with the allocated treatment or where there was contamination of one group, the question should be answered 
no. For studies where the effect of any misclassification was likely to bias any association to the null, the question should be answered yes. 
1 0 0 
Were the main outcome measures used accurate (valid and reliable)? 
For studies where the outcome measures are clearly described, the question should be answered yes. For studies which refer to other work or 
that demonstrates the outcome measures are accurate, the question should be answered as yes. 
1 0 0 
4. Internal validity - confounding (selection bias) 
Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) 
recruited from the same population?  
For example, patients for all comparison groups should be selected from the same hospital. The question should be answered unable to 
determine for cohort and case control studies where there is no information concerning the source of patients included in the study. 
 
1 
 
0 
 
0 
Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) 
recruited over the same period of time?  
1 0 0 
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For a study which does not specify the time period over which patients were recruited, the question should be answered as unable to determine. 
Were study subjects randomised to intervention groups? 
Studies which state that subjects were randomised should be answered yes except where method of randomisation would not ensure random 
allocation. For example alternate allocation would score no because it is predictable. 
1 0 0 
Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and 
irrevocable? 
All non-randomised studies should be answered no. If assignment was concealed from patients but not from staff, it should be answered no. 
1 0 0 
Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? 
This question should be answered no for trials if: the main conclusions of the study were based on analyses of treatment rather than intention to 
treat; the distribution of known confounders in the different treatment groups was not described; or the distribution of known confounders 
differed between the treatment groups but was not taken into account in the analyses. In nonrandomised studies if the effect of the main 
confounders was not investigated or confounding was demonstrated but no adjustment was made in the final analyses the question should be 
answered as no. 
1 0 0 
Were losses of patients to follow-up taken into account? 
If the numbers of patients lost to follow-up are not reported, the question should be answered as unable to determine. If the proportion lost to 
follow-up was too small to affect the main findings, the question should be answered yes. 
1 0 0 
5. Power 
Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%?  
Sample sizes have been calculated to detect a difference of x% and y%. 
 Size of smallest intervention group Score 
A <n1 0 
B n1–n2 1 
C n3–n4 2 
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D n5–n6 3 
E n7–n8 4 
F n8+ 5 
Total Quality Score: 
(Downs & Black, 1998) 
Analysis…………………………………………………………………………………………………………………………………………………………….
………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………… 
Confounds……………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………………………………………………. 
Interpretation…………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………………………………………………. 
Generalisability………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………………………………………………… 
Comments/concerns…………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………….........
.............................................................................................................................................................................................................................................................
Oxford Centre for Evidence-based Medicine Levels of Evidence (March 2009) 
(for definitions of terms used see glossary) 
Level   Therapy/Prevention,    
 Aetiology/Harm 
Prognosis Diagnosis Differential 
diagnosis/symptom 
prevalence study 
Economic and 
decision analyses 
1a SR (with homogeneity*) 
of RCTs  
SR (with 
homogeneity*) of 
inception cohort 
studies; CDR† 
validated in 
different 
populations 
SR (with 
homogeneity*) of 
Level 1 diagnostic 
studies; CDR† with 
1b studies from 
different clinical 
centres 
SR (with homogeneity*) 
of prospective cohort 
studies  
SR (with 
homogeneity*) of 
Level 1 economic 
studies 
1b Individual RCT (with 
narrow Confidence 
Interval‡) 
Individual inception 
cohort study with > 
80% follow-up; 
CDR† validated in 
a single population 
Validating** cohort 
study with good††† 
reference standards; 
or CDR† tested within 
one clinical centre 
Prospective cohort 
study with good follow-
up**** 
Analysis based on 
clinically sensible 
costs or 
alternatives; 
systematic 
review(s) of the 
evidence; and 
including multi-way 
sensitivity analyses 
1c All or none§ All or none case-
series 
Absolute SpPins and 
SnNouts†† 
All or none case-series Absolute better-
value or worse-
value analyses 
†††† 
2a SR (with homogeneity*) 
of cohort studies 
SR (with 
homogeneity*) of 
either retrospective 
cohort studies or 
untreated control 
groups in RCTs 
SR (with 
homogeneity*) of 
Level >2 diagnostic 
studies 
SR (with homogeneity*) 
of 2b and better studies 
SR (with 
homogeneity*) of 
Level >2 economic 
studies 
2b Individual cohort study 
(including low quality 
RCT; e.g., <80% follow-
up) 
Retrospective 
cohort study or 
follow-up of 
untreated control 
patients in an 
RCT; Derivation of 
CDR† or validated 
on split-sample§§§ 
only 
Exploratory** cohort 
study with good††† 
reference standards; 
CDR† after 
derivation, or 
validated only on 
split-sample§§§ or 
databases 
Retrospective cohort 
study, or poor follow-up 
Analysis based on 
clinically sensible 
costs or 
alternatives; limited 
review(s) of the 
evidence, or single 
studies; and 
including multi-way 
sensitivity analyses 
2c "Outcomes" Research; 
Ecological studies 
"Outcomes" 
Research  
 Ecological studies Audit or outcomes 
research 
3a SR (with homogeneity*) 
of case-control studies 
 SR (with 
homogeneity*) of 3b 
and better studies 
SR (with homogeneity*) 
of 3b and better studies 
SR (with 
homogeneity*) of 
3b and better 
studies 
3b Individual Case-Control 
Study 
 Non-consecutive 
study; or without 
consistently applied 
reference standards 
Non-consecutive 
cohort study, or very 
limited population 
Analysis based on 
limited alternatives 
or costs, poor 
quality estimates of 
data, but including 
sensitivity analyses 
incorporating 
clinically sensible 
variations. 
4 Case-series (and poor 
quality cohort and case-
control studies§§) 
Case-series (and 
poor quality 
prognostic cohort 
studies***) 
Case-control study, 
poor or non-
independent 
reference standard  
Case-series or 
superseded reference 
standards 
Analysis with no 
sensitivity analysis 
5 Expert opinion without 
explicit critical appraisal, 
or based on physiology, 
bench research or "first 
principles" 
Expert opinion 
without explicit 
critical appraisal, 
or based on 
physiology, bench 
research or "first 
principles" 
Expert opinion 
without explicit critical 
appraisal, or based 
on physiology, bench 
research or "first 
principles" 
Expert opinion without 
explicit critical appraisal, 
or based on physiology, 
bench research or "first 
principles" 
Expert opinion 
without explicit 
critical appraisal, or 
based on economic 
theory or "first 
principles" 
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Notes for Oxford Centre for Evidence-based Medicine Levels of Evidence  
Users can add a minus-sign "-" to denote the level of that fails to provide a 
conclusive answer because:  
 EITHER a single result with a wide Confidence Interval 
OR a Systematic Review with troublesome heterogeneity.  
Such evidence is inconclusive, and therefore can only generate Grade D 
recommendations.  
* By homogeneity we mean a systematic review that is free of worrisome 
variations (heterogeneity) in the directions and degrees of results between 
individual studies. Not all systematic reviews with statistically significant 
heterogeneity need be worrisome, and not all worrisome heterogeneity need be 
statistically significant. As noted above, studies displaying worrisome 
heterogeneity should be tagged with a "-" at the end of their designated level. 
† Clinical Decision Rule. (These are algorithms or scoring systems that lead to a 
prognostic estimation or a diagnostic category.) 
‡ See note above for advice on how to understand, rate and use trials or other 
studies with wide confidence intervals. 
§ Met when all patients died before the Rx became available, but some now 
survive on it; or when some patients died before the Rx became available, but 
none now die on it. 
§§ By poor quality cohort study we mean one that failed to clearly define 
comparison groups and/or failed to measure exposures and outcomes in the 
same (preferably blinded), objective way in both exposed and non-exposed 
individuals and/or failed to identify or appropriately control known 
confounders and/or failed to carry out a sufficiently long and complete follow-
up of patients. By poor quality case-control study we mean one that failed to 
clearly define comparison groups and/or failed to measure exposures and 
outcomes in the same (preferably blinded), objective way in both cases and 
controls and/or failed to identify or appropriately control known confounders. 
§§§ Split-sample validation is achieved by collecting all the information in a single 
tranche, then artificially dividing this into "derivation" and "validation" 
samples. 
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†† An "Absolute SpPin" is a diagnostic finding whose Specificity is so high that a 
Positive result rules-in the diagnosis. An "Absolute SnNout" is a diagnostic 
finding whose Sensitivity is so high that a Negative result rules-out the 
diagnosis. 
‡‡ Good, better, bad and worse refer to the comparisons between treatments in 
terms of their clinical risks and benefits. 
††† Good reference standards are independent of the test, and applied blindly or 
objectively to applied to all patients. Poor reference standards are haphazardly 
applied, but still independent of the test. Use of a non-independent reference 
standard (where the 'test' is included in the 'reference', or where the 'testing' 
affects the 'reference') implies a level 4 study. 
†††† Better-value treatments are clearly as good but cheaper, or better at the same 
or reduced cost. Worse-value treatments are as good and more expensive, or 
worse and the equally or more expensive. 
** Validating studies test the quality of a specific diagnostic test, based on prior 
evidence. An exploratory study collects information and trawls the data (e.g. 
using a regression analysis) to find which factors are 'significant'. 
*** By poor quality prognostic cohort study we mean one in which sampling was 
biased in favour of patients who already had the target outcome, or the 
measurement of outcomes was accomplished in <80% of study patients, or 
outcomes were determined in an unblinded, non-objective way, or there was 
no correction for confounding factors. 
**** Good follow-up in a differential diagnosis study is >80%, with adequate time 
for alternative diagnoses to emerge (for example 1-6 months acute, 1 - 5 years 
chronic) 
Grades of Recommendation 
A consistent level 1 studies  
B consistent level 2 or 3 studies or extrapolations from level 1 studies 
C level 4 studies or extrapolations from level 2 or 3 studies  
D level 5 evidence or troublingly inconsistent or inconclusive studies of any 
level 
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"Extrapolations" are where data is used in a situation that has potentially clinically 
important differences than the original study situation. 
(Howick et al., 1998) 
Table of Evidence Glossary 
Absolute risk reduction (ARR): The difference in the event rate between control group 
(CER) and treated group (EER): ARR = CER - EER.  
Bias: Any tendency to influence the results of a trial (or their interpretation) other than the 
experimental intervention.  
Blinding: A technique used in research to eliminate bias by hiding the intervention from the 
patient, clinician, and/or other researchers who are interpreting results.  
Case-control study: The observational epidemiologic study of persons with the disease (or 
other outcome variable) of interest and a suitable control (comparison, reference) group of 
persons without the disease. The relationship of an attribute to the disease is examined by 
comparing the diseased and nondiseased with regard to how frequently the attribute is 
present or, if quantitative, the levels of the attribute, in each of the groups. 
Case-series: A group or series of case reports involving patients who were given similar 
treatment. Reports of case series usually contain detailed information about the individual 
patients. This includes demographic information (for example, age, gender, ethnic origin) 
and information on diagnosis, treatment, response to treatment, and follow-up after 
treatment. (NCI Dictionary)  
CER: Control event rate; see event rate.  
Clinical practice guideline: A systematically developed statement designed to assist health 
care professionals and patients make decisions about appropriate health care for specific 
clinical circumstances.  
Cochrane collaboration: A worldwide association of groups who create and maintain 
systematic reviews of the literature for specific topic areas.  
Cohort study: The analytic method of epidemiologic study in which subsets of a defined 
population can be identified who are, have been, or in the future may be exposed or not 
exposed, or exposed in different degrees, to a factor or factors hypothesized to influence the 
probability of occurrence of a given disease or other outcome. The main feature of cohort 
study is observation of large numbers over a long period (commonly years) with comparison 
of incidence rates in groups that differ in exposure levels. 
Confidence interval (CI): The range around a study's result within which we would expect 
the true value to lie. CIs account for the sampling error between the study population and the 
wider population the study is supposed to represent. See p11  
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Confounding variable: A variable which is not the one you are interested in but which may 
affect the results of trial.  
Critically appraised topic (CAT): A short summary of an article from the literature, 
created to answer a specific clinical question.  
Decision analysis: The application of explicit, quantitative methods to analyse decisions 
under conditions of uncertainty.  
Diagnosis: The process of determining health status and the factors responsible for 
producing it; may be applied to an individual, family, group or community. The term 
applied both to the process of determination and to its findings. 
Diagnostic Test: Any medical test performed to confirm, or determine the presence of 
disease in an individual suspected of having the disease, usually following the report of 
symptoms, or based on the results of other medical tests. Some examples of diagnostic tests 
include performing a chest x-ray to diagnose pneumonia, and taking skin biopsy to detect 
cancerous cells. (Harvard Guide to Diagnostic test) 
EER: Experimental event rate; see Event rate.  
Effectiveness: A measure of the benefit resulting from an intervention for a given health 
problem under usual conditions of clinical care for a particular group.  
Efficacy: A measure of the benefit resulting from an intervention for a given health problem 
under the ideal conditions of an investigation.  
Event rate: The proportion of patients in a group in whom an event is observed.  
Forrest plot: A diagrammatic representation of the results of individual trials in a meta-
analysis.  
Funnel plot: A method of graphing the results of trials in a meta-analysis to show if the 
results have been affected by publication bias.  
Heterogeneity: In systematic reviews, the amount of incompatibility between trials 
included in the review, whether clinical (i.e. the studies are clinically different) or statistical 
(i.e. the results are different from one another).  
Historically Controlled Study: A control study recruiting control subject(s) for whom data 
were collected at a time preceding that at which the data are gathered on the group being 
studied. 
Inception cohort study: A group of individuals identified for subsequent study at an early, 
uniform point in the course of the specified health condition, or before the condition 
develops. 
Incidence: The number of new cases of illness commencing, or of persons falling ill, during 
a specified time period in a given population.  
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Intention-to-treat: Characteristic of a study where patients are analysed in the groups to 
which they were originally assigned, even though they may have switched treatment arms 
during the study for clinical reasons.  
Likelihood ratio: The likelihood that a given test result would be expected in a patient with 
the target disorder compared to the likelihood that the same result would be expected in a 
patient without that disorder.  
for a positive test result = LR+ = sensitivity/(1-specificity)  
for a negative test result = LR- = (1-sensitivity)/specificity  
Local and current random census 
Local: Of or belonging to or characteristic of a particular locality or  
neighbourhood 
Current: Occurring in or belonging to the present time 
Random sample: A sample that is arrived at by selecting sample units such that each 
possible unit has a fixed and determinate probability of selection. 
Census: An enumeration of a population, originally intended for purposes of taxation and 
military service. Census enumeration of a population of a population usually records 
identities of all persons in every place of residence, with age, or birth date, sex, occupation, 
national origin, language, marital status, income, and relationship to head of household in 
addition to information on the dwelling place. 
Local and current random sample survey 
Local: Of or belonging to or characteristic of a particular locality or neighbourhood 
Current: Occurring in or belonging to the present time 
Random sample: A sample that is arrived at by selecting sample units such that each 
possible unit has a fixed and determinate probability of selection. 
Survey: An investigation in which information is systematically collected but in which the 
experimental method is not used. 
Local non-random sample 
Local: Of or belonging to or characteristic of a particular locality or neighbourhood 
Non-random sample: A sample selected by a non-random method, and as a result, some 
elements of the population have no chance of selection. For example, a scheme whereby 
units are selected purposively would yield a non-random sample. Again, a sample obtained 
by taking members at fixed intervals on a list is a non-random sample unless the list was 
arranged in a random order. (OECD) 
Mechanism-based reasoning: Involves an inference from mechanisms to claims that an 
intervention produces a patient-relevant outcome. Such reasoning will involve an inferential 
chain linking the intervention (such as antiarrhythmic drugs) with a clinical outcome (such 
as mortality). (Howick) 
MeSH: Medical Subject Headings: a thesaurus of medical terms used by many databases 
and libraries to index and classify medical information.  
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Monitoring Test: Any medical test performed to confirm, or determine the presence of 
disease in an individual suspected of having the disease, usually following the report of 
symptoms, or based on the results of other medical tests. Some examples of diagnostic tests 
include performing a chest x-ray to diagnose pneumonia, and taking skin biopsy to detect 
cancerous cells. (Harvard Guide to Diagnostic test) 
Nested Case-control study: A case control study in which cases and controls are drawn 
from the population in a cohort study. As some data are already available about both cases 
and controls, the effects of some potential confounding variables are reduced or eliminated. 
In this type of case control study, a set of controls is selected from subjects, i.e. non-cases, at 
risk at the time of occurrence of each case that arises in a cohort, thus allowing for the 
confounding effect of time in the analysis. 
n-of-1 trial: A variation of a randomized controlled trial in which a sequence of alternative 
treatment regimens is randomly allocated to a patient. The outcomes of regimens are 
compared, with the aim of deciding on the optimum regimen for the patient.  
Negative predictive value (-PV): The proportion of people with a negative test who are 
free of disease.  
Number needed to treat (NNT): The number of patients who need to be treated to prevent 
one bad outcome. It is the inverse of the ARR: NNT=1/ARR. Numbers needed to harm 
(NNH)-the number of patients who, if they received the experimental treatment, would lead 
to one additional person being harmed compared with patients who receive the control 
treatment; calculated as 1/ARI.  
Observational study: A family of studies in which investigators compare people who take 
an intervention with those who do not. The investigators neither allocate patients to receive 
the intervention not administer the intervention. Instead, they compare records of patients 
who had taken an intervention and been treated in routine practice with similar patients who 
had not taken the intervention. The most common observational designs are case-studies, 
case-series, case-control studies, cohort studies, and historically controlled studies. 
(Howick) 
Odds: A ratio of events to non-events. If the event rate for a disease is 0.2 (20%), its non-
event rate is 0.8 and therefore its odds are 2/8.  
p value: The probability that a particular result would have happened by chance.  
Positive predictive value (+PV): The proportion of people with a positive test who have 
disease.  
Post-test probability: The probability that a patient has the disorder of interest after the test 
result is known.  
Pre-test probability: The probability that a patient has the disorder of interest prior to 
administering a test.  
Post-marketing surveillance: A procedure implemented after a drug has been licensed for 
public use, designed to provide information on the actual use of the drug for a given 
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indication and on the occurrence of side effects, adverse reactions, etc. A method for 
epidemiologic study of adverse drug reactions. 
Prevalence: The baseline risk of a disorder in the population of interest.  
Prevention: Prevention refers to measures taken by an individual or a society to prevent 
disease happening or its consequences. In general, prevention includes a wide range of 
interventions, aimed at reducing risks to health. These are grouped into three categories: 
 Primary prevention: refers to strategies used to prevent a disease happening in the 
first place. An example may be salt reduction to prevent an individual becoming 
hypertensive. Medication can be used in primary prevention such as the use of blood 
lowering or cholesterol lowering drugs to lower the risk of a stroke or heart attack. 
 Secondary prevention: refers to strategies used in those with an existing disease 
which prevent recurrence, or significant morbidity. For example, in someone who 
has a heart attack cholesterol lowering drugs are used to lower the risk of 
subsequent heart attack and death. 
 Tertiary prevention: refers to the prevention of long term chronic disease 
progression, physical deterioration and attendant suffering. For example, removing 
allergens which may aggravate asthmatic patients; screening for eye, renal, eye, and 
foot problems among diabetics to reduce the risks of complications. 
Prognosis: The prospect of survival and recovery from a disease as anticipated from the 
usual course of that disease or indicated by special features of the case. 
Prognostic cohort study: 
Publication bias: A bias in a systematic review caused by incompleteness of the search, 
such as omitting non-English language sources, or unpublished trials (inconclusive trials are 
less likely to be published than conclusive ones, but are not necessarily less valid). 
Quasi-experimental studies 
Participants are allocated to the intervention and the control groups; they do not randomly 
assign to create the comparison groups.  
Non-randomised controlled studies – Individuals are allocated to a concurrent comparison 
group, using methods other than randomisation. (Increases the risk of bias) 
Before-and-after study – Comparison of outcomes in study participants before and after the 
introduction of an intervention. Comparisons may be in the same sample of participant or in 
different samples. 
Interrupted time series- Multiple observations over time that are ‘interrupted’, usually by an 
intervention or treatment. 
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Randomized trial: An epidemiological experiment in which subjects in a population are 
randomly allocated into groups, usually called study and control groups, to receive or not 
receive an experimental preventive or therapeutic procedure, manoeuvre, or intervention. 
The results are assessed by rigorous comparison of rates of disease, death, recovery, or other 
appropriate outcome in the study and control groups. 
Randomised cross-over trials – all participants receive all interventions. The sequence of 
interventions is randomised. 
Cluster randomised trials – clusters of people rather than individual are randomised to 
different interventions 
Relative risk (RR) (or risk ratio): The ratio of the risk of an event in the experimental 
group compared to that of the control group (RR=EER / CER). Not to be confused with 
relative risk reduction (see below).  
Relative risk reduction (RRR): The percentage reduction in events in the treated group 
event rate (EER) compared to the control group event rate (CER): RRR = (CER-EER) / 
CER.  
Sensitivity: The proportion of people with disease who have a positive test.  
Specificity: The proportion of people free of a disease who have a negative test.  
Systematic review: The application of strategies that limit bias in the assembly, critical 
appraisal, and synthesis of all relevant studies on a specific topic. Systematic reviews focus 
on peer-reviewed publications about a specific health problem and use rigorous, 
standardized methods for selecting and assessing articles. A systematic review differs from a 
meta-analysis in not including a quantitative summary of the results. 
Treatment benefits: Positive patient-relevant outcome associated with an intervention, 
quantifiable by epidemiological measures such as absolute risk reduction (ARR) and 
number needed to treat (NNT). 
Validity: The extent to which a variable or intervention measures what it is supposed to 
measure or accomplishes what it is supposed to accomplish. The internal validity of a study 
refers to the integrity of the experimental design. The external validity of a study refers to 
the appropriateness by which its results can be applied to non-study patients or populations. 
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Sampling techniques:  
Technique Descriptions 
Stratified 
random 
Random sample from identifiable groups (strata), subgroups, etc. 
Multistage A sample which is selected by stages, the sampling units at each stage being 
sub-sampled from the (larger) units chosen at the previous stage.  
The sampling units pertaining to the first stage are called primary or first stage 
units; and similarly for second stage units, etc. 
Purposive Hand-pick subjects on the basis of specific characteristics 
Quota Select individuals as they come to fill a quota by characteristics proportional to 
populations 
Opportunistic  Either asking for volunteers, or the consequence of not all those selected 
finally participating, or a set of subjects who just happen to be available 
Non 
probability 
A sample of units where the selected units in the sample have an unknown 
probability of being selected and where some units of the target population 
may even have no chance at all of being in the sample.  
Forms of non-probability sampling are numerous, such as voluntary samples 
(only responses of volunteers are used), quota samples, expert samples 
Probability Probability samples are selected in such a way as to be representative of the 
population. They provide the most valid or credible results because they 
reflect the characteristics of the population from which they are selected (e.g., 
residents of a particular community, students at an elementary school, etc.). 
There are two types of probability samples: random and stratified 
Source: Black, T. R. (1999). Doing quantitative research in the social sciences: An integrated 
approach to research design, measurement, and statistics. Thousand Oaks, CA: SAGE Publications, 
Inc. (p. 118) 
  
 
 
 
 
 
 
 
 
 
 
Appendix III: Oxford Centre for Evidence-based Medicine Levels of Evidence (March 
2009) 
Level  Therapy/Prevention,    
 Aetiology/Harm 
Prognosis Diagnosis Differential 
diagnosis/symptom 
prevalence study 
Economic and 
decision analyses 
1a SR (with homogeneity*) 
of RCTs  
SR (with 
homogeneity*) of 
inception cohort 
studies; CDR† 
validated in 
different 
populations 
SR (with 
homogeneity*) of 
Level 1 diagnostic 
studies; CDR† with 
1b studies from 
different clinical 
centres 
SR (with homogeneity*) 
of prospective cohort 
studies  
SR (with 
homogeneity*) of 
Level 1 economic 
studies 
1b Individual RCT (with 
narrow Confidence 
Interval‡) 
Individual 
inception cohort 
study with > 80% 
follow-up; CDR† 
validated in a 
single population 
Validating** cohort 
study with good††† 
reference standards; 
or CDR† tested 
within one clinical 
centre 
Prospective cohort 
study with good follow-
up**** 
Analysis based on 
clinically sensible 
costs or 
alternatives; 
systematic 
review(s) of the 
evidence; and 
including multi-way 
sensitivity analyses 
1c All or none§ All or none case-
series 
Absolute SpPins and 
SnNouts†† 
All or none case-series Absolute better-
value or worse-
value analyses 
†††† 
2a SR (with homogeneity*) 
of cohort studies 
SR (with 
homogeneity*) of 
either 
retrospective 
cohort studies or 
untreated control 
groups in RCTs 
SR (with 
homogeneity*) of 
Level >2 diagnostic 
studies 
SR (with homogeneity*) 
of 2b and better studies 
SR (with 
homogeneity*) of 
Level >2 economic 
studies 
2b Individual cohort study 
(including low quality 
RCT; e.g., <80% follow-
up) 
Retrospective 
cohort study or 
follow-up of 
untreated control 
patients in an 
RCT; Derivation of 
CDR† or validated 
on split-
sample§§§ only 
Exploratory** cohort 
study with good††† 
reference standards; 
CDR† after 
derivation, or 
validated only on 
split-sample§§§ or 
databases 
Retrospective cohort 
study, or poor follow-up 
Analysis based on 
clinically sensible 
costs or 
alternatives; limited 
review(s) of the 
evidence, or single 
studies; and 
including multi-way 
sensitivity analyses 
2c "Outcomes" Research; 
Ecological studies 
"Outcomes" 
Research  
 Ecological studies Audit or outcomes 
research 
3a SR (with homogeneity*) 
of case-control studies 
 SR (with 
homogeneity*) of 3b 
and better studies 
SR (with homogeneity*) 
of 3b and better studies 
SR (with 
homogeneity*) of 
3b and better 
studies 
3b Individual Case-Control 
Study 
 Non-consecutive 
study; or without 
consistently applied 
reference standards 
Non-consecutive 
cohort study, or very 
limited population 
Analysis based on 
limited alternatives 
or costs, poor 
quality estimates of 
data, but including 
sensitivity analyses 
incorporating 
clinically sensible 
variations. 
4 Case-series (and poor 
quality cohort and case-
control studies§§) 
Case-series (and 
poor quality 
prognostic cohort 
studies***) 
Case-control study, 
poor or non-
independent 
reference standard  
Case-series or 
superseded reference 
standards 
Analysis with no 
sensitivity analysis 
5 Expert opinion without 
explicit critical 
appraisal, or based on 
physiology, bench 
research or "first 
principles" 
Expert opinion 
without explicit 
critical appraisal, 
or based on 
physiology, bench 
research or "first 
principles" 
Expert opinion 
without explicit 
critical appraisal, or 
based on physiology, 
bench research or 
"first principles" 
Expert opinion without 
explicit critical 
appraisal, or based on 
physiology, bench 
research or "first 
principles" 
Expert opinion 
without explicit 
critical appraisal, or 
based on economic 
theory or "first 
principles" 
Appendix IV: Studies retrieved after the final retrieval date from the automatic alerts 
Search one  
 
Date 
retrieved 
from auto 
retrieval 
Study Reason for exclusion 
03/6/13 (Kirshner et al., 
2012) 
Diagnosis: Pegfilgrastim-induced bone pain 
Intervention: Not an appropriate intervention study. This 
study conducted an RCT exploring interventions for 
pegfilgrastim-induced bone pain. 
30/05/13  (Gopalakrishnan, 
Dhakoji, Menon, 
& Nair, 2012) 
Intervention: Not an appropriate intervention study. This 
study analysed the factors that predispose to persistent 
hydrocephalus and the need for a postoperative 
cerebrospinal fluid diversion procedure. 
18/05/13 (Easby, Potts, 
Kirby, & Sartori, 
2012) 
Intervention: Not an appropriate intervention study. The 
aim of this study was to adapt the adult ‘distress 
thermometer’ for a paediatric oncology population 
18/05/13  (Hondebrink et 
al., 2013) 
Intervention: Not an appropriate intervention study. 
18/05/13  (Vecchio et al., 
2013) 
Intervention: Not an appropriate intervention study. Abuse 
of energy drinks among young people. 
11/05/13 (Pucci et al., 
2012) 
Diagnosis: Benign heart tumours 
Intervention: Not an appropriate intervention study. To 
evaluate the role of histology in diagnosis and management 
of biologically benign heart tumours causing life-
threatening symptoms and even death in children and 
foetuses. 
11/05/13 (Steinhausen & 
Helenius, 2013) 
Diagnosis: ADHD 
Intervention: Not an appropriate intervention study. This 
study focused on chromosomal abnormalities and suggests 
concerns that medication with MPH for ADHD might 
increase the risk of cancer. 
09/05/13 (Sung et al., 
2013) 
Intervention: Not an appropriate intervention study. 
Children's Oncology Group is conducting randomized 
controlled trials to determine prophylaxis strategies that 
will reduce infections in high-risk populations. 
11/04/13 (Bilek, 2013) Intervention: Not an appropriate intervention study. The 
overall goal of this study was to provide a detailed analysis 
of the scale and scope of allegations involving illegal 
marketing and promotion of pharmaceutical products 
brought by the U.S. government to recover money spent on 
pharmaceutical products via Medicaid due to alleged 
activity that violates one or more federal laws related to 
health care fraud 
23/03/13 (Rabah et al., 
2013) 
Intervention: Not an appropriate intervention study. The 
study reported a case of chondroblastic osteosarcoma of 
right humerus presented with right frontal lobe metastasis 
in a 10-year-old girl with small pulmonary lesions. 
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16/02/13 (Bruny & 
Crombleholme, 
2013) 
Intervention: Not an appropriate intervention study. The 
review outlines the current approaches to prenatal imaging, 
differential diagnosis, antenatal natural history, and the 
available treatment options for the most commonly 
prenatally diagnosed malignant tumours. 
14/02/13 (Montano & 
Young, 2012) 
Population: Transitional (paediatrics to adult) 
Diagnosis: ADHD 
Intervention: Not an appropriate intervention study. The 
study reviewed, from the adult primary care provider 
perspective, the barriers to continuity of care and their 
implications for patients with ADHD who transition from 
paediatric to adult health care. 
14/02/13 (Nicholls, 
Hildenbrand, 
Aggarwal, 
McCarthy, & 
Daly, 2012) 
Diagnosis: paediatric cancers, traumatic brain injury (TBI), 
and sickle cell disease amalgamated in the results 
09/02/13 (Lance, Lanier, 
Andrew Zabel, 
& Comi, 2013) 
Diagnosis: Sturge Weber Syndrome 
09/02/13 (Padovani, 
André, Constine, 
& Muracciole, 
2012) 
Intervention: Not an appropriate intervention study. we 
review the underlying mechanisms and clinical 
consequences of CRT-induced neurocognitive damage in 
survivors of paediatric brain tumours 
09/02/13 (Sharp, Finlay, 
& Kevitiyagala, 
2013) 
Intervention: Not an appropriate intervention study. 
The article explored if methylphenidate was useful in 
treating fatigue in children with a brain tumour. 
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Date 
retrieved 
from auto 
retrieval 
Study Reason for exclusion 
08/06/13 (Hales & 
Wharam, 
2012) 
Intervention: Not an appropriate intervention study.  The paper 
defines the limitations of using adult high-grade glioma 
decision making 
08/06/13 (Lucena & 
Moreno-
Ortiz, 2013) 
Diagnosis: Polycystic ovary 
Population: Adult 
Intervention: Not an appropriate intervention study.  This 
paper present a case of a woman with polycystic ovary who 
was treated using in vitro maturation techniques 
06/6/13 (Combs et 
al., 2013) 
Intervention: Not an appropriate intervention study. This paper 
developed a practical prognostic score to predict survival 
outcome after re-irradiation. 
03/6/13 (Prasad, 
Mendelow, 
& Gregson, 
2008) 
Diagnosis: Hodgkin Lymphoma 
Intervention: Not an appropriate intervention study. This study 
considers neurocognitive deficits can exist in patients that do 
not receive traditional cranial nervous system therapy. 
03/6/13 (Wolden et 
al., 2012) 
Diagnosis: Hodgkin's Lymphoma 
Intervention: Not an appropriate intervention study.  A 
randomized comparison study by the children's oncology 
group of chemotherapy looking at patient  with and without 
radiotherapy with Hodgkin's Lymphoma 
03/6/13 (Ramsey et 
al., 2013) 
Intervention: Not an appropriate intervention study. This study 
replicated the finding that inherited variations in SLCO1B1 are 
the most important genetic variations influencing methotrexate 
clearance.  
 03/6/13 (Gordon et 
al., 2013) 
Diagnosis: Advanced Hodgkin lymphoma 
Intervention: Not an appropriate intervention study. The aim of 
this paper was to determine if failure-free survival was 
superior in patients treated with the Stanford V regimen 
compared with doxorubicin, bleomycin, vinblastine, and 
dacarbazine. 
25/05/13 (Zoicas, 
Droste, 
Mayr, 
Buchfelder, 
& Schöfl, 
2013) 
Diagnosis: Obesity 
Population: Adults 
Intervention: Not an appropriate intervention study.  The paper 
tested whether Glucagon-like peptide-1 analogues were also 
effective in the treatment of obesity and associated metabolic 
alterations in patients with hypothalamic disease.  
18/05/13  (Brown, 
Kolade, 
Staton, & 
Patel, 2013) 
Intervention: Not an appropriate intervention study. The aim of 
the study was to implementation of a new addiction medicine 
curriculum at a single internal medicine program provided an 
opportunity for knowledge assessment in a select population of 
health professionals. 
18/05/13  (Backberg, 
Westerbergh, 
Al-Saffar, 
Lindeman, & 
Helander, 
2013) 
Intervention: Not an appropriate intervention study. The article 
explores trends in intoxications of novel psychoactive 
substances. 
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20/04/13 (Bhalla, 
2013) 
Intervention: Not an appropriate intervention study. 
21/03/13 (Yap et al., 
2012) 
Intervention: Not an appropriate intervention study. This paper 
illustrated the therapeutic benefit of aripiprazole for treatment 
of mental status changes associated with resection of a 
posterior fossa tumour 
16/03/13  (Plotkin et 
al., 2013) 
Intervention: Not an appropriate intervention study. The 
authors proposed an updated diagnostic criteria to incorporate 
new clinical and genetic findings since 2005. 
16/02/13 (Chafe, 
Drodge, 
Krauze, 
Dundas, & 
Wilson, 
2011) 
Intervention: Not an appropriate intervention study. 
16/03/13  (Yust & 
Slattery, 
2012) 
Intervention: Not an appropriate intervention study. The 
purpose of this article was to review the classes of medications 
found in over-the-counter, the epidemiology of their use, the 
pharmacology and clinical toxicity of specific medications, 
dextromethorphan abuse, and the management of children 
presenting with overdose or adverse effects. 
02/03/13 (Sorrell, 
Espenschied, 
Culver, & 
Weitzel, 
2013) 
Intervention: Not an appropriate intervention study. In this 
article, they review the clinical relevance of germline 
mutations in the TP53 tumour suppressor gene to current 
healthcare practice, including the optimal ways to identify 
patients with Li-Fraumeni syndrome, to recognize the core 
cancers associated with Li-Fraumeni syndrome, and to develop 
strategies for early detection of Li-Fraumeni syndrome-
associated tumors 
09/02/13 (Siddique, 
Sreenivasan, 
Comi, & 
Germain-
Lee, 2013) 
Diagnosis: Sturge-Weber syndrome 
 
09/02/13 (Brinkman et 
al., 2013) 
Population: Adults 
Intervention: Not an appropriate intervention study. The study 
explored the extent to which psychoactive medication 
treatment is associated with adverse effects on specific 
neurocognitive processes. 
09/02/13 (IŞIK, 
SİLAV, 
GÜÇLÜER, 
& Elmaci, 
2012) 
Intervention: Not an appropriate intervention study.  The 
review presents the clinical features, diagnostic methods and 
management of cranial teratomas based on our experience and 
the literature. 
09/02/13 (Joshi, 
Singh, & 
Shellhaas, 
2013) 
Diagnosis: Epilepsy 
Intervention: Not an appropriate intervention study. The study 
reviewed a variety of interventions designed to maximize 
seizure control and thereby optimize their neurodevelopmental 
outcomes 
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Section/Topic # Checklist Item Reported 
on page 
Title    
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 
Abstract    
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number. 
 
4-5 
Introduction    
Rational 3 Describe the rationale for the review in the context of what is already known. 13-63 
Objective 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS). 
66 
Methods    
Protocols and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number. 
69-77 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow‐up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale. 
66-67 
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched. 
69-71 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated. 
69-
71/150-
182 
 
153 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis). 
71-75 
Data collection 
process 
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators. 
65-67 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made. 
71-77 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis. 
54-57 
Summary of 
measures 
13 State the principal summary measures (e.g., risk ratio, difference in means). 71-75 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis. 
76-77 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies). 
71-75 
Additional analysis 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
N/A 
Results    
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram. 
79 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations. 
80-92 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12). 
93-96 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
80-92 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of N/A 
183 
 
consistency. 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see Item 15). 80-95 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]). 
N/A 
Discussion    
Summary of 
evidence 
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers). 
104-117 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias). 
118-127 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research. 
123-133 
Funding    
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review. 
N/A 
 
 
 
 
